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1 Introduction 
 
1.1 Metastasis 
Metastasis is a multistage process during which malignant cells spread from the primary tumor to 
distant organs (Récamier, 1829; Talmadge and Fidler, 2010). Despite significant improvements in 
diagnosis and therapies, 90% of deaths from cancer are due to metastases that are resistant to 
conventional therapies (Fidler, 2003; Weigelt et al., 2005). Therefore, there are many gaps in our 
knowledge about metastasis. Understanding molecular players and processes involved in 
metastasis should lead to effective, targeted approaches to prevent and treat cancer metastasis.   
 
During last decades many attempts have been allotted to unravel underlying mechanisms 
of metastasis and only few recent discoveries led to some mechanistic aspects of the process 
(Hanahan and Weinberg, 2011; Talmadge and Fidler, 2010; Valastyan and Weinberg, 2011). All 
molecular findings and supporting clinical data suggest a stepwise cascade for carcinoma 
invasion-metastasis including (1) local invasion of primary tumor cells through surrounding 
extracellular matrix (ECM) and stromal cell layers, (2) intravasation of cancer cells into the 
lumen of blood vessels, (3) surviving circulation within the vasculature, (4) arresting at distant 
organ sites, (5) extravasation into the parenchyma of distant tissues, (6) surviving in distant 
possible hostile microenvironments, and (7) reinitiating their proliferative programs at metastatic 
sites, in order to form micrometastases, and followed by generation of macroscopic, clinically 
detectable neoplastic growths (the step often referred to as ‘‘metastatic colonization’’; Figure 1) 
(Chaffer and Weinberg, 2011; Fidler, 2003; Valastyan and Weinberg, 2011). Since we are going 
to investigate mechanisms of dissemination in early and late course of tumour development, local 
invasion as the first distinctive step comes to the main focus.  
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Figure 1.  Cascade of metastasis. Clinically detectable metastases represent the end products of a complex series of cell-biological events, 
which are collectively termed the invasion-metastasis cascade. During metastatic progression, tumor cells exit their primary sites of 
growth (local invasion, intravasation), translocate systemically (survival in the circulation, arrest at a distant organ site, extravasation), 
and adapt to survive and thrive in the foreign microenvironments of distant tissues (micrometastasis formation, metastatic 
colonization). Carcinoma cells are depicted in red (Valastyan and Weinberg, 2011). 
 
1.2 Local invasion and migration  
During local invasion, cancer cells must acquire the ability to migrate and invade which implies 
an alteration in the genetic programs and phenotypic characteristics of cancer cells. In addition, 
cancer cells in the primary site are surrounded by a complex microenvironment comprising 
numerous cells including endothelial cells of the blood and lymphatic circulation, stromal 
fibroblasts and a variety of bone marrow-derived cells including macrophages, myeloid-derived 
suppressor cells, different types of monocytes and mesenchymal stem cells (Joyce and Pollard, 
2009). It is increasingly apparent that crosstalk between cancer cells and cells of the neoplastic 
stroma is involved in the acquired capability for invasive growth and metastasis (Egeblad et al., 
2010; Qian and Pollard, 2010; Joyce and Pollard, 2009; Kalluri and Zeisberg, 2006). Hence, local 
invasion on one hand depends on the phenotype and genotype of tumor cells and on the other 
hand is an outcome of crosstalk between cancer cells and microenvironment (Chiang and 
Massague, 2008).  
 
Another component of tumor microenvironment is extra-cellular matrix (ECM). 
Interaction of ECM with cancer cells plays important role during local invasion and migration of 
cancer cells. When cancer cells grow at the primary sites, they interact with the adjacent ECM 
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and initiate binding via adhesion molecules (Hynes, 2002). Depending on the cell type and ECM 
substrate, focal contact assembly and migration can be regulated by different components of 
ECM such as integrins which connected the ECM to the cytoskeletons of cells (Friedl and Wolf, 
2003). Suggesting, depending on the genotype of cells and composition of microenvironment, 
cancer cells can use different types of migration comprised of amoeboid and mesenchymal 
migration and in a singular or a multicellular process. Moreover, microinvasion can also happen 
as a result of protrusion of cells from the proliferative tumor (Friedl and Alexander, 2011).   
 
When epithelial-derived tumors metastasize, the basal membrane is the first barrier that 
invading cells have to breach into. For breaching through the basal membrane, mechanisms and 
players all are conserved across species as well as cancer cells (Sherwood, 2006). Maybe the best 
characterized cell migration and invasion program shared between normal development and 
cancer is EMT (epithelial to mesenchymal transition) which is also conserved across species. The 
EMT emerged from abundant observations that demonstrated downregulation of E-cadherin in 
human carcinomas (Berx and van Roy, 2009), goes along with changes in the expression of genes 
encoding other cell-to-cell and cell-to-ECM adhesion molecules (Cavallaro and Christofori, 
2004). These changes were found to confer abilities to invade, to resist apoptosis, and to 
disseminate (Hanahan and Weinberg, 2011; Mani et al., 2008; Polyak and Weinberg, 2009). This 
mechanism is similar to what was originally described for the normal early embryonic 
development (Micalizzi et al., 2010). Hence, it was not surprising when researchers found that 
molecular pathways classically associated with EMT, including Snail/Slug, Twist, Six1, Cripto, 
TGF-β, and Wnt/β-catenin, are highly conserved across species (Micalizzi et al., 2010; Nieto, 
2013). Moreover, carcinoma cells that have passed through an EMT show stem-like state. It was 
speculated that stem cell character is critical in dissemination and launching new colonies of 
cancer cells in distant site (Chaffer and Weinberg, 2011).  
 
1.3 Cancer stem cells in metastasis  
A successful metastasis requires not only a local invasion, but also a property to support cancer 
cell growth in the primary site and the metastatic niche. Even among heterogeneous tumors only 
subsets of cells which are known as cancer stem cells (CSCs) support a proliferation hierarchy 
(Beck and Blanpain, 2013). They are defined as cancer cells able to initiate tumor growth in host 
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organs and differentiate into non-CSC (Clarke and Fuller, 2006; Palmer et al., 2012). The current 
CSC concept holds that disease relapse and later progression is largely due to the intrinsic therapy 
resistance of CSC, and. therefore, a successful eradication of cancer is only possible if the applied 
therapies are able to target CSC (Gupta et al., 2009). 
 
There are several reasons that favor the view that cancer stem cells are the main migratory 
population in the primary site and the ultimate metastatic cells in the distant site: (1) Metastases 
of most carcinomas recapitulate the hierarchy and organization of their primary tumours 
(Brabletz et al., 2005); (2) Cells that have undergone EMT demonstrate CSC-like characteristics 
(Chaffer and Weinberg, 2011). It has also been shown that CSC spontaneously undergo 
Mesenchymal-Epithelial Transition (MET) which helps extravasation in the distant sites (Mani et 
al., 2008); (3) Signaling pathways regulating stemness (e.g. Wnt/β-catenin) are selectively 
expressed in the migratory front of tumors (Brabletz et al., 2005); (4) Migration of stem cells not 
only has a pivotal role during embryogenesis, but adult stem cells (also known as tissue stem 
cells) can also increase their migratory activity when their microenvironment is altered. For 
example, these cells play a key role in tissue damage repair - tissue injury activates 
developmental programs by activating adult stem cell migration to the site of damage (Imitola et 
al., 2004; Scadden, 2006); (5) It has frequently been observed that metastatic cells are carrying 
stem cell signatures. For example in breast cancer it was shown that there was similarity between 
gene expression profiles of breast cancer stem cells and the normal mammary stem cells 
(MaSCs). Interestingly, the stem cell phenotype is dominant in the metastatic lesion and 
disseminated cancer cells (Balic et al., 2006; Lawson et al., 2009). Therefore, it may be a 
plausible hypothesis that metastatic cancer cells are stem like cells. 
 
1.4 Mammary gland development and breast cancer 
The mammary gland, which distinguishes mammals from all other animals, works as an organ to 
produce and secrete milk for nourishing offsprings. The full development of this organ happens 
after birth (Inman et al., 2015). Terminal end buds (TEBs) are the main structures seen at the 
birth. TEBs are club-shaped structures comprising an outer layer of cap cells and a multilayered 
inner core of cells called body cells, appear at the tips of the ducts and start to invade the fat pad. 
After birth, mammary development is arrested until puberty, when extensive elongation of the 
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ducts and secondary branching takes place. Upon hormonal induction during puberty, 
proliferation within the TEBs results in ductal elongation and lumen formation. Consequently, 
TEBs disappear because of the limits of the fat pad space and ceasing of growth (Watson and 
Khaled, 2008).  
 
The tissue architecture of mammary gland consists of different cell types: epithelial cells 
that form the ductal network of the gland; adipocytes, which constitute the fat pad and in which 
the ductal network is embedded; vascular endothelial cells, which make up the blood vessels; 
stromal cells, including fibroblasts; and a variety of immune cells. The epithelium in the 
mammary gland can be divided into two types: luminal and basal. The luminal epithelium forms 
the ducts and the secretory alveoli, whereas the basal epithelium consists essentially of 
myoepithelial cells (Sternlicht, 2005).  These two types of epithelium form a bi-layered structure 
of simple epithelium that is embedded within the fatty stroma (Figure 2; (Watson and Khaled, 
2008)). Comparative molecular studies of different normal mammary epithelial gene expression 
signatures and different subtypes of breast cancer have suggested that distinct cells of origin may 
give rise to the different subtypes (Visvader and Stingl, 2014). 
 
Figure 2. Schematic diagram depicting the salient architectural features of TEBs and their subtending ducts, including their 
fibroblast-rich stromal collar and high mitotic index. Though there is no evidence that normal ductal cells ever cross 
the basal lamina, thinning of the basement membrane (dotted lines) does seem to occur at the tips of invading ducts as a 
result of their partial enzymatic degradation and/or incomplete de novo synthesis. Stromal macrophages and eosinophils 
are also depicted (Sternlicht, 2005). 
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Extensive lineage tracing studies in mammary gland have been performed to define 
mammary stem cell (MaSC) population. The latest results suggested that the pubertal gland 
contains several different stem and progenitor cell populations, including bipotent stem cells that 
give rise to both the luminal and myoepithelial cells of the duct, or mono potent which give rise 
to luminal and alveolar cells alone.(Inman et al., 2015). The importance of MaSC became evident 
when it was seen that the MaSC/basal signature is most closely aligned with the expression 
profile of more aggressive subtypes of breast cancer (Shehata et al., 2012). Interestingly, mouse 
MaSCs are ER/PgR negative, and are localized in the basal compartment of mouse mammary 
epithelium in close proximity of ER/PgR positive mature luminal epithelial cells. It has been 
suggested that MaSCs need hormone receptor expressing cells for their expansion (Asselin-Labat 
et al., 2006).  
 
Progesterone, estrogen and their nuclear receptors play essential roles during mammary 
gland morphogenesis. However, they are differently acting on mammary epithelial cells. While 
estrogen is mostly responsible for elongation of ducts (Ciarloni et al., 2007), progesterone 
induces side branching and expansion of epithelial structure into the mammary fat pad (Brisken, 
2013). Progesterone induces mouse MaSC proliferation and expansion via RANKL (Figure 3; 
(Brisken, 2013; Joshi et al., 2010)). Furthermore, progesterone inhibits tight junction formation 
and terminal differentiation in mammary epithelial cells. The progressive reduction of PgR 
expression that occurs during late pregnancy has also been suggested to contribute to the onset of 
lactation and terminal differentiation of mammary epithelial cells (Ismail et al., 2002). It has been 
speculated that the impact of progesterone on MaSCs expansion and proliferation targets them for 
further cell transformation events leading to breast cancer (Joshi et al., 2010). The expansion of 
the MaSC pool by progesterone has been also suggested as underlying mechanism of the 
observation that menstrual cycling predisposes to breast cancer (Asselin-Labat et al., 2010).  
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Figure 3. Models of cell-intrinsic and paracrine mechanisms of progesterone induced cell proliferation in the mouse mammary 
epithelium. A hormone receptor (HR)+ cell is indicated by a grey nucleus. Progesterone induces the expression of receptor activator of 
nuclear factor-κB (NF‑κB) ligand (RANKL) secretion, which triggers the proliferation of adjacent HR– cells. (Brisken, 2013). 
 
Steroid hormone receptors, PgR (progesterone receptor) and ER-α (estrogen receptor 
alpha) also serve as markers of breast cancer subtypes. These subtypes were originally identified 
by gene expression studies, which confirmed the fundamental distinction between hormone 
receptor positive and negative cancers. Nuclear hormone receptor negative subtypes comprise 
triple-negative cancer (negative for HER2/ERα/PgR), the basal-like subtype, and cancers with 
Her2 gene amplification. Nuclear receptor positive subtypes comprise the luminal types which 
are further divided into luminal A and B (Bombonati and Sgroi, 2011) and form the majority of 
breast cancers. Luminal A tumours express ERα and/or PgR and differ to luminal B with higher 
proliferation rate (as frequently assessed by Ki-67 staining) or HER2 expression levels. Patient 
prognosis differs for various subtypes. Luminal A subtype has an overall good prognosis, and can 
be treated by hormone therapy. Her2-amplified breast cancers have a poor prognosis and are 
treated by targeted therapy using trastuzumab or lapatinib. However, no specific therapy is 
currently available for the other subtypes, although the prognosis of basal and luminal B tumors 
is poor (Adelaide et al., 2007; Bombonati and Sgroi, 2011; Williams et al., 2009). 
 
Her2 and triple negative breast cancer are enriched with stem-like (May et al., 2011; 
Velasco-Velazquez et al., 2011). Consistently, it was shown that expression of Her2 induces 
stemness in mammary epithelial cells (Ginestier et al., 2007; Korkaya et al., 2008), which is 
partly mediated via the canonical NF-κB pathway and RANKL (Liu et al., 2010a). RANKL is a 
direct regulated target gene of progesterone (Brisken, 2013). Moreover, it was shown that 
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progesterone and its receptor modulate Her2 signalling and induce Her2 nuclear translocation 
(Beguelin et al., 2010). Therefore, progesterone on one hand regulates mammary gland side 
branching and migration of epithelial cells into the fat pad and on the other hand may regulate 
stemness in a crosstalk with Her2.  
 
1.5 Early versus late dissemination of cancer cells 
Until to date, many functional studies addressing mechanisms of metastasis used cell lines 
derived from advanced tumours or metastases. This appears to be justified as long as late 
metastatic dissemination from large tumours is the prevailing concept of metastasis (Fearon and 
Vogelstein, 1990; Hanahan and Weinberg, 2000). The late dissemination model holds that the 
majority of aberrations accumulate within the primary tumour before additional genetic hits lead 
to metastatic spread (Fearon and Vogelstein, 1990; Jones et al., 2008). Though intriguing at first 
sight this concept is inconsistent with some clinical and experimental observations. For example, 
it is well known that small tumours can indeed seed metastases and T1 stage (i.e. small) tumours 
diagnosed with metastasis at primary presentation are not such a rare event in clinical settings. 
Since it has been convincingly deduced from large epidemiological and imaging studies of breast 
cancer that growth of metastases takes several years (Engel et al., 2003), T1M1 (patients already 
diagnosed with primary tumours and suffering metastasis) stage cancers must have seeded cells 
when they were composed of less than 10
5
 – 106 tumour cells (Klein and Holzel, 2006). In 
addition, “cancer of unknown primary”, a condition where metastasis is detected in the absence 
of a detectable primary tumour, comprises about 5% of all hospitalized cancer patients, and 
therefore is as frequent as esophageal cancer (Abbruzzese et al., 1994; van de Wouw et al., 2002). 
Therefore, cancer cells should have departed the primary lesion very early and before the 
acquisition of fully malignant phenotypes.  
 
More empirical evidences come from the analysis of DCCs isolated from bone marrow 
before and after manifestation of metastasis. Genetic data indicated that DCCs from the two 
stages (M0, without metastasis, and M1, with metastasis) of metastatic spread differ (Klein et al., 
2002; Schmidt-Kittler et al., 2003) and it was suggested that they might have disseminated early 
and evolved in parallel to the primary tumor (Figure 4; (Klein, 2009)). Subsequently, studies in 
transgenic mouse models (Eyles et al., 2010; Hüsemann et al., 2008; Rhim et al., 2012) and in 
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patients with in-situ carcinomas (Banys et al., 2012; Hüsemann et al., 2008; Sanger et al., 2011) 
corroborated this concept.  
 
 
Figure 4. Evolution of malignancy. (Top) The late metastasis model places selection of genetic and epigenetic alterations mostly inside the 
primary tumor. If so, late-disseminating cells are genetically similar to the primary tumor, which can be used as a surrogate marker to 
choose a drug against disseminated tumor cells. (Bottom) By contrast, early-disseminated tumor cells accumulate such alterations at 
distant sites and diverge genetically from the primary tumors. Consequently, they may respond differently to drugs that are 
administered systemically (Klein, 2008). 
 
1.6 Balb-NeuT as a mouse model for early dissemination  
The ERBB2 (also known as HER2) receptor is a tyrosine kinase receptor that belongs to the 
epidermal growth factor receptor (EGFR) family. The rat homologue of the ERBB2 gene is called 
the NEU gene and was originally identified from chemically-induced neuroblastomas1 (Schechter 
et al., 1984). Amplification of ERBB2 has been observed in 20–30% of sporadic human breast 
cancers and, correlates with poor patient outcome (Slamon et al., 1987; Slamon et al., 1989). 
HER2 overexpression and amplification is also seen in subsets of gastric, esophageal, and 
endometrial cancers and also associated with poor prognosis (Mimura et al., 2005; Morrison et 
al., 2006; Yano et al., 2006). Moreover, when breast cancer patients with HER2 amplification 
were treated with trastuzumab (Herceptin), a neutralizing monoclonal ERBB2 antibody, 
prolonged disease-free survival were observed when compared to control patients (Robert et al., 
2006).   
 
After first hints indicated a prominent role of Her2 in breast cancer, transgenic animal 
models for study breast cancer related Her2 subtype were generated. Transgene regulation via the 
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mouse mammary tumour virus-long terminal repeat (MMTV-LTR) promoter was ideally suited 
for this purpose, as it directs the high-level expression of a transgen specifically in the mammary 
epithelium (Sinn et al., 1987). These attempts resulted in different ERBB2-driven breast cancer 
murine models with different growth kinetics of tumors. It was speculated that these differences 
are due to the type of insert (wild type or activated mutant form), the background of host strains 
and some technical differences such as insertion site and copy number of inserts (Ursini-Siegel et 
al., 2007). 
 
The over-expression of wild type Neu resulted in mammary tumors with a long latency 
about 1 year (Muller et al., 1988). Thus, researchers shifted to the use of an activated form of Neu 
(NeuT). The first NeuT mice were generated by Philip Leder’s Group in FVB mouse strain 
(Muller et al., 1988). Tumors of this model were arising in a stochastic fashion in different organs 
other than mammary gland and, therefore, Libero Clerici’s group tried to overcome that problem 
by changing vector construct and strain of mice. They changed to CD1 strain and generated a 
new NeuT model, but tumor onset was not similar in the following generations as well as some 
problems in the fertility of transgenic mice (Lucchini et al., 1992). Guido Forni’s group 
developed the Balb-NeuT mouse model for the first time by breeding transgenic CD1 random-
bred breeder male mouse with BALB/c females (Boggio et al., 1998). They generated a BALB/c 
background mouse model carrying the mutated rat HER-2/neu oncogene (Tg-NeuT; amino acid 
664 ValGlu) driven by the MMTV promoter. This mouse model is known as one of the fastest 
Her2-driven breast tumor forming model (Figure 5) with a constant onset of tumors in offsprings 
and little involvement of other organs. However, MMTV–NEU mice models serve not only as a 
simple breast cancer model, but also many studies used and are using these models in concert 
with additional transgenic animals, to identify key candidate genes and correlated signaling 
involved in various biological processes in tumor biology (Ursini-Siegel et al., 2007). 
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Figure 5. Progression of HER-2/neu carcinogenesis in untreated Balb–NeuT. Histology shows that ductular atypical hyperplasia (a) is 
already evident and widely distributed in all mammary glands at 3 weeks of age. This hyperplasia progresses to carcinoma in situ (b) 
between weeks 13 and 17, and then to an invading lobular carcinoma (c) (Boggio et al., 1998). 
 
 
1.7 Aim of work 
Although, many studies support the concept of early dissemination of cancer cells, the concept of 
parallel progression of primary tumors and metastasis is still under debate (Valastyan and 
Weinberg, 2011). That is because experimental data derived from cell lines suggest metastasis to 
be a consequence of increasing aggressiveness and loss of differentiation, acquisition of 
epithelial-mesenchymal transition and genetic deterioration. Therefore, it is unclear how early-
disseminated, “normal-like” cancer cells should be able to successfully overcome critical 
metastatic steps (Valastyan and Weinberg, 2011) unlike late disseminating cancer cells thought to 
be similar to primary tumor cells. Based on previous data from the Balb-NeuT model and 
patients, this work aims to elucidate underlying mechanisms responsible for early dissemination 
of tumor cells in breast cancer.  
 
In the Balb-NeuT model, we previously noted that dissemination was not only an early 
event but also observed that the frequency of DCCs in bone marrow did not increase with tumor 
size (Figure 6; (Hüsemann et al., 2008)).  
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Figure 6. Progression of local and systemic disease in Balb-NeuT mice over time. Left panel: Increase of tumor area. Right panel: number of 
CK+ (red dots) and HER-2+ (blue dots) cells per 5 x 105 bone marrow. Number of disseminated cancer cells does not increase by 
increasing tumor size (Hüsemann et al., 2008). 
 
The same was true for breast cancer patients, suggesting that both in mice and men 
seeding propensity is relatively (i.e. related to the number of tumor cells) lower in large as 
compared to small cancers. Moreover, even in breast cancer patients without histologically 
invasive cancers but pre-invasive lesions such as atypical ductal hyperplasia (ADH) or in situ 
carcinomas (DCIS), we could detect DCCs in bone marrow as in mice (Hüsemann et al., 2008). 
Therefore, this project was designed to address several critical questions in this regard:  
1) How do breast cancer cells disseminate in very early stage before tumor manifestation? 
2) To what extent are early disseminated cancer cells fit to colonize and form metastasis?  
3) Which mechanism reduces metastatic seeding from advanced stages of cancer growth?  
4) What is the relevance of our findings to human data and disease courses in breast cancer? 
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2 Materials and Methods 
 
2.1 Methods 
2.1.1  Animal Experiments 
2.1.1.1 Maintenance 
Balb-NeuT transgenic mice were obtained through collaboration with Dr. Guido Forni and 
maintained in our facilities according to the European Union guidelines. All animal experiments 
were performed according to the EU and national institutional regulations (Government of Upper 
Palatinate, 55.2-2532.1-27/14). Mice were screened at 3 to 4 weeks of age for hemizygosity 
(neuT
+
/neuT
-
), and negative littermates served as wild-type BALB/c mice controls. Mammary 
glands of Balb-NeuT female mice were inspected twice a week and arising tumors were 
measured in two perpendicular diameters.  
 
2.1.1.2  Surgery  
Mice were anaesthetized with Midazolam 5mg/kg, Fentanyl 0,05mg/kg, Medetomidin 0,5mg/kg 
i.p. Thorax and abdomen were shaved, and skin was incised from caudal to cranial region in the 
midline. For sphere injection experiments, 50 spheres (see section 2.1.3.4 for sphere generation) 
were mixed with matrigel (final concentration was 40%) and injected into the fourth right 
mammary gland of BALB/c mice. In case of tissue transplantation, a piece (approximately 1 
mm
3
) of donor mammary tissue from 4-week-old Balb-NeuT mice or PT (21-23 week-old) was 
implanted in the cleared mammary fat pad of recipient mice. The skin was closed by a suture 
using polygelatin string and anesthesia was antagonized with Flumazenil 0,5mg/kg, Atipamezol 
2,5mg/kg, Naloxon 1,2mg/kg s.c.. Postoperative analgesia was achieved by Buprenorphin (0,1 
mg/kg) s.c.. Curative surgery or sacrifice of mice was done when the diameter of tumors was 
between 5-10 mm.  
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2.1.1.3 Mice dissection  
Mice were sacrificed by asphyxiation with CO2 or by cervical dislocation. The organs of interest 
were either embedded in paraffin (see section 2.1.1.5 for paraffin embedding tissue) or used for 
snap freezing (see section 2.1.1.6 for tissue snap frizzing). The following organs were preserved 
for the later immunohistochemical analysis: 1) mammary glands, 2) tumors, 3) lungs, 4) liver and 
5) spleen. Bone marrow was prepared by the protocol described in the next section (section 
2.1.1.4). 
 
2.1.1.4   Bone marrow preparation for staining 
Tibias and femurs were collected either from BALB/c or Balb-NeuT in PBS or basal medium. 
The soft tissue surrounding the bones was removed. Epiphyses were cut with scissors to flush out 
the bone marrow. Using a 26G needle and 1 ml syringe the bone marrow was flushed out into a 
50 ml tube. Alternatively, for some experiments the flushed bones were put into a mortar to break 
the bones using mortar and pestle. The broken bones were washed with 1x PBS to collect the 
remaining bone marrow cells after flushing. Afterwards, the cells were pooled and centrifuged at 
200x g for 10 min. The supernatant was discarded and the pellet was resuspended in 9 ml of 1x 
PBS. The cell suspension was slowly and carefully overlaid onto 6 ml of 65% percoll in a 15 ml 
tube to form a layer and centrifuged for 20 min at 1000x g to remove erythrocytes. The 
interphase was then carefully collected using a 5 ml pipette and transferred into a new 50 ml tube. 
The tube was filled up with 1x PBS and centrifuged for 10 min at 500x g for washing the cells. 
The cells were resuspended in 5 ml of 1x PBS and counted. Finally, 5 x 10
5
 cells were dropped 
on adhesion slides.  
 
2.1.1.5 Extent of dissemination relative to tumour area 
Data were taken from reference (Hüsemann et al., 2008). Briefly, gland/tumour areas were 
calculated from 270 mammary glands/tumours of 27 mice assuming the shape of an ellipse/circle 
for each tumour. The tumour area of mammary glands without palpable (i.e. not measurable by a 
caliper) tumours was set to 0.1 mm
2
 (i.e. assuming a diameter of 350 µm of a total, circular 
hyperplastic lesion within a mammary gland) for lesions from week 4 to week 9 old mice and 0.4 
mm
2
 for week 11 mice. The adjustment for week 11 was based on a microscopic evaluation 
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revealing an about fourfold increase in hyperplastic lesions. CK positive cells from 27 mice were 
calculated as the mean of single disseminated cells per 10
6
 BM cells. 
 
2.1.1.6 Paraffin embedding of murine tissue samples  
The dissected tissue samples were fixed in a 4% paraformaldehyde (PFA) solution for 12 h. 
Following fixation, the samples were washed 3 times in 1x PBS. The major obstacle during the 
tissue sectioning represents residual water in the embedded tissue. Therefore, dehydration of the 
paraffin embedded samples was achieved by series of washing steps in alcohol (70%, 85% and 
100% ethanol, each step 1 hour). Then the fixed and dehydrated tissue was washed twice for 30 
min in 100% xylene. This step serves not only the removal of alcohol from the tissue, but also 
facilitates the penetration of the paraffin during the subsequent embedding. After three incubation 
steps with paraffin (parablast embedding media), tissues were embedded. Paraffin embedded 
tissue is stored at room temperature.  
2.1.1.7 Tissue snap freezing 
Tissue were labeled appropriately and packed in aluminum foils. Then, they were drawn in 50 ml 
falcon filled with 2-methyl butane.  Falcon tube has carefully been placed into the liquid nitrogen. 
Complete freeze is achieved at ~60 seconds (90 seconds maximum for larger specimens). Finally, 
samples were removed and stored in -80⁰C freezer. These samples have been used for RNA 
extraction or IHC staining. 
2.1.2 Laser Microdissection and microarray analysis 
Laser microdissection was performed to dissect metastatic lesions from lung, primary tumors, 
epithelial layers of mammary glands of Balb-NeuT mice at the time point of EL, and BALB/c 
mice at different age. Small pieces summing up to 10
5
 μm2 for each sample were catapulted into a 
cap with 10 μl paramagnetic oligo-dT bead suspension and lysis buffer. The extraction of mRNA 
and microarray experiments were performed as described previously (Hartmann and Klein, 
2006).  
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2.1.3 Cell culture experiments 
2.1.3.1 Cell lines 
All used cell lines, characteristics and media are listed in section 2.2.8. Cell lines were preserved 
in liquid nitrogen in appropriate medium containing 5% DMSO. They were propagated until 70% 
confluence apart from the cases when the experimental strategy implied differently. Cell lines 
were detached using Trypsin/EDTA and re-plated in an appropriate cell density. All cells were 
incubated at 37°C with 5% CO2 and were routinely tested for mycoplasma and were found to be 
negative. 
 
2.1.3.2 Cell culture treatments 
Steroid hormones (progesterone, aldosterone, β-estradiol, testosterone, and hydrocortisone) were 
dissolved in ethanol. Rankl and Wnt4 were dissolved according to the manufacturer’s 
instructions. Cells were cultured 24 hours before treatment in appropriate densities. The desired 
concentration of that given hormone or factors were prepared in fresh media and added to the 
cultured cells only after cells were washed 2 times with PBS. These treatments were repeated for 
three times in each 24 hours interval. Cells were washed 2 times with PBS and fresh media 
containing additives were added. Three hours after last treatment, cells were washed 2 times with 
PBS and harvested with cell scraper for RNA or protein extraction. 
 
2.1.3.3 Cell density experiments 
TUBO cells were cultured in 3 x 10
4
 cells/cm
2
 for
 
high density and 5.2 x 10
3
 cells/cm
2 
for low 
density experiments. PT primary cells were cultured in 10.6 x 10
4
 cells/cm
2
 for
 
high density and 
2.2 x 10
3
 cells/cm
2 
for low density experiments. Criterions for human cell lines, was 100% 
confluency for high density and 20-30% confluency for low density.  For hormone treatment and 
comparisons between low and high density experiments, cells were incubated for 76 h and fresh 
hormone treatment as well as washing (PBS 2x) was done in 24 h intervals. I avoided changing 
medium and washing steps during incubation of cells when miRNA analyses were aim of 
experiment. In migration experiments 10
4
 cell/well were seeded (24 well migration chambers) for 
low density and 5 x 10
4  
cell/well for high density. For migration experiments (see section 2.1.5) 
low density was 1 x 10
4
 cells per well (24 well plate) and high density was 5 x 10
4
 cell per well. 
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For sphere culture experiments (see section 2.1.3.5) low density was 10
3
 cells/ml and high 
density was 10
4
 cell/ml. 
 
2.1.3.4  Primary cultures  
Mammary glands were collected either from BALB/c or Balb-NeuT in a 50 ml tube with PBS. 
The tissue was minced with surgical blades to small pieces and digested in basal medium 
(DMEM/F12, 100 nM HEPES buffer, 10 mg/ml insulin, 0.5% BSA and 0.5x 
penicillin/streptomycin) with 200 U/ml collagenase, 10 ng/ml EGF and 200 U/ml hyaluronidase. 
The tissue was digested for 1.5-2 hours at 37° C in the incubator mixed every 1 hour. The 
digested tissue was transferred to a 50 ml tube. After a first centrifugation step of 1 min at 80 g to 
isolate the organoids the supernatant was collected into a new 50 ml tube and centrifuged at 200 g 
for 3 min to isolate mammary epithelial cells (MEC) which are in the pellet fraction. The 
supernatant consist of fibroblastic cells. Cells were re-suspended in DMEM medium (for primary 
2D culturing) or basal medium (for sphere culturing), counted and cultured in appropriate 
densities in plates.  
2.1.3.5 Sphere culture 
The epithelial cells isolated after digestion were re-suspended in basal medium and subsequently 
cultured in a density of 5×10
4
 cells/ml in ultra- low adherent plates coated with 1.2% poly-
HEMA. Sphere culture medium was basal medium supplemented with 2% B27, 10 μg/ml EGF, 
10 ng/ml bFGF, 20 ng hIL6 (a gift of Dr. Stefan Rose-John Christian-Albrechts-University, Kiel, 
Germany), 4 ng/ml heparin, 5 ng/ml Gro-α, and in case of progesterone treatment with 10 nM 
progesterone. Sphere cultures were incubated at 37°C with 5% CO2 and 7% O2 and spheres were 
screened after 10 days. Size and number of mammospheres was inspected under light microscope 
and measured using Zeiss Axiovision software after 10-14 days.  
 
Sphere assay for cell lines was performed similarly. Cultured cells were tripsinized and 
dissociated to single cell suspension. Then, cells were re-suspended in basal medium and seeded 
in appropriate densities in poly-HEMA coated plates. Size and number of spheres was inspected 
under light microscope and measured using Zeiss Axiovision software after 3-5 days. 
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2.1.3.6 Preparation of poly-HEMA and low attachment plates 
To prepare coating solution, 2.4 g of poly-hydroxy-ethyl-methyl-acrylate (poly-HEMA) were 
added to 20 ml of 95% ethanol and put on a shaker at 65° C to dissolve for ~8 hours. To the 
above dissolved poly-HEMA, 80 ml of 95% ethanol was added and mixed. The prepared solution 
could be stored indefinitely at 4° C. Poly-HEMA solution was added to the cell culture dishes at a 
final density of 0.8 mg/cm (w/v). The plates were dried overnight in a sterile hood with lids 
slightly opened. The poly-HEMA-coated plates can be stored indefinitely until use at +4° C. 
 
2.1.3.7 Sphere counting 
Spheres were counted after 10-14 days for primary cells and 3-5 days for cell lines. Only spheres 
with size bigger than 50 µm were counted. Sphere counting for cell lines were done by screening 
whole plates in10X magnification of microscope. In case of primary cell culture when number of 
spheres increased to thousand or more (i.e. progesterone or Wnt4/Rankl treatment), each plate 
were centrifuged in 1000 g for 5 minutes. Sphere pellet was resuspended in 1 ml PBS and 20 µl 
of sphere suspension was taken while pipetting was processing by 1ml pipettor.  That was done in 
triplicates for each plate and the 20 µl sphere suspension were spread as one strip-line in the 
surface of one empty culturing plate. The average number of spheres in all strip-lines multiplied 
to factor 50 in order to estimate total number of spheres per plate.        
 
2.1.3.8  Conditioned medium preparation 
Cell media supernatant of confluent cultured cell has been collected in 50 ml tubes and 
centrifuged for 10 min at 1000xg to pellet cells and cell debris. The supernatant was sterile 
filtered through a 0.22 µm filter to remove any cells in the conditioned medium. The medium was 
used immediately or stored at -80° C until further use. Target cells for treatment were cultured 24 
hours before. 
 
2.1.3.9 Transwell assay 
Transwell insert with a microporous membrane of 0.4 µm were used to separate the upper and 
lower compartments. The microporous membrane allows only soluble factors to pass through 
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between the compartments. EL cells were cultured in the lower chamber and PT cells were 
cultured in the upper chamber. Both were cultured in a density of 10
6
 cells per well of 6 well 
plates (DMEM 10% FCS; Figure 7). 
 
 
 
 
 
Figure 7. Schematic representation of transwell assay experimental setup. 
2.1.4 Differentiation of mammosphere cells 
Chamber slides were coated with a layer of 100 % matrigel. Then freshly isolated and digested 
single cells from mammary glands or primary tumors were seeded on the top of solidified 
Matrigel (Figure 8). The differentiation condition was as previously described (Debnath et al., 
2003; Ghajar and Bissell, 2008). The formation of acini was monitored every 24 h for 4 weeks. 
The media was changed every 3 days. Additionally, a long time sphere culture was performed to 
evaluate differentiation. Spheres were kept in culture without passaging for 5 weeks but with 
adding fresh medium every week. The formation of acini like structures was used as criterion for 
differentiation. I recorded the time point when EL and PT cells formed acini structures upon 
control or progesterone treatment conditions. 
 
 
Figure 8. Schematic representation of differentiation assay experimental setup. 
 
2.1.5 Migration/Invasion assays 
2.1.5.1 3D Migration/Invasion assay  
Transwell inserts (Corning; cat no: 3422) with 8 µm pores were coated with 40% matrigel.  4x10
4
 
cells from cell lines and 10
5
 cells isolated from tissue or spheres were resuspended in FCS-free 
medium before seeding. Cells were then seeded in 200 µl of FCS-free medium (DMEM) on the 
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top of matrigel layer and FCS medium (DMEM) was added to the lower chamber (Figure 9). For 
additional treatments both upper and lower media were supplemented with progesterone (10 nM), 
Wnt4 (5 ng/ml) or Rankl (50 ng/ml). After 72 hours incubation of cells isolated from 
mammospheres or freshly digested tissues, inserts were removed and cells were fixed with 
methanol (-20
0
C for 10 min) and stained with trypan blue. Cells were counted from 3 fields (4x 
magnification) when visualized under the microscope.  
 
 
 
 
 
 
Figure 9. Schematic representation of migration/invasion assay experimental setup. 
2.1.5.2 Stem cell migration assay 
To evaluate stemness of migratory cells, we established new invasion-sphere formation assay 
where the cells were sandwiched between two layers of 40% matrigel in the upper chamber and 
the lower chamber was coated with poly-HEMA. Lower medium was mammosphere medium 
which has been described in sphere assay section (Figure 10). After 72 hours, inserts have been 
removed, fixed and stained with trypan blue for single cell migration analysis. 600 µl of fresh 
sphere medium was added to the lower chamber and cells incubated for 14 days until spheres 
were counted.  
 
 
 
 
 
Figure 10. Schematic representation of migration-Sphere formation assay experimental setup. 
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2.1.6  Proliferation assay 
Single cell suspensions were cultured in 96 well plates and proliferation was evaluated by XTT 
colorimetric assay kit (Roche; cat no: 11465015001) based on manufacturers instruction. Cell 
seeding concentration was 3000 cells/well which was done in 6 replications. The media were 
supplemented with investigated factors (see appropriate experiments) or hormones as well as 
vehicle and were changed every second day. 
 
2.1.7   Staining 
2.1.7.1 Haematoxylin and eosin staining  
Paraffin embedded tissue was cut into 5 µm sections onto poly-L-lysine-coated slide. Sections 
were dewaxed in Xylol for 10 min twice and rehydrated first in 100% ethanol for 3 min and then 
in 80% ethanol for 3 min. The sections were washed in PBS for 1 min thrice and incubated with 
hematoxylin for 45 sec. The slides were rinsed in tap water for a short duration and washed in tap 
water for 30 min in a glass cuvette. Eosin (0.1%) was added to the tissue sections and after 2 min 
they were washed with ddH2O for 1 min. The stained sections were dehydrated in 70% ethanol 
for 2 min, 100% ethanol for 2 min and finally in xylol for 15 min. Mounting gel was added to the 
tissue sections and a cover slip was placed carefully on the gel avoiding bubbles and were left to 
dry overnight. 
 
2.1.7.2 Bone marrow staining for DTC detection 
At least 10
6
 cells per mouse were stained to detect positive cells. Blocking solution (5% rabbit 
serum in 1x TBS) was added to the slides to rehydrate the cells and to block unspecific binding of 
antibodies to the cells. After 20 min the blocking solution was discarded and primary antibody 
against CK 8 and 18 (all antibodies and working concentrations are listed in section 2.2.6) was 
added and incubated for 60 min. The primary antibody was discarded and slides were washed 3 
times for 3 min in 1x TBS. Then slides were incubated with the secondary antibody for 25 min, 
and washed 3 times for 3 min in 1x TBS followed by incubation with ABC complex for 25 min. 
Finally, the development system of the BCIP/NBT for alkaline phosphatase enzymatic substrate 
was added for 10 min. The slides were washed 3 times for 3 min and screened for CK8/18 
positive cells. The positive cells were typically violet-to-black in color. TUBO, a tumor cell line 
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derived from a murine primary mammary tumor of Balb-NeuT which expresses CK8/18, was 
used as a positive control.  
 
2.1.7.3 Immunohistochemistry  
For PgR and Her2 immunohistochemistry of tissues, 5 µm sections of paraffin blocks were 
collected onto poly-L-lysine-coated slides. Samples were dewaxed by two 5-min washes in 
xylene and rehydrated with graded alcohol by 5-min washes and a final wash in water. A 
standard Tris-EDTA buffer and pressure cooking was the antigen retrieval procedure and then 
sections were blocked in 0.3% H2O2 in TBS and 10% normal goat serum. Sections were 
incubated for 1 hour with primary antibody and after washing secondary antibody (Vector lab 
PK4001 or PK5000) was added based on manufacturers suggested dilution (see section 2.2.6). 
After washing with PBS, sections were stained using the ABC detection system (Vector 
laboratory) according to the manufacturer’s instruction. Visualization was performed with 
chromogen reagent (Dako; cat no: 10046560) according to manufacture instructions. 
 
2.1.7.4   Immunofluorescence staining 
For staining of cells from monolayer cell culture, cells were seeded onto 24 well culture plates in 
appropriate density. After 72 hours incubation, cells were washed with PBS and fixed with 4% 
PFA for 10 minutes. Then, cells were permeabilized with 0.2% triton X100 followed by washing 
steps and blocking with 1% BSA, 5% serum of species of secondary antibody in PBS at room 
temperature  for 1 hour, followed by incubation with primary antibody (see 2.2.6) for 1 h at room 
temperature. Cells were then washed three times with PBS and incubated with labeled secondary 
antibody (Jackson ImmunoResearch Laboratory Inc) for 1 h at room temperature. For a nuclear 
counterstain, cells were incubated for 10 min with DAPI 0.5 µg/ml (Sigma). For the staining of 
spheres in differentiation experiments, mammospheres were picked and transferred to a 24 well 
cell culture plate and incubated for 8 h in sphere medium in order to fix them to the surface. The 
subsequent protocol was as for monolayer cell culture staining. For staining of cells attached to 
the inserts from migration experiments, inserts were used directly after migration (see migration 
section), for blocking step and IF staining as monolayer cell culture staining. Images were 
captured on an Axio Vert 200M microscopy (Carl Zeiss Microscopy).  
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2.1.8   PCR 
2.1.8.1 Quantitative PCR 
All mRNA extractions were performed by RNeasy kit (Qiagen) according to manufacturer’s 
instructions. For miRNA extraction miScript II RT Kit (Qiagen) was used. cDNA was generated 
using reverse transcriptase kits (Qiagen). Finally, 25 ng of cDNA was used for qPCR. 
Quantitative PCR was performed using a Light Cycler instrument (Roche) and Fast Start Master 
SYBR Green Kits (Roche). Data analysis was done using the RelQuant software (Roche) with a 
reference gene and a calibrator (reference) sample in every run. Mouse reference cDNA served as 
a positive control. Measurements that showed unspecific products in the melting curve analysis 
were discarded from further analysis. Expression levels are given relative to β-actin for gene 
expression analyses and RNU6 for miRNA analyses (for primers and their sequences see section 
2.2.5). All primers were synthesized by Eurofins MWG Operon Company.  
 
2.1.8.2 PCR 
End-point PCR for different genes (see section 2.2.5 for primers and sequences) was done 
according to table 1 and under the program listed in table 2.   
 
Table 1. Ingredient of a PCR reaction 
Volume  Reagent  
7,15 μl  Ultra-pure DEPC- water  
1 μl  PCR buffer + dNTP  
0,5 μl  Forward oligonucleotide (8 μM concentration)  
0,5 μl  Reverse oligonucleotide (8 μM concentration)  
0,25 μl  BSA  
0,1 μl  Taq DNA-polymerase  
0,5 μl  DNA  
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Table 2. PCR program 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.8.3  Agarose gel electrophoresis  
Amplified products of the specific PCR were separated with gel electrophoresis, on1.5% agarose 
in TBE buffer with ethidium-bromide (0,5 μg/ml). Samples were mixed with a loading dye and 
loaded in the gel. PCR amplicons were separated at 160 V for 45 min. 
 
2.1.9   Viral transduction  
2.1.9.1 Construction of the lentiviral/Retroviral particles 
The 293T cells were propagated in DMEM media supplemented with 10% FCS and L-glutamine. 
The transfection ability of the 293T cells depends on the culture conditions. Therefore, 6 x 10
6
 
cells were seeded in a 10 cm cell culture dishes 15h before the transfection. Transfection was 
performed once the cells reached 70% confluence. Transfection medium (DMEM; 10% FCS) 
containing 25 μM chloroquine was added 45 min before the start of transfection. Chloroquine’s 
function is to block plasmids degradation in the endosome/lysosome system which increases 
transfection rate (Ciftci and Levy, 2001; Erbacher et al., 1996). Half an hour to two hours after 
chloroquine addition the medium was replaced by transfection mixture. 
Temperature Time 
94 ⁰C 2:00 min 
58 ⁰C 0:30 min 
72 ⁰C 2:00 min 
94 ⁰C 0:15 min 
58 ⁰C 0:30 min 
72 ⁰C 0:20 min 
Repeat steps from step 4 to 6 (14 times) 
94 ⁰C 0:15 min 
58 ⁰C 0:30 min 
72 ⁰C 0:20 min 
Repeat steps from step 8 to 10 (24 times) 
72 ⁰C 2:00 min 
4 ⁰C ∞ 
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The composition of the transfection mixture was: 
 
For PgR-B (Lentiviral) particles: 
 
 5 μg pMD2G (envelope plasmid), 
 20 μg psPAX2 (packaging plasmid), 
 20 μg lentiviral plasmid (GeneCopeia; Cat no: Z5911) 
 
For Her2 (Retroviral) particles: 
 
 5 μg pCMV-VSV-G  (envelope plasmid from Addgene), 
 20 μg pUMVC3 (packaging plasmid from Addgene), 
 20 μg lentiviral plasmid (pLXSN-NNeu was obtained from Dr. Lisa Petti, Albany Medical 
Center, Albany, NY) (Petti and Ray, 2000), 
 
Then, water was added up to 250 μl, and finally 250 μl of 0.25 M CaCl2 solution was added (see 
transfection solution). This mixture was diluted into 2x HEBS buffer solution (see transfection 
solution). The final volume of transfection was 1 ml for one 10 cm plate. The transfection 
mixture was added drop wise to HEK-293T cells. The medium was replaced 6h after the 
transfection mixture was added. The addition of the transfection mixture is taken as the start point 
of the S2 work. Therefore, all work was performed according to the safety recommendation 
prescribed for the S2 work. The viral particles were collected 48h and 72h post transfection and 
stored at -80⁰C. 
2.1.9.2 Transfection Solutions  
CaCl2 0.5 M  
 
36.75 g CaCl2 2H2O,   
Add H2O (twice distilled / Millipore, additionally sterilized) up to 100 ml. 
Sterile filter and store at 4° C (3-6 months) or aliquot and store at -20° C for longer time.  
 
2x HeBS  
 
1.63 g NaCl  
0.074 g KCl  
32 
 
1 ml 1M HEPES buffer 
 0.021 g  Na2HPO4 
Add distilled H2O up to 90 ml 
PH 7.05 adjusted with NaOH (at RT)  
Fill up to 100 ml with H2O  
Sterile filter and store at 4° C (3-6 months) or aliquot and store at -20° C for longer time.  
After thawing to room temperature, pH was measured again  
 
Chloroquine  
 
25 mM stock solution in water (25µM final working concentration). 
 
2.1.9.3 Determination of virus titer 
Virus titer represents the number of the virus particles in 1 ml. Determination of the virus titer 
was performed using gradient treatment in target cell lines. Cells were propagated in a 12-well 
plate. The cells (4 x 10
4
 cells/well) were plated and propagated overnight at 37 °C. On the next 
day, medium was removed, cells were washed and virus diluted in 1:10, 1:100, 1:1000, 1:10000 
and added to the cells. After 24 hours, 10 µg/ml puromycin for lentiviral transduction and 1000 
µg/ml G418 was added for retro viral transduction. Titer of the produced virus (Transforming 
Units per milliliter =TU/mL) was determined by the following equation: 
Number of discrete colonies/ dilution factor= TU/mL 
The best dilution is the one which is less or equal to the number of seeded cells, because that will 
avoid multiplicity of integration (MOI) in target cells. 
 
2.1.9.4 The selective propagation of the transduced cells 
Lenti-/retroviral vectors used for the stabile integration and expression of the PgR-B/Her2 
contain genes for the puromycin (lentiviral particles for PgR-B) and neomycin (retroviral 
particles for Her2) resistance. Therefore, transduced cells have stable integrated and expressed 
gene for antibiotic resistance. Treatment of transduced cells with antibiotic depletes uninfected 
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cells. Positively transduced clones were expanded and screened for PgR and/or Her2 levels by 
western blot analysis and qPCR.  
 
2.1.1   Western blot analysis 
2.1.9.5 Protein extraction and quantification 
Protein was extracted from cell lines or fresh tissues using lysis buffer (RIPA buffer; Sigma) 
supplemented with protease inhibitors (protease cocktail; Thermo scientific). For homogenization 
of tissue samples, they were punched with a piston in liquid nitrogen to become powder and then 
subjected for RIPA digestion. RIPA digestion was done in shaker at 4 °C for 15-30 minutes. 
After centrifugation of digested cells/tissues, they were centrifuged and supernatant used for 
protein measurement and western blotting. Protein quantification was subjected for BCA protein 
assay kit (Thermo scientific) and their concentrations were equalized by adding appropriate RIPA 
buffer.   
2.1.9.6 Gel electrophoresis 
Quantified protein lysates were mixed with SDS loading dye and heated for 10 minutes at 95°C 
to denature protein structures. Then, 30 µg proteins were loaded on SDS-PAGE gels. The 
composition of used gels can be seen in tables 3 and schematic set up of gel electrophoresis is 
shown in figure 11. Gel chambers and electrophoresis power supply were from Biorad (See list of 
devices in 2.2.4 section). Gels were running in constant 40 V and every 15-30 minutes have been 
checked until the blue dye run out of lower edge of gel. Composition of running buffer can be 
seen in table 4. 
Table 3. Composition of stacking and resolving gels 
 
 
 
 
 
 
 
 
Resolving 
gel 6% 
H2O 6,7 ml 
3M Tris pH 9 1,3 ml 
Acrylamid 30 2,3 ml 
20 % SDS 50µl 
TEMED 10µl 
10% APS 50µl 
Stacking 
gel 
 
 H2O 2,6 ml 
1M Tris pH 6,8 420 µl 
Acrylamid 30 550 µl 
20 % SDS 17 µl 
TEMED 5 µl 
10% APS 33 µl 
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Figure 11. Schematic representation of the SDS PAGE setup. The upper part of gel is stacking and the lower is resolving gel. The stacking gel 
is needed to concentrate/pack all the proteins in one band, so that they will start migrating in the running gel all at the same time. The 
running gel allows separation of the proteins in the sample based on their molecular weight. Both side lanes were used for protein size 
marker which helps to predict the position of protein of interest. Upper and lower chambers were filled with running buffer (table 4) 
and proteins migrate from negative to positive pole.   
 
Table 4.  SDS loading dye composition 
 
 
 
 
 
 
2.1.9.7 Semi Dry Blotting 
Next, proteins have been transferred from gel onto a polyvinylidene difluoride membrane 
(Millipore, Billerica, MA, USA). That was semi dry method in which membrane coupled to gel 
and sandwiched between wet Whatmann paper papers. Composition of blotting buffer can be 
seen in table 5. Blotting was done at 20 V for 30 minutes. Then, membrane containing proteins 
were dried in air and strips (based on protein size marker roughly predicted that carry our protein 
of interest) have been cut.    
 
Table 5. Blotting buffer composition 
5 x blotting buffer (2L) 1x Blotting buffer 
125 mM Tris base (30,2 g /2 L) 200 ml 5 x buffer 
1920 mm glycine (144 g /2 L) 600 ml Millipore 
- - - - - - - - - - - - - -  200 ml methanol 
 
Running Buffer 10X 1X 
Glycine 288 g 28.8 g 
Tris base 60.4 g 6.04 g 
SDS 20 g SDS (200ml 10%SDS) 2 g 
ddH2O 1.8 l 1 l 
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2.1.9.8 Protein detection 
Blocking of membrane was done with 6% skim milk for 2 hours on shaker in room temperature 
and immunoblotting with the primary antibodies was done overnight at 4 °C (for antibody 
concentration see section 2.2.6). Washing was done 3 times and 5 minute each with TBST (see 
table 6 for composition). It was followed by incubation with the horseradish peroxidase-
conjugated secondary antibody for 30 minutes. The blots were visualized using substrate kit (GE 
Healthcare) and bands were visualized by Imagequant LAS 4000 (GE Healthcare). 
 
Table 6. TBST buffer composition 
TBS 10x (concentrated TBS) 
24.23 g Tris HCl 
80.06 g NaCl 
800 ml H2O (dissolve) 
make up to 1l by adding H2O 
set PH at 7.6 and 2ml Tween 20 was added for 1x buffer 
 
2.1.10 miRNA analyses and sequencing 
For exosomes isolation ultracentrifugation method was used as previously described (Thery et al., 
2006). Exosomes pellet was resuspended in fresh medium and used for T47D cell line treatments 
and PgR expression was checked in different time points. For miRNA sequencing we used 4x10
6
 
cells and exosomes were isolated from confluent TUBO cell line medium. The miRNA cloning 
and sequencing was done in the same way as described recently (Dueck et al., 2014).  Briefly, all 
pooled samples were run in a MiSeq sequencer (Illumina) for 80 cycles single end run. In this 
sequencing run MiSeq reagent kit Version 3 was used. Data analysis was done using in house 
written scripts. Sequences were mapped - without any mismatches allowed - against murine 
miRNAs listed in miRBase version 20 (June 2013; www.mirbase.org). The minimum length of 
reads was set to 18 nt. Annotated miRNA-reads were normalized as RPM-Values regarding the 
total number of mapped reads in the respective library. Mimic miRNA were ordered from 
Eurofins MWG Operon company and all sequences are in section 2.2.7. For miRNA transfection 
we used reverse transfection protocols recommended by RNAiMAX (Life Technology) 
instruction and 50 nm concentration of miRNA. 
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2.1.11  Analysis of Breast Cancer Patients: 
We analyzed data of 2239 patients from the Department of Oncology and Obstetrics, University 
of Tubingen. DCC status was assessed according to the Consensus protocol (Fehm et al., 2006), 
using the anti-cytokeratin antibody A45B/B3 and evaluating 2 x 10
6
 bone marrow cells. PgR 
expression of primary tumors was categorized into PgR staining scores 0-1 for absent expression; 
2-8 for intermediate expression and 9-12 for high expression. Her2 status of primary tumors was 
categorized into the staining score 0 for absence of Her2 staining (IHC negative); score 1 and 
score 2 without Her2 amplification (IHC positive) and into score 2 with Her2 amplification and 3 
(which is known to be caused by Her2 amplification; FISH positive). 
 
2.1.12   Bioinformatic and Statistical analysis  
Statistical analyses and estimation of variation within each group of data were performed using 
GraphPad Prism V6. For in vivo experiments, sample size was estimated using G*Power (version 
3). For each experiment, mouse numbers are given in the figures or the text. All in vitro and 
primary culture experiments were performed at least in triplicate and student’s t-test was applied 
for comparisons. For comparison of qPCR results of EL-signature between different groups, gene 
wise t-test p-values were combined using Stouffer's method. For all other experiments we applied 
the D’Agostino-Pearson omnibus normality test. When sample size was sufficiently large (n≥8) 
and were not distributed normally according to the D’Agostino-Pearson test (p≤0.05) we applied 
the Mann-Whitney test. A linear regression test (F-test for slopes) was used to compare 
proliferation curves and tumour growth. For comparing numbers between different groups we 
applied Fisher’s exact or if the sample numbers were at least 5 in each condition the chi-square 
test. All p values represent two tailed values. All p values and statistical tests are mentioned in the 
figures and legends.  Genomatix (version 2.0) (https://www.genomatix.de) was used for signaling 
pathway analysis and oPOSSUM (version 1) (http://opossum.cisreg.ca/oPOSSUM3/) for 
transcription factor binding site (TFBS) enrichment. For miRNA binding enrichment we used 
DIANALAB (http://diana.cslab.ece.ntua.gr/) and for the identification of target miRNAs for 
single target genes the miRANDA software (http://www.microrna.org/microrna/home.do) was 
used.  
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2.2 Materials 
 
2.2.1 Reagent 
Product Manufacturer Cat. Number 
2-Log DNA-Ladder 1kb  NEB N32005 
AB/AP-System  DAKO AK-5000 
AB/HRP-System  DAKO PK-4000 
AB-Serum  Bio-Rad 805315 
Acetic acid Merck, Darmstadt 100063 
Agarose  Sigma-Aldrich  A3038 
Aldostrone Sigma-Aldrich A9477-5mg 
Amonium per-sulfate Sigma-Aldrich A3678 
Ampicillin AppliChem GmbH, Darmstadt A0839 
B27  Invitrogen 17504-44 
BCIP/NBT  BioRad 1706432 
B-estradiol  Sigma-Aldrich E4389 
bFGF  Sigma-Aldrich F0291 
Bovine serum albumin (BSA), 20 mg/ml Roche 10711454001 
Bromphenol blue Sigma-Aldrich B3269 
BSA  Roche 1071145001 
Chloroform Sigma-Aldrich 25690 
Chloroquine Sigma-Aldrich C6628 
Cholera toxin Sigma-Aldrich C9903 
Collagenase Sigma-Aldrich C0130 
Collagenase Type I CellSystems biotech LS4196 
Cortisone Sigma-Aldrich C2755-1g 
DAB  DAKO K3468 
DAPI Roche, Penzberg 32670 
dATP, 100 mM GE Healthcare  27-1850-04 
dCTP, 100 mM GE Healthcare 27-1860-04 
DEPC-H2O  Invitrogen  750023 
dGTP, 100 mM GE Healthcare 27-1870-04 
Diluent C Sigma-Aldrich CGDIL-6x10 ml 
DMEM  Pan-Biotech P04-03500 
DMEM/F12  Pan-Biotech P04-41500 
EGF Sigma-Aldrich E9644 
Eosin  Sigma-Aldrich 54802 
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Ethanol absolute  J.T. Baker 8006 
Ethidium bromide (1 %)  Sigma-Aldrich E8751 
Eukitt (Mounting gel)  Sigma-Aldrich 03989-100ML  
Expand Long Template Enzyme Mix Roche 11 759 060 001 
FCS  PAN Biotech P30-3702  
Fetal bovine serum (FBS) Pan Biotech, Aidenbach P30-1506 
Formaldehyde Merck, Darmstadt 104003 
Formamide Merck, Darmstadt 344 205 
Formamide, deionized Sigma-Aldrich F9037 
Goat serum DAKO X0907 
GRO-α RnDsystems 275GR 
Halt Protease inhbitor Thermo scientific 1862209 
Hematoxylin Sigma-Aldrich MHS16 
Heparin Sigma-Aldrich H3149 
Hyaluronidase Type IV-S Sigma-Aldrich H4272 
Hybond ECL nitrocelelluse paper GE Healthcare RPN203E 
Hydrocortisone Sigma-Aldrich H0888-1gr 
Igepal  Sigma-Aldrich I3021-50ML 
Insulin Sigma-Aldrich I9278 
Isopropanol  Fluka 59300-2.5ML 
Levamasol Sigma-Aldrich L9756 
L-Glutamin (200 mM)  Pan-Biotech P04-80100 
Matrigel  BD Biosciences 356231 
Matrigel  growth factor reduced, phenol red free Corning 356231 
Methanol  VW 1.06009.2500  
Methyl cellulose Sigma-Aldrich M0512-100G 
Mouse serum  DAKO X0910 
MseI 50 U/µl  New England Biolabs R0525M 
Nomegestrol acetate (NOMAC)  Sigma-Aldrich SML0133-5MG 
OPA Plus  Amersham Biosciences,  27-0901-02 
Panscript Taq-Polymerase  PAN Biotec MB-30010250 
Paraformaldehyde VW 104005 
Penicillin/Streptomycin (10 U/µL)  Pan-Biotech P1-010 
Percoll  Amersham Biosciences 17089102 
PKH26  Sigma-Aldrich MINI26-1KT 
Polyhema  Sigma-Aldrich P3932 
Precision Plus Protein Dual Color standards Biorad 161-0374 
Progestrone Sigma-Aldrich P8783-5gr 
Protein Size Marker New England Biolabs P7702S 
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Proteinase K  Roche 3115828001 
RIPA Sigma-Aldrich R0278 
Rotipherase gel 30 (37:5:1) Roth 3029.2 
RPMI 1640  Pan-Biotech P05-17500 
SDS loading dye  RoTH K929.1 
Sodium citrate  Sigma-Aldrich 73894-100ML 
T4 DNA Ligase  Roche 10799009001 
TEMED Roth 2367.3 
Testostrone   Sigma-Aldrich T15000-1G 
Tween 20  Sigma-Aldrich P9416 
Xylol  Roth 9713.3 
RNAiMAX Life Technology 13778030 
Polygelatin string Ethicon, Germany  
 
 
2.2.2 Consumable 
Product Manufacturer Cat. Number 
Adhesion slides Roth   H8701 
Filter (0.22 µm) Roth   P666.1 
Syringe needles (26G) Braun  C7181 
Cell culture plates Schubert and Weiss, OMNILAB FALC351007 
Cell culture flasks Sarsted 831.810.302 
Glass slides Langenbrinc 03-0001 
6 well plates Greine 657160 
Reaction tubes 1,5 ml  CLN Gmb CLN-BÖT1.5 
Reaction tubes 0,2 ml Abgen AB-0337 
Transwell plates (10 cm, 0.4 µm pore) Cornin 3419 
6.5mm Transwell with 8.0µm Pore 
Polycarbonate Membrane Insert Corning 3422 
CaCl2 Sigma  C5080 
NaCl Sigma S7653 
Kcl Sigma P9541 
HEPES Sigma H7523 
Chloroquine   C6628 
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2.2.3 Kits 
Name of kit Manufacturer Cat. Number 
PKH26 general cell membrane labeling Sigma-Aldrich PKH26GL 
DAB-System  DAKO K3468 
ABC-HRP-System  Vector Laboratories PK-4000 
MTT Roche 11465007001 
RNeasy mini-kit Qiagen 74104 
Revers trascript Qiagen 205311 
Pierce BCA protein assay Thermo scientific 23227 
ECL  Detection kit for western blotting GE Healthcare RPN2109 
Plasmid purification Qiagen 12381 
DNA Gel Extraction Kit Qiagen 28706 
DNA extraction Mini Kit  Qiagen 51304 
 
2.2.4 Devices 
Device Company 
Axio Imager Z1 Fluorescence microscope Zeiss, Göttingen 
Balance Kern, Balingen 
BenchMark Ultra Ventana, USA 
Capillary holder for micromanipulation Eppendorf, Hamburg 
Cell culture incubator Heraeus, Hanau 
Cell culture incubator Heraeus, Hanau 
Cell culture laminar flow Heraeus, Hanau 
Centrifuge Heraeus, Hanau 
Centrifuge Eppendorf, Hamburg 
Centrifuge, tabletop Grant Bio, USA 
Centrifuge, tabletop Eppendorf, Hamburg 
Cytospine Centrifuge Hettich, USA 
DM RXA Fluorescence microscope Leica, USA 
Cauterizer Fine Science Tools, Hedelberg 
FACS Canto II BD Biosciences, USA 
Electrophoresis gel chamber Biostep, Jahnsdorf 
Photometer, GeneQuant II Pharmacia Biotech, USA 
Laser micro-dissection microscope P.A.L.M, Bernried 
19 LSR II flow cytometer BD Bioscience, USA 
Magnetic stirrer VELP Scientifica 
MJ Research Peltier Thermal Cycler PTC-200 Bio-Rad 
MJ Research Peltier Thermal Cycler Tetrad Bio-Rad 
Multipipette Stream Eppendorf, Hamburg 
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Neubauer- Cell counter Schubert und Weis, Munich 
Optical microscope Optech, Canada 
Pipette controller Brand, Wertheim 
pH-meter Eutech Instruments, The Netherlands 
Pipettes (2 µl, 20  µl, 200  µl, 1000 µl) Eppendorf, Hamburg 
Power supply for gel chamber electrophoresis MRC, Israel 
Pump KNF, Freiburg 
StuartTM Scientific roller mixer Stuart Scientific, UK 
Thermo mixer Eppendorf, Hamburg 
UV illuminator Intas, Gottingen 
Vortex mixers VELP Scientifica, Italy 
Water bath Memmert, Schwabach 
Trans Blot SD cells Bio-Rad 
Mini-PROTEAN Tetra Cell Bio-Rad 
Cell culture incubator Heraeus  
Flourescence microscope Leica  
Heat block thermo mixer 5436 Eppendorf 
Inverted microscope Leica  
Refrigerated centrifuge Eppendorf  
Micromanipulator Microinjector 5242, Eppendorf 
MJResearch  Peltier Thermal Cycler PTC-200 Bio-Rad 
Voltmeter EPS 200 Pharmacia Biotech 
UV-screen  INTAS 
Video camera  INTAS 
Water bath Memmert 
Centrifuge  Eppendorf  
Cytospin centrifuge Hettich  
Dissection tools for murine surgery Heiland 
Imagequant LAS 4000 GE Healthcare 
Emax microplate reader  Molecular devices, LLC, US 
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2.2.5 Primers 
Gene  5' Primer 3' Primer 
AHNAK GTCTTTGTTCAGGAGGTG                CCCATGGTATTCAGCAAC  
Nfatc3 GGAGCAAACCAAAGCCTG     CTCGGCTACCTTCAGTTTC 
Stac3 GATTCTTCCCTCCAAACTTC          TAACCACCAGCTTCATCTC 
Zc3hav1 TTCTTCCACTCCTGTCCC                         TTCTGCTCCACATCCTTC 
Baz2a AGTCTCTGGTAGTGGTGATG        TGCTTCATTCTCTTCCCAC 
Nr3c2 CTTTCCGCCTGTCAATGC             TCATCTCCACACACCAAGCAG 
Zfp780b TGGATGCTACTCAGAAGGTC      CCTGTCTGTTTCTTCCTTCA 
Nr3c1  CAAGGGTCTGGAGAGGACAA TACAGCTTCCACACGTCAGC 
B.actin  GTGACAGCATTGCTTCTGTG TCTCAAGTCAGTGTACAGGC 
Wint4  GCCATCGAGGAGTGCCAATAC GCCACACCTGCTGAAGAGATG 
PgR A&B  AAGCCAGTTTGAAGAGATG ATTCAAGCAGTACAGGTGG 
PgR B  AAAGGATCCGCAGGTTCTC GGCGAGACTACAGACGACAC 
Esr1(α)  CCTCCCGCCTTCTACAGGT CACACGGCACAGTAGCGAG 
AR  GAACTACATCAAGGAACTCG TATGGGACTTGATTAGCAG 
Esr2 (β)  TCTCTTCCCAGCAGCAGTC GCATTCAGCATCTCCAGC 
RANKL  CCTCACCATCAATGCTGC TACGCTTCCCGATGTTTC 
  Human Primers   
Gene  5' Primer 3' Primer 
PgR A&B  CCAGCCAGAGCCCACAATAC GTTGTGCTGCCCTTCCATTG 
B.actin  TGGACATCCGCAAAGACCTG GGGTGTAACGCAACTAAGTCAT 
ER-α TTGGCCAGTACCAATGACAA GGCAGCTCTTCCTCCTGTTT 
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2.2.6 Antibodies 
Name of antibody 
Cat. 
Number Manufacture Working Concentration 
β-actin antibody A5441-.5ML Sigma-Aldrich 1/20,000 for WB 
PR (C-20) sc-539 santa cruz Biotech 1/100 
ER-α (MC-20) sc-542 santa cruz Biotech 1/100 for WB 
AR (N-20) sc-816 santa cruz Biotech 1/100 for WB 
ER-β (H-150) sc-8974 santa cruz Biotech 1/100 for WB 
NR3C2 (GR (p-20)) sc1002 santa cruz Biotech 1/100 for WB 
NR3C1 ( GR ( M-20) )  sc-1004 santa cruz Biotech 1/100 for WB 
Sca1  130093222 militeny biotech 1/500 for WB 
EpCAM-Alex647 (clone: G8.8) 118212 Biolegend 1/200 for WB 
c-erbB-2 (Her2 (clone: PK)) for WB and 
IHC DLN-12083 Dianova 1/500 for WB 
Keratins K8/K18 (GP11) GP11 Progen Biotechnik 1/200 for IHC 
Rabbit IGg  Sc-2027 santa cruz Biotech 1/200 for IHC 
Goat anti Rabbit-AF 488 A11017 Life Technologies 1/200 for IF 
Goat anti mouse-Cy3 115-166-003 
Jackson 
ImmunoResearch 1/200 
Goat anti Guinea pig-Cy3 106-165-003 
Jackson 
ImmunoResearch 1/200 
Guinea Pig IgG CR4 Sino Biologival Inc. 1/100 
Anti mouse HRP NA931 GE Healthcare 1/2000 for WB 
Anti Rabbit HRP NA934 GE Healthcare 1/2000 for WB 
Anti Goat HRP sc-2020 santa cruz Biotech 1/2000 for WB 
 
2.2.7 miRNAs 
miRNA Ref Sequence mimic miRNA  Mimic Sequence 
mmu-miR-30a-5p uguaaacauccucgacuggaag mmu-miR-30a-5p F TGTAAACATCCTCGACTGGAAG 
  
mmu-miR-30a-5p R CTTCCAGTCGAGGATGTTTACA 
mmu-miR-30a-3p cuuucagucggauguuugcagc mmu-miR-30a-3p F CTTTCAGTCGGATGTTTGCAGC 
    mmu-miR-30a-3p R GCTGCAAACATCCGACTGAAAG 
mmu-miR-21a-5p uagcuuaucagacugauguuga mmu-miR-21a-5p F TAGCTTATCAGACTGATGTTGA 
  
mmu-miR-21a-5p R TCAACATCAGTCTGATAAGCTA 
mmu-miR-25-3p cauugcacuugucucggucuga mmu-miR-25-3p F CATTGCACTTGTCTCGGTCTGA 
    mmu-miR-25-3p R TCAGACCGAGACAAGTGCAATG 
mmu-miR-92a-3p uauugcacuugucccggccug mmu-miR-92a-3p F TATTGCACTTGTCCCGGCCTG 
  
mmu-miR-92a-3p R CAGGCCGGGACAAGTGCAATA 
mmu-miR-340-5p uuauaaagcaaugagacugauu mmu-miR-340-5p-F TTATAAAGCAATGAGACTGATT 
    mmu-miR-340-5p-R AATCAGTCTCATTGCTTTATAA 
mmu-miR-9-5p ucuuugguuaucuagcuguauga mmu-miR-9-5p-F TCTTTGGTTATCTAGCTGTATGA 
  
mmu-miR-9-5p-R TCATACAGCTAGATAACCAAAGA 
mmu-miR-92a-1-5p agguugggauuugucgcaaugcu mmu-miR-92a-1-5p F AGGTTGGGATTTGTCGCAATGCT 
    mmu-miR-92a-1-5p R  AGCATTGCGACAAATCCCAACCT 
mmu-miR-21a-3p caacagcagucgaugggcuguc mmu-miR-21a-3p F CAACAGCAGTCGATGGGCTGTC 
    mmu-miR-21a-3p R GACAGCCCATCGACTGCTGTTG 
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2.2.8 Cell lines 
Cell line Species Origion Medium 
TUBO Mouse Breast cancer A gift from Dr. Guido 
Forni , Department of Clinical and 
biological science, university of 
Turin, Italy 
DMEM+20% FCS, 2mM L-Glutamat, 
1%P/S 
MM3MG Mouse Mouse Mammary normal epithelial 
cells from BALB/c background, 
ATCC: CRL-6376 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S 
MM3MG-Her2 Mouse Normal Mammary epithelial cell line 
transduced with wild type Rat Her2 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S + G418 (500 µg/ml) 
SKBR3 Human mammary gland/breast; derived from 
metastatic site: pleural effusion, 
ATCC® HTB-30™ 
RPMI 1640 + 10% FCS, 2mM L-
Glutamat, 1% P/S + 1mM Napuruvat 
MCF10A Human Normal Mammary epithelial cell 
line, ATCC® CRL-10317™  
DMEM/ F12, 1% pen/Strep, 5% horse 
Serum, 20 ng/mL EGF, 0,5 µg/mL 
Hydrocortisone, 0,1 µg/mL cholera 
Toxin, 10 µg/mL insulin 
4T1 Mouse Tumorgenic cell line from 
spontaneous mammary tumors 
derived from BBALB/c. (A gift from 
Dr. Fred Miller, Michigan Cancer 
Foundation, Detroit USA) 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S 
MM3MG-PgR Mouse Normal Mammary epithelial cell line 
transduced with wild type human 
PgR B 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S + Puromycin (10 µg/ml) 
T47D Human mammary gland; derived from 
metastatic site: pleural effusion 
ATCC® HTB-133™ 
RPMI 1640 + 10% FCS, 2mM L-
Glutamat, 1% P/S 
MDA231 Human mammary gland/breast; derived from 
metastatic site: pleural effusion, 
ATCC® HTB-26™ 
RPMI 1640 + 10% FCS, 2mM L-
Glutamat, 1% P/S 
BT474 Human mammary gland; breast/duct 
ATCC® HTB-20™ 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S 
MCF7 Human mammary gland, breast; derived 
from metastatic site: pleural effusion, 
ATCC® HTB-22™ 
RPMI 1640 + 10% FCS, 2mM L-
Glutamat, 1% P/S + 1mM Napuruvat 
MDA361 Human mammary gland/breast; derived from 
metastatic site: pleural effusion, 
ATCC® HTB-26™ 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S 
HCC 1569 Human mammary gland; breast, 
ATCC® CRL-2330™ 
RPMI 1640 + 10% FCS, 2mM L-
Glutamat, 1% P/S 
Cama Human mammary gland/breast; derived from 
metastatic site: pleural effusion, 
ATCC® HTB-21™ 
RPMI 1640 + 10% FCS, 2mM L-
Glutamat, 1% P/S 
HS578T Human mammary gland/breast, 
ATCC® HTB-126™ 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S 
66cl4 Mouse Tumorgenic cell line from 
spontaneous mammary tumors 
derived from BBALB/c. (A gift from 
Dr. Fred Miller, Michigan Cancer 
Foundation, Detroit USA) 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S 
67NR Mouse Tumorgenic cell line from 
spontaneous mammary tumors 
derived from BBALB/c. (A gift from 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S 
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Dr. Fred Miller, Michigan Cancer 
Foundation, Detroit USA) 
MDA-MB 175 Human mammary gland; breast/duct; derived 
from metastatic site: pleural effusion, 
ATCC
®
 HTB-25
™
 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S 
ZR751  
Human 
mammary gland; breast/duct; derived 
from metastatic site: pleural effusion, 
ATCC
®
 HTB-132
™
 
RPMI 1640 + 10% FCS, 2mM L-
Glutamat, 1% P/S 
Htert-HME Human Normal Mammary epithelial cell 
line, ATCC® CRL-10317™ 
DMEM/ F12, 1% pen/Strep, 5% horse 
Serum, 20 ng/mL EGF, 0,5 µg/mL 
Hydrocortisone, 0,1 µg/mL cholera 
Toxin, 10 µg/mL insulin 
BT549 Human mammary gland; breast/duct; derived 
from metastatic site: pleural effusion, 
ATCC
®
 HTB-122 
RPMI 1640 + 10% FCS, 2mM L-
Glutamat, 1% P/S 
HCC1806 Human mammary gland; breast/duct; derived 
from metastatic site: pleural effusion, 
ATCC
®
 HTB-132
™
 
RPMI 1640 + 10% FCS, 2mM L-
Glutamat, 1% P/S 
HCC1937 Human mammary gland; breast/duct; derived 
from metastatic site: pleural effusion, 
ATCC
®
 HTB-2336
™
 
RPMI 1640 + 10% FCS, 2mM L-
Glutamat, 1% P/S 
MDA231 Human mammary gland; breast/duct; derived 
from metastatic site: pleural effusion, 
ATCC
®
 HTB-26
™
 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S 
MDA468 Human mammary gland; breast/duct; derived 
from metastatic site: pleural effusion, 
ATCC
®
 HTB-132
™
 
 
DMEM+10% FCS, 2mM L-Glutamat, 
1%P/S 
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2.1.2 Special cell culturing media 
Medium Composition Final conc 
Basal medium 
500 ml DMEM/F12   
5 ml HEPES buffer 1 M 10 mM 
5 mlPen/Strep 100 unit/ml 1x 
BSA 0.50% 
500 µl Insulin 10μg/μl 10 µg/ml 
Sphere medium  
48.8 ml basal medium   
1 ml B27  50X 1x 
50 µl EGF 10 ng/μl 10 ng/ml 
50 µl heparin 4 ng/μl 4 µg/ml 
20 µl bFGF 25 ng/μl 10 ng/ml 
25 µl GRO-α 10 ng/ml 5 ng/ml 
50 µl HIL-6  20 ng/μl 20 ng/ml 
Differentiation Medium 
25 ml Hams/F12   
1.25 ml FCS 5% 
25 μl Insulin 10 mg/ml  10 µg/ml 
50 μl EGF 10 µg/ml  20 ng/ml 
125 μl Hydrocortisone 0.1 mg/ml  0.5 µg/ml 
250 μl Cholera Toxin 10 µg/ml  100 ng/ml 
Digestion medium 
10 ml Basal medium   
100 μl hyaluronidase 10 mg/ml 100 U/ml 
100 μl collagenase 33 µg/ml  300 U/ml 
10 µl EGF 10 ng/μl 10 ng/ml 
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2.2 Abbreviation  
 
bp  Base pair 
BCIP  
5-Bromo-4-chloroindol-3-ol dihydrogen phosphate ester 
mono-p-toluidinium salt 
BM Bone marrow 
BSA  Bovine serum albumin 
bFGF Basic fibroblast growth factor 
cDNA  Complementary deoxyribonucleic acid 
CGH  comparative genomic hybridization 
CM Conditioned medium 
CK  Cytokeratin 
CSC Cancer stem cell 
DTC Disseminated Tumor cell 
DCC Disseminated cancer cell 
ddH2O  Deionized distilled water 
DNA  Deoxyribonucleic acid 
DMSO Dimethyl sulphoxide 
EGF Epidermal growth factor 
EpCAM Epithelial cell adhesion molecule 
FITC  Fluorescein isothiocyanate 
GRO-α Growth related oncogene-alpha 
HE  Haematoxylin-Eosin 
ICC  Immunocytochemistry 
IgG  Immunoglobulin G  
IHC  Immunohistochemistry 
HIL-6 Hyper-interleukin-6 
MEC Mammary epithelial cells 
MMTV  Mouse-mammary tumor virus 
MRD  Minimal residual disease 
PBS  Phosphate buffer saline 
PCR  Polymerase chain reaction 
PFA  Para-formaldehyde 
RT  Room temperature 
PR progesterone receptor (Protein) 
PgR progesterone receptor (Gene) 
ESR1/ER-α Estrogen receptor alpha 
ESR2/ER-β Estrogen receptor Beta 
Her2/Erbb2 erb-b2 receptor tyrosine kinase 2 
Sca-1 Stem cell antigen-1 
SDF-1 Stromal derived factor-1 
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TBM  Tumor bone marrow  
TBS  Tris buffer saline 
TMEC Tumor mammary epithelial cells 
TW Transwell 
UV  Ultra violet 
WT, wt Wild type 
EL Early lesion 
PT Primary tumor 
Met Metastasis 
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3 Results 
 
3.1 Cancer cell dissemination starts at early stages in Balb-NeuT model  
In Balb-NeuT mice activation of transgene starts at week 4 when menstrual cycles of mice starts 
and secreted progesterone activates MMTV promoter (Figure 12). From our previous works, we 
could detect disseminated cancer cells (DCC) shortly after activation of the Her2-transgene at 
puberty, i.e. between week 4 and 9. At this time point, lesions represent the morphology of 
Atypical Ductal Hyperplasia (Figure 12).  
 
 
 
Figure 12. Time course of mammary tumor development in Balb-NeuT mice. From the 4th week of life, cells in the not yet completely formed 
ducts of the mammary glands express the protein product of Neu-T oncogene. From 7th to 12th week of life, expanding side buds give rise to 
atypical hyperplasia and from week 15th carcinoma in situ can be detected. These lesions grow to become invasive and palpable through the 
skin around the 19th week of life, and occupy the bulk of the subcutaneous fibro-adipose tissue from the armpits down to the sites of the two 
sets of five mammary glands on each side of the groin. Lung metastases are evident from the 27th week onwards.  
 
To analyze seeding rate of cancer cells over the course of tumor development in this 
model, we analyzed number of DCCs in the bone marrow of mice. The number of seeded cancer 
cells were constant over the full observation period until mice had to be dissected (Hüsemann et 
al., 2008). Thus we hypothesize that increase in the number of cancer cells, by tumor growth, 
does not increase number of dissemination. In order to test that we measured gland or tumour 
areas from 270 mammary glands or tumours of 27 mice at different time points of Balb-NeuT 
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model. The tumour area of mammary glands without palpable (that is, not measurable by a 
caliper) tumours was set to 0.1 mm2 (that is, assuming a diameter of 350 μm of a total, circular 
hyperplastic lesion within a mammary gland) for lesions from 4–9-week-old mice and 0.4 mm2 
for 11-week-old mice. The adjustment for 11-week-old mice was based on a microscopic 
evaluation showing an about 4-fold increase in hyperplastic lesions. Dissemination to the bone 
marrow was determined by the number of cytokeratin-positive cells per 10
6
 bone-marrow cells. 
We plotted the tumor cell seeding relative to the total tumor area as a measure of cell numbers at 
risk to disseminate and found it to be maximal at early stages and to decline as the primary 
tumors grew (Figure 13). This is the time point that mostly we see ADH lesions (Figure 12), but 
it is difficult to surly claim no DCIS exist at this time point. Therefore, we use early lesions (EL) 
hereafter in the text to reflect all possible lesions at this time point.  
The higher potency of dissemination at the EL time point drove our interests to disclose 
dissemination mechanism in these early lesions and study differences with late dissemination 
from advanced lesions.  
 
Figure 13.  Dissemination over tumor area. Primary tumor growth and tumor cell dissemination to the bone marrow (BM) in Balb-NeuT mice 
over the time (Y-axis: displays the number of detected DCCs per 106 BM cells divided by the total tumor area in mm2). Cancer cells 
were identified by anti-CK staining in bone marrow. The number of mice used per data point is written below the graph. 
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3.2 Progesterone and Her2 signaling regulate gene expression program of 
early lesions 
3.2.1 Gene expression analyses revealed an exclusive expression profile for early 
lesions 
In order to study early dissemination program, we compared expression program of early lesions, 
primary tumors, lung metastases of Balb-NeuT and normal mammary glands of BALB/c mice 
using microarray gene expression analyses. Laser microdissection was done and epithelial layers 
were dissected out from ductal structure or masses of tumor and metastasis. All samples, numbers 
and time points of sample collection are shown in table 7.  
 
Table 7. Samples used for gene expression analyses 
 
 
First, a differentially expression profile has been generated for early lesions compared to 
each of the other stages (Figure 14; microarray analyses was done by Matthias Maneck from 
Computational diagnostics group, Institute of functional genomics,  University of Regensburg). 
Then we cross-compared these three profiles and generated a gene expression profile unique to 
EL comprising 1278 gene transcripts. Next, this gene list was shortened to 300 genes by focusing 
on genes highly conserved between mouse and human (Supplementary Data 1). The conservation 
criterion was similarity in the regulatory sequences in both 3’ and 5’ of coding sequences 
between human and mouse. We checked if same miRNAs and transcription factors regulate these 
genes to be considered as conserved gene.  
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Figure 14. Microarray heatmaps. Heatmaps of genes differentially expressed between sample types (wt BALB/c non-transgenic mammary 
glands (normal, N1-10); Balb-NeuT Early lesions (EL, A1-7); Balb-NeuT primary tumors (PT, P1-19); lung metastases (Met, M1-7); 
yellow: strong expression; blue: low expression). This figure was generated by  Matthias Maneck from Institute of functional genomics, 
University of Regensburg.  
 
The gene list was further scrutinized for transcription factors (using oPOSSUM software 
version 1), and signaling pathway enrichment (Genomatix software version 2). The transcription 
binding enrichment showed that nuclear receptors family were prominent in the suggested list 
and interestingly, three members of steroid hormones including ESR, AR and NR3C1 were 
among them (Table 8). 
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Table 8. oPOSSUM TF binding enrichment and role of nuclear receptors. A short list of genes specifically expressed in EL samples (300 
genes, supplementary Data 1) was loaded into the oPOSSUM web based software (version 1). The 'TF class' column in this table indicates 
nuclear receptors as the main regulators of this profile. The 'Target gene hits' column indicates the number of genes from the 300 gene list 
which can be regulated by that specific transcription factor that is listed in the “TF binds to differentially expression profile” column. The 
'Target gene non–hits' represents the number of genes from 300 gene-list that cannot be regulated by that specific transcription factor that is 
listed in the 'TF binds to differentially expression profile' column. The 'Target TFBS hits' represents total number of binding sites on the 
whole number of genes in the 'Target gene hits' column. Numbers of target TFBS hit are higher than target gene hits because one 
transcription factor can bind several times to a gene. 
 
 
 
Similar results were obtained from the signaling pathways analyses. Steroid hormone 
receptors were among transcription factor regulators for all signaling pathways suggested by 
Genomatix software (Table 9). These analyses suggested steroid nuclear receptors and their 
regulated pathways as main candidate regulators of the EL-specific expression profile. 
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Table 9. Genomatix analyses and role of steroid hormone receptors. A shortlist of genes specifically expressed in EL samples (300 genes, 
supplementary Data 1) loaded into the Genomatix software (v2.0) to identify dominant signaling pathways or networks, which regulate these 
genes. Five different sub-tables were generated based on different criteria as provided in the heading of each table. The p-value indicates 
enrichment of the EL list in specific pathways or networks. The column entitled “number of involved genes” displays the number of genes 
from the expression profile of EL, which are involved in that particular signaling pathway or network. The rightmost five columns of each 
table display hormone nuclear receptors involved in that pathway or network. The (+) sign shows the involvement of steroid hormone 
receptors in the regulation of that given signaling pathway. Note that the progesterone receptor is not showing up in any of pathways 
possibly due to lacking information used by software or its indirect role acting via its paracrine factors. 
5 top ranking canonical signal transduction pathways 
  p value 
Number of 
involved  
genes 
ER
-α
 
ER
-β
 
P
gR
 
N
r3
C
1 
N
r3
c2
 
A
R
 
MAP kinase 3.63 e-6 19       +     
FOXA2&A3 Network 7.13E-06 18       + + + 
SMAD2&3 signaling 1.47E-05 20 +     + + + 
P38 MAPK 4.71E-05 16 +     + +   
TGFBR 
 
1.54E-04 12 +       + 
+ 
 
5 top ranking biological process networks (Gene ontology) 
  p value 
Number of 
involved  
genes 
ER
-α
 
ER
-β
 
P
gR
 
N
r3
C
1 
N
r3
c2
 
A
R
 
Transcription from RNA pol II 
promoter 
1.57E-19 67 + +   + + + 
Positive regulation of 
transcription, DNA dependent 
8.20E-19 56 +       + + 
Regulation of transcription 
from RNA pol II complex 
1.26E-18 60 +       + + 
Positive regulation of RNA 
metabolic process 
1.02E-17 56 +       + + 
Positive regulation of gene 
expression 
 
1.97E-17 56 +       + + 
5 top ranking signal transduction pathways (literature mining) 
  p value 
Number 
of 
involved  
genes 
ER
-α
 
ER
-β
 
P
gR
 
N
r3
C
1 
N
r3
c2
 
A
R
 
Developmental 1.44E-05 22         +   
CEBP beta 1.44E-05 18 +       + + 
Histone deacetylase 2.72E-05 19 +       + + 
Differentiation 6.33E-05 26 +       +   
Nuclear receptor subfamily 7.03E-05 14 +     + + + 
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5 top ranking cellular component networks (Gene ontology) 
  p value 
Number of 
involved  
genes 
ER
-α
 
ER
-β
 
P
gR
 
N
r3
C
1 
N
r3
c2
 
A
R
 
Nucleoplasm 1.07E-11 56 + +   + + + 
Transcription factor complex 2.18E-10 22 + +   + + + 
Nucleus 
 
2.38E-10 135 + +   + + + 
Nuclear lumen 
 
4.38E-10 87 + +   + + + 
Nuclear part 
 
5.27E-10 74 + +   + + + 
5 top ranking molecular function networks (Gene ontology) 
  p value 
Number of 
involved  
genes 
ER
-α
 
ER
-β
 
P
gR
 
N
r3
C
1 
N
r3
c2
 
A
R
 
Sequence specific DNA binding 
transcription factor activity 
 
6.16E-31 71 + +   + + + 
Nucleic acid binding transcription 
factor activity 
 
6.59E-31 71 + +   + + + 
Sequence specific DNA binding 
 
1.17E-27 57 + +   + + + 
Sequence specific DNA binding 
RNA pol II transcription  
 
9.28E-23 32 + +   + + + 
Regulatory region DNA binding 
 
 
1.53E-22 37 + +   + + + 
 
 
Next, we checked the expression of all steroid hormone receptors in samples which used 
for microarray experiments (samples in Table 7). Our qPCR results showed all of them, except of 
ERα, were up-regulated in EL samples compared to Mets and PTs (Figure 15), which underlined 
obtained results of bioinformatics analyses (Tables 8 and 9). 
 
 
Figure 15. Quantitative PCR for mRNA expression of steroid hormone receptors in the microarray analyzed samples.  Quantitative PCR 
for mRNA expression of all steroid hormone receptors in samples of EL, early lesions; PT, advanced primary tumor; Met, lung 
metastasis). All steroid hormone receptors except of ER-α are upregulated in EL samples compared to PTs and Mets. Samples are 
shown in Table 7 and are the same which used for gene expression analyses in Fig 14.  
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3.2.2 Progesterone as regulator of EL gene expression profile 
To test whether steroid hormones induce the expression of genes characteristic for EL, we 
performed in vitro stimulation of mammary cells by steroid hormones. To monitor EL signature 
activation, five up-regulated genes in EL from microarray analyses were selected and used as 
surrogate markers of signature activation. Therefore, we used Nr3c1 as it had the highest number 
of target genes from the differentially expressed gene list (Table 8) and Nr3c2 that was the main 
one involved in governing pathways (Table 9). AHNAK, Baz2a and Nfatc3 were selected from 
the highly upregulated profile (supplementary Data 1). All surrogate markers comprising 
AHNAK, Baz2a, Nfatc3, Nr3c1 and Nr3c2, were first confirmed by qPCR for their induced 
expression in EL (Figure 16). The qPCR primers were designed between exons close to the 3’ 
UTR of genes ant tried to cover all possible isoforms of target gene. All primers were tested for 
their efficiency and specificity of amplification. The specificity of amplification was checked by 
a single melting curve in the end of qPCR. The efficiency of each primer was checked by the 
efficiency calculator program of light cycler software. 
 
 
Figure 16. Early lesion signature. Five genes up-regulated genes in the EL samples were selected as EL surrogate signature (Fold change of each 
gene for EL over average expression of PTs and metastases). Samples are shown in Table 7 and are the same which used for gene 
expression analyses in Fig 14.  
 
Then, primary cultures derived from mammary glands of 7-9 week old Balb-NeuT mice 
were exposed to all steroid hormones including estrogen, progesterone, aldosterone, cortisol, and 
testosterone. All mammary glands of mouse were pooled (three mice were used; see method 
section for primary culture) and cells were dissociated mechanically and enzymatically. 
Mammary epithelial cells were sorted by density centrifugation and cultured in the routine cell 
culture conditions. Hormones were added in different concentrations comprising 1, 10 and 100 
nM. The experiment lasted 75 hours and fresh media plus fresh hormones were added every 24 
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hours. At the harvesting day, cells were treated with fresh media and hormones and harvested 
after 3 hours. After, RNA extraction (three samples for each condition) and c-DNA synthesize, 
qPCR was done (technical duplicate or triplicate per sample) to evaluate changes in the 
expression of genes of the EL signature in the treated samples compared to controls. Among all 
tested hormones, progesterone was the only steroid hormone that generated the EL surrogate 
signature constantly over different applied concentrations (Figure 17).  
 
Figure 17. Hormone treatment of EL primary culture and qPCR evaluation of EL-signature. Hormone responsiveness of digested fresh 
tissue of 7-9 week old Balb-NeuT samples. Primary cultures (2.6 x 104 cells/cm2) were treated with progesterone (P), estrogen (E), 
aldosterone (A), cortisol (C), and testosterone (T) in different concentrations (1, 10, and 100 nM) or vehicle (ethanol; untreated) for 75 
hours. Only progesterone could induce expression of the complete EL signature. All p-values, Student’s t-test and Stouffer’s combined 
probability test; all error bars correspond to standard deviation (Mean ±SD).
 
After confirmation that progesterone induced the surrogate EL-signature, we next wanted 
to check if this induction effect is dependent on age and strain of mice (NeuT or wild type strain; 
3 mice per condition pooled and three c-DNA samples were derived; qPCRs were done in 
duplicate or triplicate technical replication; see method section for sample preparation). 
Therefore, we compared hormone responsiveness of EL and PT cells as well as normal mammary 
epithelial cells from mice having the same age as mice with EL (week 9). Interestingly, only EL 
cells of 9-week old Balb-NeuT mice, but not wild type mammary cells or PT cells, were 
responding to treatment with up-regulation of the surrogate genes (Figure 18).  
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Figure 18. Hormone treatment of primary cultures from different tissues and qPCR evaluation of EL-signature. Progesterone induction of 
the EL signature (10 nm vs. ethanol vehicle) only in mammary cells from young transgenic mice. All p-values, Student’s t-test and
Stouffer’s combined probability test; all error bars correspond to standard deviation (Mean ±SD). 
 
These results suggested that response to progesterone is dependent on the expression of 
Her2 (only Balb-NeuT was responding) and may also be a stage-specific program (only EL was 
responding). To test this hypothesis, immunohistochemistry was done for progesterone receptor 
(PgR) and Her2 expression on the three tissue types. Early lesions showed the highest 
coincidence between PgR (strong expression) and Her2 (moderate expression) stained cells 
(Figure 19). Primary tumors completely lost PgR expression which explained why progesterone 
treatment could not induce the signature in these cells. 
 
 
Figure 19. PgR and Her2 staining in tissues. Immunohistochemistry of PgR (nuclear; brown; upper panel) and Her2 (membrane; brown; lower 
panel; scale bar = 100 µm).  Note that highest overlap between Her2 and PgR expression is in the EL stage. There is low expression of 
Her2 before EL and there is complete loss of PgR in the later stages. 
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3.2.3 Her2 and progesterone cooperate to generate EL signature 
We asked if the EL surrogate signature was the consequence of MMTV-promoter-driven 
expression of Her2 in transgenic animals, because the MMTV-promotor is responding to 
progesterone. We checked TUBO cells, a cell line derived from a Balb-NeuT primary tumor, and 
additional BALB/c derived cell lines 4T1, 67NR and MM3MG to evaluate their gene expression 
response to progesterone exposure (10 nM progesterone; progesterone treatment condition was 
75 h with 24 h intervals for washing and refreshing media). In addition to TUBO cells, 4T1 cells 
responded to progesterone by up-regulating the EL surrogate signature (Figure 20), indicating 
that the signature does not depend on the MMTV promoter driving Her2 because 4T1 cells are 
not transgenic for MMTV-driven Her2.  
 
 
Figure 20. Cell line treatment with progesterone and qPCR evaluation of EL-signature. Progesterone induced the EL signature in TUBO and 
4T1 cells (however, only in low cell density: 5.2 x 103 cells/cm2), but not in 67NR and MM3MG cells. All p-values, Student’s t-test 
and Stouffer’s combined probability test; all error bars correspond to standard deviation (Mean ±SD). 
 
Further investigation was done to find the differences of steroid hormone receptors and 
Her2 in the responding and non-responding cell lines at protein level. Protein blotting results 
revealed that the B form of PgR (PgR-B), the main isoform in mammary gland development and 
morphogenesis (Aupperlee et al., 2005; Fernandez-Valdivia et al., 2005; Mulac-Jericevic et al., 
2003), and Her2 were only expressed in responding cell lines, i.e. 4T1 and TUBO (Figure 21 A). 
To further confirm that surrogate marker expression truly depends to the progesterone 
stimulation, TUBO cells were exposed to increasing concentrations of progesterone (1 nM - 100 
nM) and noted a dose-dependent up-regulation of Nr3c1, Nr3c2, AR, and PgR (Figure 21 B). 
Likewise, progesterone induced Her2 expression in TUBO and 4T1 cells in a dose-dependent 
manner (Figure 21 B-C). These results also showed a concomitant upregulation of PgR and Her2 
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upon progesterone treatment similar to what has been observed in IHC results of EL which 
showed higher overlap between Her2 and PgR expression in this stage (Figure 19). Hence, we 
hypothesized that upregulation of Her2 is induced by PgR and to test that, I transduced the Her2 
and PgR-B-negative MM3MG cells with PgR-B and observed an up-regulation of Her2 (Figure 
21 D). Further corroboration was done by protein analysis of tissues where I observed that higher 
expression of PgR-B at 9 week old mammary glands, even wild type one, is correlated with slight 
upregulation of Her2 (Figure 21 E). ELs strongly express PgR and moderately express Her2 but 
advanced lesions completely lost PgR while Her2 was strongly expressed (Figure 21 E, Figure 
19). Collectively, these results suggested that genetic program of early lesions in this model is 
governed by fine tune expression of Her2 and PgR and interplay between their signaling.  
 
 
Figure 21.  Protein analyses of steroid hormone receptors and Her2 (A) Western blot analyses of progesterone and estrogen receptors and 
Her2 in hormone responding (4T1 and TUBO) and non-responding (MM3MG) cell lines. Note the presence of Her2 and progesterone 
receptor B in 4T1 and TUBO cells as opposed to the non-responding MM3MG cells. (B) Progesterone treatment of TUBO cells and 
protein analyses for steroid hormone receptors and Her2, demonstrates up-regulation of Her2, Nr3c1, Nr3c2, AR and PgR by 
progesterone. (C) Progesterone treatment up-regulates Her2 in 4T1 cells. (D) Overexpression of PgR B in the MM3MG cell line up-
regulates Her2 expression. (E) Higher expression of PgR-B in young mammary glands, up-regulates slightly Her2 expression. See 
supplementary data 4 for the original blotting figures.   
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3.3 Progesterone signaling regulates the migration program in EL and is 
linked to side branching and morphogenesis  
 
3.3.1 Role of Progesterone in side branching and morphogenesis  
We aimed to evaluate the link between progesterone-induced EL signature and the migratory 
behavior of cancer cells by performing in vitro migration/invasion assays. Because progesterone 
is known as the main regulator of mammary gland side branching and this function is mediated 
by progesterone-induced cytokines (Brisken et al., 2000; Brisken and O'Malley, 2010), Wnt4 and 
Rankl were included into the analysis. Accordingly, we checked their relevance by analyzing 
mRNA expression levels in fresh frozen samples (PT, 6 mice; EL, 4 mice; BALB/c 8 weeks old, 
5 mice; BALB/c 25 week old, 4 mice; each mouse was used as one sample; qPCR was done as 
technical duplicate or triplicate for each sample) and found mRNA upregulation of these factors 
in EL samples which was in parallel to PgR expression (Figure 22 A). Next, we tested if the 
progesterone effect on EL signature works through these paracrine factors (3 mice per condition 
pooled and three c-DNA samples were derived; qPCRs were done in duplicate or triplicate 
technical replication; see method section for sample preparation). Interestingly, Wnt4 and Rankl 
can regenerate EL signature and their combined action resulted in strong responses (Figure 22 B). 
 
Figure 22.  Wnt4 and Rankl are mediators of progesterone impacts (A) Quantitative PCR for PgR, Rank, Rankl and Wnt4, shows higher 
expression of PgR, Wnt4 and Rankl in EL compare to PT samples.  Note strong expression of Rank in primary tumors. (B) Primary cultures 
of EL treated with progesterone, Wnt4 and Rankl. Wnt4 and Rankl also generate full EL signatures and act in an additive manner. All error 
bars correspond to standard deviation (Mean ±SD). 
 
 
 
62 
 
The observation that inducer (progesterone) and mediator (Wnt4 & Rankl) 
physiologically regulating side branching and morphogenesis, were also inducing the EL 
signature, encouraged us to hypothesize that mammary side branching mechanisms might be 
recruited in early lesions and exploited for migration and dissemination. To support this notion, 
we compared (collaboration with Julio A. Aguirre-Ghiso’s lab from Mount Sinai School of 
Medicine, New York) the rate of PgR positive cells in ducts that are distal (advancing tree away 
from the nipple - more dynamic developmental tissue) and proximal to the origin (closer to the 
nipple - more stable differentiated ducts; 2 mice per age point; Figure 23 A) in wild-type mice. 
We found that the distal and more invasive part of the duct displayed a higher percentage of PgR
+
 
cells than the proximal ducts (Figure 23 A-B). This difference was evident at 5 weeks of age and 
clearer at 12 weeks when PgR
+
 epithelial cells drop even more in the differentiated structures 
(Figure 23 B).  
 
 
 
 
 
Figure 23. PgR staining in posterior anterior epithelial structures of mammary gland (A) PgR (green) staining at 5 weeks and 12 weeks of 
age (scale bar = 100 µm). (B) The percentage of PgR cells per duct was quantified using dye separation images (n=20 ducts, two mice/age 
group) in the proximal and distal portions of the gland (relative to the origin; LN, lymph node). All p values calculated based on Student’s t-
test; error bars correspond to standard error of the mean (Mean ±SEM) and numbers in the top of each column shows number of screened 
ducts (at least three mice for each time point). Note that LN was helping to assure about position of ducts as distal or proximal. This figure 
generated by Julio A. Aguirre-Ghiso’s lab from Mount Sinai School of Medicine, New York. 
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3.3.2 Progesterone and its paracrine factors regulate in vitro migration of PT and 
EL cells 
To test if the same players governing side branching and morphogenesis are also involved in 
migration of early lesion cells; we tested migration ability of these cells exposing to progesterone 
and induced paracrine factors. Cells were seeded on the top of a layer of 30% matrigel in the 
upper side of inserts of transwell plates. After 72 hours cells migrated to the lower side of insert 
fixed and stained with trypan-blue and visualized under the microscope. Migration events were 
evaluated for mammary epithelial cells from 9 (EL-derived) and 22 (PT-derived) week-old Balb-
NeuT mice either directly isolated from tissues or obtained from dissociated mammosphere. The 
results from both approaches were very similar. Progesterone and its paracrine signals, Wnt4 and 
Rankl, induced migration of cells from EL-derived samples and suppressed it in cells from 
primary tumors (Figure 24 A, and B for tissue-derived cells and Figure 24 C, and D for sphere-
derived cells; see supplementary data 3 for the raw numbers and replications). These results 
suggested that progesterone and its paracrine signals induced migration of EL similar to their 
induction of mammary side branching during mammary epithelial morphogenesis. 
 
 
Figure 24.  Role of progesterone and its paracrine factors in migration of EL and PT cells. Photomicrograph of migration assay and 
quantification. Trypan blue staining of EL and PT cells after migration (scale bars = represent 500 µm). Progesterone and its paracrine 
mediators Wnt4 and Rankl induce migration of EL but not PT cells. Cells were derived from tissue digestion (A-B) or sphere cultures after 
dissociation (C-D) and 1 x 105 cells were seeded in each migration well (24 well plate). Scale bars in panels A and C represent 500 µm. 
Panels B and C display the number of migrated cells. All p-values, student's t-test; all error bars correspond to standard deviation (Mean 
±SD). 
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3.4 Progesterone signaling regulates migration, stemness, and proliferation of 
cancer cells 
 
3.4.1 Higher sphere formation ability of young mammary epithelial cells  
In addition to the motility and invasion, progesterone-induced paracrine signals are known to 
activate mammary stem cells (MaSCs) during mammary gland development. This and the notion 
that stem-like cells are regarded as prime candidates for metastasis founders, prompted us to 
explore the impact of progesterone-induced paracrine signals on MaSCs and progenitor cells. 
Mammary epithelial cells from 9 week-old Balb-NeuT and wild type mice and from primary 
Balb-NeuT-derived tumors were cultured under ultra-low adherent conditions in mammosphere 
medium (Liao et al., 2007), where the number of sphere-forming cells informs about cells with 
stemness potential (mammary epithelial cells from ≥3 mice were pooled and at least tree plate run 
for each condition). In order to prepare single cell suspension, dissected mammary glands or PTs 
were minced mechanically to small pieces and dissociate enzymatically using collagenase and 
hyaluronidase solved in basal medium. Single-cell suspensions were grown in the basal medium 
supplemented with B27, EGF, basic fibroblast growth factor (bFGF), heparin, Grow-α and HIL6  
in 3 or 5 cm plates at a density of 50,000 cells/mL. After 10-14 days sphere bigger than 50 µm 
were counted as the mammospheres.  
 
Consistent with previous reports on Her2-stimulated stemness and sphere formation 
(Ginestier et al., 2007; Korkaya et al., 2008), Balb-NeuT-derived samples displayed significantly 
higher number of spheres per plated cells than age-matched controls. Furthermore, we noted that 
8 week-old BALB/c mammary cells produced higher sphere numbers than mammary cells from 
25-week old BALB/c mice (Figure 25 A). However, EL samples produced by far the highest 
numbers of spheres. We therefore used Sca-1, as the relevant cancer stem cell marker in the Balb-
NeuT model (Grange et al., 2008), and investigated its expression in normal glands and during 
malignant growth (done in collaboration with Piero Musiani from aging research centre, Gabriele 
d'Annunzio University Foundation, Italy). Interestingly, we noted an increase of Sca-1 expressing 
cells in the EL compared to the normal glands and a decrease of epithelial cells with Sca-1 
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expression as the tumours grew large. In advanced cancers Sca-1 appeared to be expressed almost 
exclusively by endothelial cells (Figure 25 B). 
 
 
Figure 25.  Age and Her2-transgene activity regulate stemness. (A) Her2-transgenic mammary cells form more mammospheres than control 
cells. The total number of spheres formed is also higher in 9 week-old mice compared to 22 (Balb-NeuT) and 25 (BALB/c) week-old mice 
with and without transgene. Numbers in the top of each column shows number of experiments (each experiment run with ≥3 mice).  (B) IHC 
staining of Sca-1 as stem cell marker demonstrates diminishing of stem like cells during tumor development. In advanced tumours Sca-1 
staining can be observed mostly in endothelial cells. All p-values, student's t-test; all error bars correspond to standard deviation (Mean 
±SD). Sca-1 staining generated by Piero Musiani from aging research centre, Gabriele d'Annunzio University Foundation, Italy. 
 
3.4.2 Higher expression of PgR in young mammary glands 
To support the hypothesis that higher number of spheres in young mammary gland-derived cells 
is linked to the expression of PgR, IHC staining was performed for PgR in the FFPE samples at 
different time points of tumor development as done for sphere assay. Interestingly, by comparing 
the expression of PgR in wild type and transgenic mice of different age (week 4 vs. week 40), we 
noted a 75% reduction in PgR
+
 epithelial cells at higher age in wild type and a complete loss in 
PTs (Figure 26 A-B, and 22 A). This reduction paralleled the decreased expression of Wnt4 and 
Rankl, the prime PgR-induced paracrine signals (Figure 22 A). Therefore, expression of PgR and 
its paracrine factors is concurrent with expression of stemness markers at the mammary epithelial 
structures.  
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Figure 26.  PgR IHC staining.  (A-B) IHC staining shows higher expression PgR (brown staining)  in epithelial structures of younger mammary 
glands compare to the older one in both transgene and wild type (scale bar = 100 µm). PGR expression was reduced by 75% in 40-week-old 
wild-type mammary gland compared to 4-week-old mice and disappeared in primary tumours (see also Figs 21 and 22). All p values, 
Student’s t-test; n, number of ducts or glands (in early lesions and normal tissue) or visual fields in primary tumours; (at least three mice for 
each time point); all error bars correspond to standard deviation (Mean ±SD). 
 
3.4.3 Progesterone-induced paracrine factors regulate stemness of PT and EL cells 
Young mammary glands are enriched with PgR positive cells and express higher level of Wnt4 
and Rankl compared to older mammary glands (Figures 22A and 26). In addition, they are more 
able to form spheres (Figure 25A). We therefore tested whether stimulation of sphere formation 
by progesterone can be recapitulated by the paracrine action of Wnt4 and Rankl. Indeed, EL 
derived cells responded to progesterone and Wnt4/Rankl with the increase of sphere formation 
(p= 0.01) whereas sphere formation from primary tumor samples was suppressed by Wnt4 and 
Rankl (p= 0.003; Figure 27; mammary cells from ≥3 mice pooled and ≥ 3 samples were used for 
sphere formation assay like 3.4.1). Therefore, sphere formation as a stemness trait of cancer cells 
in this model is regulated by progesterone signaling. Depend on the stage which cancer cells are 
derived from, progesterone signaling either induces (for EL cells) or suppresses (for PT cells) 
stemness.  
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Figure 27.  Role of progesterone and its paracrine factors in sphere formation of EL and PT cells. Progesterone and its paracrine factors induce 
sphere forming ability of EL and suppress it for PT cells. All p-values, student's t-test; all error bars correspond to standard deviation (Mean 
±SD). 
 
3.4.4 Stemness feature of migrating cells 
The similarity of migration and stemness behavior of EL and PT cells in response to progesterone 
and induced paracrine signals, prompted us to test the stemness of migrating cells. EL or primary 
tumor derived cells were plated on matrigel that covered the membrane of a transwell chamber. 
After migration through matrigel, we counted mammosphere formation in the lower chamber, 
where we prevented cell adhesion by poly-HEMA coating of surface (Figure 28 A). After 72 
hours of incubation, inserts were removed and stained. As before, EL samples displayed a higher 
number of migratory cells. Over the next 7 days, we could detect significantly higher numbers of 
spheres in the lower chambers of EL samples than of primary tumor samples (Figure 28 B and 
C). All steps, including migration (p=0.001; Student’s t-test) and sphere formation (p=0.005; 
Student’s t-test) were significantly induced by progesterone treatment. We conclude that 
progesterone induces migration of stem-like cells which might also encompass the ability of 
DCCs for distant outgrowth.  
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Figure 28.  Migration and sphere formation assay. (A) Schematic of combined migration and sphere assay. The lower chamber is filled with 
serum-free sphere medium and bottom is covered with poly-hema to prevent adhesion and enable sphere formation. (B-C) Micrograph of 
migration-sphere formation assay (scale bar = 500 µm) and quantification. All p-values, student's t-test; all error bars correspond to standard 
deviation (Mean ±SD). 
 
3.5 Her2 expression levels determine migratory vs. proliferative 
cellular responses 
We found that progesterone stimulates migration and sphere formation via its paracrine factors. 
In addition we found while EL signature, migration and stemness depends on co-signaling of PgR 
and Her2, but strong expression of Her2 in PT cells changes these phenotypes. Therefore, we 
asked what role the expression level ("dose") of Her2 expression plays in this scenario. 
 
3.5.1 Progesterone-induced paracrine factors act as inducer of stemness and 
migration for EL-like cells and supressor for PT-like cells 
To test role of Her2 expression in this model, we transduced MM3MG cells, a normal mouse 
mammary epithelial cell line which weakly expresses Her2 and PgR (Figure 21 A), with PgR-B 
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or Her2 and assessed their sphere formation and migration abilities (similar to what described in 
3.4.1-3; see method sections for more details). Overexpression of PgR-B (MM3MG-PgR B) 
decreased the migration of these cells but they were not responding to progesterone. Similarly, 
PgR overexpression reduced sphere formation of these cells (Figure 29 A-C). Conversely, Her2 
overexpression increased sphere formation and migration of cells. Therefore, the migratory cells 
are PgR negative cells; either non-transduced cells (MM3MG) or Her2 (MM3MG-Her2) cells; 
those were selected to further test them for impact of progesterone signaling in migration and 
sphere formation. 
 
 
Figure 29.  PgR and Her2 expression and evaluation of migration and sphere formation. (A-B) Overexpression of PgR-B in MM3MG cells 
reduced migration while Her2 overexpression (MM3MG-Her2) increased migration. Progesterone did not alter migration of PgR B-
overexpressing cells (MM3MG-PgR B). (D) Overexpression of PgR-B in MM3MG cells reduced sphere formation ability while Her2 
overexpression increased it. All p-values, student's t-test; N.S, not significant; all error bars correspond to standard deviation (Mean ±SD). 
 
In the co-culture experiments, we observed that co-culturing of MM3MG with MM3MG-
PgR or addition of Wnt4/Rankl to MM3MG cells induced their migration and addition of 
Wnt4/Rankl induced sphere-forming ability of MM3MG cells (Figure 30 A-C). In contrast, 
MM3MG-PgR cells or addition of Wnt4/Rankl suppressed migration of MM3MG-Her2 cells. 
The two cytokines also suppressed MM3MG-Her2 sphere formation (Figure 30 D-F). These 
results indicate that 1) MM3MG-Her2 cells behave like Balb-NeuT PT cells, 2) MM3MG cells 
behave like EL cells, 3) expression of PgR suppressing migration and sphere formation, but 
MM3MG-PgR cells can influence migration and sphere formation of neighboring cells.  
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Figure 30.  Migration and stemness of Her-negative and positive cells under activation of progesterone signaling (A-B) Migration of 
MM3MG cells after treatment with progesterone (P), Wnt4 + Rankl, or 1-to-1 mixing of MM3MG  with MM3MG-PgRB cells. Progesterone 
or paracrine factors (Wnt4+Rankl) induce migration of MM3MG cells. Co-culture with MM3MG-PgRB increases migration of MM3MG 
cells. (C) Progesterone or Wnt4+Rankl induce sphere formation of MM3MG cells. (D-E) Migration assay for MM3MG-Her2 cells.  
MM3MG-Her2 cells after treatment with progesterone, Wnt4/Rankl, or mixing (1-to-1) with MM3MG-PgRB cells. Wnt4+Rankl suppress 
migration of MM3MG-Her2 cells. Also, presence of MM3MG-PgRB cells decreases migration. (F) Progesterone or Wnt4+Rankl suppress 
sphere formation of MM3MG-Her2 cells. All p-values, student's t-test; all error bars correspond to standard deviation (Mean ±SD). 
 
To test that the effect of PgR
+ 
cells on neighboring cells goes via paracrine signals, we 
used neutralizing antibody against Rankl and chemical Wnt inhibitor (IWP2) in migration and 
sphere forming assays (migration and sphere assays for primary culture like what described in 
3.4) of EL cells while they were simultaneously treated by progesterone. Interestingly, these 
inhibitors completely abrogated impact of progesterone on migration and stemness of EL cells 
(Figure 31).   
 
Figure 31. Progesterone. Inhibition of Wnt and Rankl diminished impacts of progesterone on stemness and migration. Abrogation of Wnt  
by IWP-2 (chemical inhibitor of Wnt production) or nAb-Rankl (neutralizing antibody) reduces migration (left panel) and stemness (right 
panel) of EL cells. All p values, Student's t-test; all error bars correspond to standard deviation (Mean ±SD). 
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3.5.2 Her2 expression level defines types of responses to the progestrone signaling 
Next, we aimed to check impact of Her2 on in vitro proliferation of cancer cells in the context of 
suggested mechanism. To test that, XTT assay was performed for Her2 transduced cell line and 
primary cultures of EL and PT cells. We noted that transduction of Her2 into MM3MG cells 
increases their basal proliferation. Progesterone induced paracrine signals further stimulated 
proliferation of Her2 expressing cells but suppressed it in parental Her2 negative cells (Figure 
32A). Similarly, Wnt4 and Rankl suppressed proliferation of cells from EL samples, while 
stimulating proliferation of primary tumor-derived cells (Figure 32 B).  
 
 
Figure 32. Differential proliferation response of EL and PT cells to Wnt4/Rankl. XTT proliferation assay was done for primary cultures of EL 
and PT cells. Cells were cultured in 5000 cell/well in 96 well plate. Each single point is result of hexaplicated experiment. Cells were treated 
every second day with fresh medium contained wnt4/Rankl or vehicle (PBS). (A) Overexpression of Her2 increases proliferation of 
MM3MG cells (MM3MG-Her2). Wnt4 plus Rankl further increase proliferation of MM3MG-Her2 cells, but decrease proliferation of 
parental (MM3MG) cells. (B) Wnt4 plus Rankl treatment induces proliferation of primary cultured PT cells, but reduces it in EL-derived 
cells. All p-values, linear regression, F-test for slopes; all error bars correspond to standard deviation (Mean ±SD).  
 
We hypothesized that strong expression of Her2 may act as a key mediator for phenotype 
switching in epithelial cells. Thus, we reduced Her2 signaling by increasing doses of lapatinib 
(Her2 inhibitor; Figure 33 A) in MM3MG-Her2 cells and noted that intermediate inhibition of 
Her2 pathway decreased the inhibitory effect of Wnt4 and Rankl on migration (Figure 33 B). 
These results suggested that depend on the level of Her2 expression, cancer cells translate effects 
of progesterone induced factors for either proliferation (advanced cancer cells; strong Her2 
expression) or dissemination (early cancer cells; weak expression of Her2). 
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Figure 33. Low-moderate Her2expressing cells respond to progesterone signaling in their migration. (A) Protein blotting shows that 
lapatinib inhibits Her2 signaling by decreasing phosphorylated form. (B) Reduction of Her2 signaling overrides the inhibitory effect of Wnt4 
and Rankl and increases migration.  Note that complete abrogation of Her2 by high lapatinib dosage reduces migration. All p values, 
Student's t-test; all error bars correspond to standard deviation (Mean ±SD). See supplementary data 4 for the original blotting figures. 
 
3.5.3 Her2 and PgR expression in the migratory cells 
To analyze PgR and Her2 status of migratory cells from migration experiments, cells that reached 
to the other side of inserts were stained for two proteins. While MM3MG-PgR cells strongly 
suppressed migration of MM3MG-Her2 cells (Figure 30D-F), but those few migratory cells were 
MM3MG-Her2 cells (Figure 34 A). Moreover, staining revealed EL cells arriving to the other 
side of migration chambers were negative for PgR expression but weakly expressed Her2 (Figure 
34 B).  
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Figure 34.  Low-moderate expressing Her2 are the migratory cells in EL. (A) Cells that migrated to the other side of the migration chamber 
were stained for Her2 (FITC green) and PgR/ER-α (Cy3 red). MM3MG-Her2 cells were mixed with the MM3MG-PgRB and they have been 
checked for presence of Her2 and PgR after migration. None of migrating cells expressed PgR. (B)  EL cells (upper panel) did not express 
PgR and displayed faint Her2 staining (brightness of Her2 and PgR staining in EL samples was increased by 50% for better visualization in 
the picture). Double-positive T47D cells (lower panel) did not migrate but were fixed onto the filter to serve as positive staining control.  
 
 
We further aimed to characterize in vitro migratory cells by staining for other markers 
including CK8 and CK5. Results showed none of these markers beeing expressed in the 
migratory cells, which could be due to an activation of  EMT program during migration which 
reprogrames these epithelial cells ( Table 10).  
 
Table 10. Summary of IF staining of migratory cells (N.T - not tested).  
 
 
74 
 
3.6 In vivo support for the identified mechanism 
So far, all in vitro results on cell lines and primary cultures suggested an early dissemination 
program which is mediated by progesterone and fine-tuned by Her2 signaling. Progesterone 
signaling induced migration and stemness of EL cells which had low Her2 expression and 
suppressed these traits in PT cells which had strong Her2 expression. In addition, the migration 
program of early lesion seems to be related to mammary epithelial cell side branching and 
morphogenesis. Moreover, the migration phenotype was concomitant to stemness characteristics. 
To further prove these findings in vivo, we hypothesized that 1) EL tissues which are enriched in 
PgR cells, should disseminate more, 2) if the stemness is presented in disseminated cells, EL 
cells, should be able to form more metastases, 3) PgR expressing cells would provide a favorable 
environment for dissemination of EL and suppression environment for dissemination of  PT cells. 
For this purpose, a large number of mice in different setting of experiments were used and I got 
kind help of Milan Obradovic, Christian Werno, Carolin Ehrl and Christian Reimelt for these 
experiments. 
 
3.6.1 Proliferation and metastasis properties of PT and EL  
In the first in vivo experiments we transplanted recipient wild type BALB/c mice with either 1 
mm
3
 pieces from mammary glands of 4-5 week old Balb-NeuT mice (n=151) or with 1 mm3 
pieces from an advanced primary tumor (>22 weeks of age; n=34) into the cleared mammary fat 
pad. This generated a model with a single primary tumor that can be removed by surgery and 
followed during extended observation periods for metastasis formation. We performed surgery of 
recipients to remove the resulting primary tumors at a size between 5-10 mm. Thereby; we 
mimicked clinical stratification of similar T stages that allowed for sufficient follow-up time for 
metastases to emerge. All details and design of experiment is depicted in figure 35. 
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Figure 35.  Schematic of the transplantation protocols for mammary gland or PT tissue pieces into wild type recipients. Pieces (~1 mm3) of 
4 week-old mammary glands (i.e. tissue before activation of the Her2-transgene) or PTs of Balb-NeuT mice were transplanted into cleared 
fourth fat pads of young (4 week old) BALB/c mice. When tumors reached a size of 5-10 mm curative surgery was performed and mice were 
followed (median 17 weeks), dissected and screened for lung metastases. 
 
Interestingly, the time point for surgical intervention was significantly different for the 
two groups: primary tumor-derived tumors were resected at a median time point of 12.9 weeks 
(tumor pieces were perfectly viable, i.e. not necrotic), while gland-derived tumors at week 23 (p< 
0.001; Figure 36 A). After surgery, we followed mice from both groups for median of 17 weeks 
(Figure 36 B), when mice were dissected and inspected for macrometastasis formation in the 
lungs (Figure 36 C). We noted a significant difference for lung metastasis formation (p<0.0001; 
chi-square test): about twice as many metastases were generated from EL lesions (101/151 
transplanted gland pieces; 66.8%) compared to primary tumor lesions (10/35 transplanted tumor 
pieces; 28.5%; Figure 36 D). These results indicate that PT cells are more proliferative and less 
metastatic compared to EL cells. 
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Figure 36. Tumor growth and metastasis of EL and PT (A) Tumor formation time after transplantation of tumor pieces or untransformed 
transgenic mammary glands into wild-type siblings.  A curative surgery was done for mice when they developed tumor in size of 5-10 mm. 
Time to form a big tumor was 23 and 12 weeks for gland and tumor piece, respectively. (B) Mice left for a median of 17 weeks after curative 
surgery until the time they were sacrificed and monitored for macrometastases in their lungs. (C) This picture shows examples of tumor and 
lung metastasis in the analyzed mice. (D) Macrometastasis formation in gland- and tumor piece transplanted animals. N.S, not significant; p 
values, in A and B calculated by Mann-Whitney test, in D calculated by chi-square test; data in A and B presented with median. The 
transplantation experiments were done by Milan Obradovic, Carolin Ehrl and Christian Reimelt. 
 
3.6.2 Proliferation and metastasis traits are constant phenotypes over the time  
We raised two hypotheses for induced metastasis formation by transplanting EL: first, in the 
gland-derived model the longer period to tumor formation (i.e. to reach 5-10 mm tumors) 
influences metastases formation; second, there are intrinsic differences between cells 
disseminating from the gland and the PT-derived models independent of the time period before 
surgery. To test first hypothesis, we compared metastatic mice with similar kinetic of tumors 
from both models (Figure 37A) and compared their metastatic success (Figure 36 A). 
Interestingly, we noted a much higher rate of lung metastases in the gland model than in the PT-
derived model (Figure 37B, 67.5% vs. 41%; p=0.03; chi-square test). Together, the data suggest 
that intrinsic differences between the gland- and tumor-derived models are prevailing over time 
considerations. The criterion which determined how long we kept the mice after curative surgery 
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was the general health conditions of mice. When a mouse appeared sick, it was dissected and 
inspected for macrometastasis. Interestingly, when we looked at time when mice were kept after 
curative surgery until dissection, we saw that mice from tumor model stayed longer compared to 
the gland model (Figure 37C). These results indicate that ELs have a higher intrinsic metastatic 
potency compare to PT cells.  
 
 
Figure 37. Metastasis phenotype is independent of tumor kinetics. (A) Recipient mice were with similar tumor kinetic having been selected 
(B) Macrometastasis formation in gland- and tumor piece transplanted animals. Gland model cause more metastatic mice than tumor model 
regardless of tumor kinetics. (C) Longer time keeping after curative surgery does not result to more metastases for PTs. Mice with similar 
primary tumor kinetic were compared for the time they have been dissected. N.S, not significant; p values, in A and C calculated by Mann-
Whitney test, in B calculated by chi-square test; data in A and C presented with median.  
 
3.6.3 Higher metastatic property of EL cells comes from higher dissemination  
The lower rates of metastasis in the tumor model suggested that late cancer cells have a dominant 
proliferation phenotype, while dissemination is the dominant phenotype in early cancer cells. We 
hypothesized that the number of disseminated cancer cells of EL should be higher than of PT 
cells in the same window of time but their tumor forming ability, as reflected by their 
proliferation rate, should be lower.  In order to control number of transplanted cells and to get 
sure that cells are tumor initiating cells, we used spheres instead of pieces of tissue. Epithelial 
cells were sorted from fresh tissue and cultured in vitro to form spheres, and then 50 spheres were 
injected to the fourth mammary gland of recipient mice. For the EL model we transplanted 17, for 
the PT model 23 recipients. After 8 weeks, when the first mouse developed a primary tumor of 
about 5-10 mm in diameter, all mice were sacrificed and 10
6
 bone marrow cells were analyzed 
for DCCs by CK8/18 staining. The majority of PT-spheres transplanted mice (20/23; 87%) 
formed tumors, but none of EL transplanted mice developed tumors (Figure 38 A) within this 
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time window (p<0.0001). However, the number of mice that harbored DCCs in the bone marrow 
as well as the number of DCCs per positive bone marrow were significantly higher in EL-derived 
models as compared to PT-derived models (p=0.04; chi-square test for detection rate; p=0.0003 
for cell number; Mann-Whitney test; Figure 38 B and C). These results depict a clear difference 
in proliferation and metastatic dissemination of EL and PT cells. 
 
Figure 38. Dissemination and proliferation of PT and EL cells. (A-B) Tumor volume and dissemination to BM at week 8 after transplantation 
of PT or EL-derived spheres. (C) Number of DCCs (per 106 bone marrow cells) in positive mice at week 8 after transplantation of PT or EL-
derived spheres. P values, in A and C calculated by Mann-Whitney test, in B calculated by Fisher exact test; data in A and C presented with 
median.  
 
3.7 PgR is the distinticive environmantal factor in regulation of dissemination 
 
3.7.1 Impact of mammary gland environment on dissemination of PT and EL cells 
The role of paracrine factors of progesterone, Wnt4/Rankl, in the in vitro migration and sphere 
formation experiments suggested that dissemination and metastasis formation can be resulted of 
intricate interactions of cancer cells and the microenvironment. To get a first glimpse into such 
microenvironmental impact in vivo, we performed transplantation studies of EL and PT cells into 
young BALB/c recipients and old recipient mice. Mammary glands of 4 week-old wild type 
BALB/c mice comprise more than twice as many PgR-positive epithelial and fibroblastic cells 
than glands from 40 week-old mice (Figures 21 E, 22 A, 26 A and B). Furthermore, EL samples 
express much higher levels of Wnt4 and Rankl compared to PT samples (Figure 22 A). 
Therefore, we compared the impact of 4 and 40 week-old recipients’ microenvironment on tumor 
formation and dissemination. Dissemination in BM was not significantly different when EL-
derived spheres were injected into the forth mammary gland of 4 or 40 week-old BALB/c mice 
(Figure 39 A). However the PgR-dense microenvironment of young mammary glands suppressed 
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dissemination from PT spheres (p=0.01; Mann-Whitney test; Figure 39 A). On the other hand, we 
found that tumors grew faster when PT-cells were transplanted into young recipients (Linear 
regression, F-test; p = 0.009; Figure 39 B). These results prove that progesterone signaling has 
inhibitory effect on dissemination of PT cells while induces their proliferation. 
 
Figure 39. Young mammary gland suppresses dissemination but induce proliferation. (A) DCC counting in BM of recipient mice (young= 4-
week-old recipient; old= 40-week old recipient) shows a reduction in young recipients of PT cells. (B) Tumors grow faster from PT-derived 
spheres in young (PgR rich environment) vs. old recipient mice. P values, in A calculated by t-test, in B calculated for slopes of curves by F-
test; data in A presented with median. 
 
However, IHC staining for PgR revealed PgR expression exclusively in lesions resulting 
from EL transplantation (Figure 40), indicating the generation of a PgR-rich environment in the 
old recipients by EL cells which may be the reason why EL cells do not disseminate less in the 
old environment.  
 
Figure 40. PgR expression in the lesions left after transplantation ofEL. EL cells transplanted in old recipient mice (40 weeks) and mice were 
sacrificed 8 weeks after transplantation. Lesions were stained for PgR which shows PgR expressing cells. 
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This was further corroborated by demonstrating that only EL but not PT cells could 
generate PgR-positive cells in 3D culture. That came from the experiments in which epithelial 
cells were sorted from freshly digested tissue and cultured in either sphere medium for 5 weeks or 
cultured between two layers of matrigel. Interestingly, Balb-NeuT-derived EL, but not PT cells, 
could differentiate in matrigel and sphere culture. Acinus-like structures, characteristic of cells 
with stem-like potential (Debnath et al., 2003; Ghajar and Bissell, 2008), were exclusively 
observed for EL cells both in matrigel and in sphere cultures and their formation was accelerated 
by progesterone (p=0.0008; Mann-Whitney test; Figure 41 A).  
 
Figure 41.  Progesterone accelerate differentiation of EL cells A) Differentiation of mammary epithelial cells from EL or PT cells in sphere 
culture (up to 35 days) or in matrigel similar to previously published conditions (Debnath et al., 2003). The formation of acinus-like 
structures is shown in matrigel (left panel) or sphere culture (right panel). No such structures were detected for PT cells during the entire 
experiment (35 days). Progesterone stimulation accelerated formation of acinus-like structures particularly under mammosphere conditions 
(NED, no evidence of differentiation; Student t-test). (B) Immunofluorescence staining for CK8/18, PgR and EpCAM reveals exclusive 
expression of PgR and CK8/18 in differentiated structures (Upper panel) as compared to undifferentiated spheres (Lower panel). 
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Finally, to show that formation of acini-like structures is a consequence of differentiation 
program, we performed immunofluorescence staining of those acini structures. Spheres and 
differentiated structures were transferred into the normal cell culture 8 hours before staining to fix 
them physically to the surface. Then a routine cell culture staining performed for CK8/18, 
EpCAM, and PgR. Our results revealed that acinus-like spheres from EL samples expressed 
cytokeratin 18 and PgR as the signs of mammary epithelial differentiation (Figure 41 B). 
Altogether, these results suggested that EL cell are more migratory and PT cells are more 
proliferative. The PgR rich environment induces dissemination of EL cells but proliferation of PT 
cells. 
 
3.7.2 PgR expression changes dissemination behaviour of cancer cells 
To test the hypothesis that PgR in the mammary gland microenvironment suppresses 
dissemination and enhances proliferation, Balb-NeuT PT-spheres were mixed with MM3MG 
cells with or without overexpression of PgR in a 1:1 ratio and transplanted. We used 40 week-old, 
largely PgR-depleted mice. Interestingly, the number of DCCs in PT: MM3MG-PgR mice fell to 
levels seen when PT cells are transplanted into young, PgR-rich recipients (Figure 42 A). 
Furthermore, transplantation of PT spheres mixed with PgR-B-transduced MM3MG cells into old 
recipients resulted in increased tumor formation after 4 weeks (5 out of 5 versus 1 out of 5; 
Figure 42 B). IHC results confirmed the presence of PgR cells as small island in the tumor mass 
(Figure 42C). In summary, these observations are consistent with our in vitro data and in vivo 
results from recipient at varying age, showing that progesterone signaling induces migration from 
EL lesions but suppressing migration from further advanced lesions. On the other hand, while 
dissemination of PT cells is suppressed by progesterone signaling, they proliferate and form 
tumor faster.  
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Figure 42.  Environmental PgR expression suppresses dissemination from primary tumor cells. (A) PT spheres were co-transplanted with 
and without 50 PgR-transduced MM3MG spheres and DCCs were counted 8 weeks later. To reduce natural PgR mediated signaling only old 
40 week BALB/c mice were used as recipients.  (B-C) PT cells formed more tumors 4 weeks post transplantation when co-transplanted with 
PgR expressing cells. IHC staining (red/brown) shows small islands of PgR expressing cells in tumors from PT spheres mixed with 
MM3MG-PgRB. N.S, not significant; p values, in A calculated by student t-test, in B calculated by fisher exact test; A is shown by median 
for individual values. 
 
3.7.3 Pregnancy induces migration of EL and proliferation of PT cells 
Our previous results indicated that progesterone signaling induces dissemination of EL cells. We 
attempted to investigate the effect of physiologically elevated progesterone levels during 
pregnancy (10-20 times over normal (Powis and Shapiro, 2015)), on dissemination and 
proliferation of cancer cells. Female transgenic mice were mated at two time points: at EL (week 
7) and at early tumour formation (week 15). At week 7 Balb-NeuT mice display early lesion, thus 
we could see if progesterone released during pregnancy induce their dissemination. Whereas in 
week 15 mice usually progress from in situ carcinomas to invasive cancers, therefore we can 
evaluate effect of progesterone signaling on proliferation of advanced cancer cell in vivo.  
 
When mice were sacrificed, mice mated at week 7 displayed higher numbers of DCCs ( 
p=0.004; Student’s t-test; Figure 43 A), whereas all mice mated at week 15 formed large tumors 
by week 18, much faster than usual (Figure 43 B-C). In conclusion, this shows that high levels of 
progesterone exert different effects depending on the age and the PgR status of the tissue. While 
progesterone induces dissemination in EL, in advanced lesions it enhances proliferation. 
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Figure 43.  Pregnancy, tumor formation and dissemination. (A) Young Balb-NeuT mice entered pregnancy (n=5, pregnant; n=6 control) at the 
time of early lesion (week 7) and sacrificed at end of pregnancy (week 12). These mice did not formed palpable tumors but showed higher 
number of DCCs compare to sterile mice as control. Student t-test; shown are median and individual values. (B-C)  A group of Balb-NeuT 
mice (n=5, pregnant; n=5 control) entered pregnancy at the time of in situ carcinoma (week 15) and sacrificed in the end of pregnancy (week 
18). All pregnant mice formed tumors faster (p=0.0004; linear regression, F test for slopes) compared to sterile mice as control. The time for 
palpable tumors in Balb-NeuT is normally after week 20. 
 
 
3.8 Cell density regulates proliferation and dissemination phenotypes 
 
Altogether, the in vivo results corroborated our in vitro findings that EL cells had more 
dissemination/migration abilities and PT cells proliferate as response to progesterone signaling. 
We saw that EL is the time point with highest overlap between PgR and Her2 expression. Once, 
cancer cells progress to more advanced stages PgR disappeared and Her2 expression got stronger. 
These changes accompanied by a switch from migration to proliferation. The remaining question 
was how these observations can be mechanistically explained. We further wanted to know how 
PgR disappeared in advanced tumors and differentiate whether a clonal selection or epigenetic 
changes governs it.  
 
3.8.1 PgR expression in PT cells regulated by cell density 
First, 160 tissues from different stages of Balb-NeuT model were screened and found none of the 
primary tumors express PgR. Her2 and PgR expression goes to opposite direction from a normal 
like structure to advanced primary tumors (Figure 44). Therefore, we hypothesized that 
overexpression of Her2 and loss of PgR apparently marks a switch from a migratory to a 
proliferative phenotype. 
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Figure 44. Loss of PgR expression during tumor growth. (A) An IHC double staining of Her2 (membrane red/pink) and PgR (nuclear brown) 
shows diminishing of PgR coincide with gradual upregulation of Her2. (B) We found no PgR expressing cells in 102 PT samples of Balb-
NeuT.  
 
We noted that PgR expression can be rescued in advanced cancer cells under certain 
conditions. For example, individual cells re-expressing PgR mRNA and protein in primary tumor 
cell cultures of only low cellular density (2.2 x 10
3
 cells/cm
2 
for low density experiments; Figure 
45), but they disappeared again when they transplanted and formed tumors, which always 
impress morphologically with high cellular density. This raised the question if density of tumor 
cells in culture or tissue might regulate the expression of PgR. 
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Figure 45.  PgR expression is silenced in tumors, can be re-activated in culture and re-silenced in vivo. IHC staining for PgR in PTs (PT1 in 
right of panel) show the absence of PgR expression. When PT digested and cultured in low densities, some cells start to re-express PgR 
(middle of panel). We generated spheres from primary cultures derived from PTs (PT1) and transplant them in wild type mice until they 
form tumors. IHC staining for PgR in the grown tumors (PT2 in left of panel) revealed again absence of PgR expression.   
 
To test this hypothesis, TUBO cells were plated at low and high cellular densities and 
tested for PgR expression. TUBO cells grown at high density (3 x 10
4
 cells/cm
2
) did not express 
PgR, while 10±5% of cells grown under low-density (5.2 x 10
3
 cells/cm
2
) conditions did (Figure 
46 A). Additionally, frequent medium change of high-density cultures induced PgR re-
expression, suggesting involvement of soluble regulators (Figure 46 B).  
 
Figure 46. Identification of the PgR regulating activity (A) Immunofluorescent staining for PgR showed that in low-density cell culture of 
TUBO cells, some cell express PgR, while that could not be seen in high density cultures. (B) Frequent medium changes and washing will 
rescue PgR expression in TUBO cell. See supplementary data 4 for the original blotting figures. 
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3.8.2 PT cells regulate PgR expression via miRNAs 
To further confirm role of soluble component of PgR regulation, we performed two additional 
experiments. First, in transwell-cultures of primary tumor cells next to EL cells, PgR expression 
was found greatly reduced in EL cells (Figure 47 A and B). Second, we exposed human PgR-
positive T47D breast cancer cells to conditioned medium prepared from TUBO cells which was 
cultured on high density and 100% confluent at the time of media harvesting. Likewise the 
transwell assay, PgR expression was reduced to 50% of controls (Figure 47C and D). Therefore, 
soluble factors are the meditators for PgR knockdown. We hypothesized that these soluble factors 
either are soluble proteins or they are miRNA containing vesicles. To find out the answer, we 
separated candidate mediators contained within the supernatant in vesicular and extra-vesicular 
fractions by ultracentrifugation. Adding both fractions to PgR-positive T47D breast cancer cells, 
The PgR-regulating activity found exclusively within the vesicular fraction that reduced PgR 
expression by about 50% (Figure 47 E). Altogether, these results suggested that TUBO and 
primary tumor cells from Balb-NeuT mice down-regulate the PgR via miRNAs, which act within 
the cells and are secreted via exosomes. 
 
Figure 47. Secretion of exosome is responsible for PgR downregulation. (A-B) A transwell assay was done for PT and EL primary culture 
cells. The qPCR and western blotting results shows a soluble activity down-regulating PgR message comes from PT. (C-D); T47D cells 
exposed to conditioned medium from TUBO cells reduce PgR expression. TUBO cells were cultured at high density (3 x 104 cells/cm2) and 
media were collected after 3 days and added to T47D cells for 24 hours. Then mRNA or proteins were checked for PgR expression. (E) The 
down-regulating activity is located in exosomes from high-density TUBO cell culture supernatants. See supplementary data 4 for the original 
blotting figures. 
 
3.8.3 miR9-5p and miR30a-5P regulate PgR expression in PTs of Balb-NeuT  
To identify miRNAs able to regulate PgR expression, we prepared miRNAs for sequencing from 
TUBO cells, and supernatants of TUBO cells. Since we also observed that PgR expression 
regulated in the opposite way to Her2 expression in the Balb-NeuT model, we hypothesized that 
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a Her2 driven miRNA mechanism might also be involved in PgR knockdown mechanism. 
Therefore, miRNAs were prepared from BALB/c derived immortalized mammary epithelial cells 
that had been transduced with a Her2-containing retrovirus (MM3MG-Her2). All miRNA 
sequencing and analyses was performed in collaboration with Gunter Meister at University of 
Regensburg. Based on miRNA sequencing (Supplementary Data 2) and bioinformatic prediction 
of PgR regulators (Figure 48 A-C), we searched for miRNAs predicted to bind PgR and miRNAs 
up-regulated by Her2.  
 
Figure 48. miRNA sequencing to identify PgR regulating miRNAs. (A) The left table lists the top 10 upregulated miRNAs in Her2 
overexpressing cells (MM3MG-Her2) compared to control (MM3MG). (B) The middle table presents the top 10 expressed miRNAs in 
TUBO cells and TUBO cell-derived exosomes. (C) The right table displays miRNAs predicted by miRanda to regulate PgR. 
 
Identified candidates were added to T47D cells. The T47D cells were transiently 
transfected with mimic miRNAs using lipofectamine reagents. After 24 hours of transfection, 
PgR expression has been checked in the mRNA level by qPCR.  We found that miR30a-5P which 
is a Her2 regulated miRNA and miR9-5P which abundantly expressed in TUBO cells and 
exosome fraction are concomitantly able to down-regulate PgR in T47D cells (Figure 49 A-B) 
down to a level of 50%.  
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Figure 49. Effect of candidate miRNAs on PgR expression in T47D cells. (A) Down-regulation of PgR mRNA by miR30a-5P and 9-5P.  (B) 
Western blot of PgR-A and B after addition of miR30a-5P and 9a-5P. See supplementary data 4 for the original blotting figures. 
 
 
3.8.4 Cell density regulates phenotypic characteristics of cancer cells 
Since we saw progesterone expression is regulated by cell density, we speculated these miRNA 
mechanisms might be regulated by density as well. Interestingly, miR9-5P expression was 
particularly sensitive to cell density in TUBO cells (Figure 50 A). We speculated that PT lesions 
are high density of cancer cells and early lesions are low density of cancer cells. Checking 
expression of miR9-5P in fresh tissue samples, revealed a 15-fold higher expression of this 
miRNA in PT samples than in EL lesions (Figure 50 B).  
 
Figure 50. Regulation of miR9-5p by cell density. (A) High cell density upregulate miR9-5P in TUBO cells (results of qPCR) (B) PT and not 
EL upregulate miR9-5P in EL compared to 8 week BALB/c mammary glands. 
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To check whether density might be also able to regulate EL program, we checked the EL 
gene signature, migration and stemness in high and low densities. First we directly demonstrated 
the impact of cell density on EL signature by plating TUBO and primary tumor cells at low 
density, which enabled progesterone-induction of the EL signature (Figure 51).  
 
 
Figure 51. Cell density and EL signature. PT and TUBO cells generate the EL signature only in low density. (Low and high densities for PT: 
2.6 x 104 cells/cm2 vs. 105 cells/cm2; for TUBO cells: 5.2 x 103 cells/cm2 vs. 3 x 104 cells/cm2). All p-values, Student’s t-test and Stouffer’s 
combined probability test; all error bars correspond to standard deviation (Mean ±SD). 
 
Next, we compared sphere formation and migration abilities of TUBO cells at low and 
high densities. Indeed, progesterone and paracrine signals induced migration and sphere-forming 
ability of low-density TUBO cells whereas high-density TUBO cells showed the observed 
repression (Figure 52 A-C). These results suggested that cell density regulates the transition from 
a migratory to a proliferative phenotype in current model. 
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Figure 52. Cell density regulates migration and sphere formation abilities. PT-derived low-density TUBO cells acquire EL phenotype: sphere 
formation (A) and migration (B-C) in response to progesterone and Wnt4/Rankl. The migration of TUBO cells in low (10000 cells /well) 
and high density (50000 cells/well). TUBO cells in low cell density positively respond to progesterone and Wnt4+Rankl by increasing 
migration. All p-values, student's t-test; all error bars correspond to standard deviation (Mean ±SD). 
 
3.8.5 Human cell line model 
Finally, we aimed to explore whether human breast cancer cell lines display similar regulatory 
circuits. We selected 16 cell lines of different breast cancer subtypes (See figure 53A for breast 
cancer subtypes of cell lines). First, we checked the expression levels of Her2 and miR9-5p. The 
mRNA expression of Her2 and miR9-5p were evaluated in high density (90-100% cell culture 
confluency) of cell lines compared to their expression in the hTERT-HME cell line (Figure 53 A-
B). Interestingly, these two transcripts were positively correlated in the PgR
-
/Her2
strong
 expressing 
cell lines but, as expected, miR9-5p was suppressed in PgR
+
 cell lines (Figure 53 B). Since miR9-
5p suppresses PgR expression and was absent in the PgR positive cell lines, confirming our 
proposed mechanism for role of this miRNA in regulating expression of PgR. 
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Figure 53. Her2 and miR9-5p expression in human breast cancer cell lines. (A) Her2 mRNA expression levels in 15 human cell lines 
compared to the h-TERT-HME cells. Different colors for name of cell lines indicate subtype of breast cancer. (B) The expression of miR9-
5p in human breast cancer cell lines compared to h-TERT-HME cells. Note that Her2 strong-expressing cell lines express more miR9-5p 
except PgR-positive lines, such as BT474 and T47D. 
 
 Next, we checked density regulation of Her2 and miR9-5p expression. The density 
criteria was 90-100% cell culture confluency for high density and 20-30% for low density. We 
found that Her2 is upregulated at high cell density in 10/16 cell lines (Figure 54A) and miR9-5p 
in 4/16 displaying strongest up-regulation at high cell density (Figure 54B). These four cell lines 
(HCC1937, MCF7, HCC1806, and SKBR3) were also showing Her2 density regulation which 
indicates recapitulation of Her2-miRNA regulation by cell density what we observed in the 
mouse model (See figures 48 and 50).  
 
Figure 54. Cell density regulation of Her2 and miR9-5p expression. (A) High cell density up-regulates Her2 at mRNA (upper panel) or protein 
levels (lower panel) in several cell lines. Only four cell lines were checked for protein level (Her2 level not influenced by cell density – 
Cama1; Her2 level regulated by cell density – HCC1806, MDA-MB-231, and MCF7). Numbers below the blots indicate fold-change of 
Her2 in high density compared to low density normalized over beta actin.  (B) Expression of miR9-5p is up-regulated by cell density in 
SKBR3, HCC1937, HCC1806, and MCF7 cell lines. Key color for the name of cell lines presented in figure 53A. See supplementary data 4 
for the original blotting figures.  
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Finally, we tested 10 cell lines for migration and found 7/10 responded positively to 
Wnt4/Rankl and the remaining three to progesterone when using low-density cells, whereas the 
same factors suppressed (or unchanged) migration in high-density cells (Figure 55). Similarly, 
albeit less effectively, sphere formation was induced only in low-density cells (Figure 55). 
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Figure 55. Cell density and regulation of migration and stemness of human breast cancer cell lines. Migration and sphere-forming potential 
of 10 cell lines grown at low and high densities, and treated with Wnt4/Rankl or progesterone. The first 7 cell lines regulate Her2 by density 
(see 4L) and their response to PIPS is similar to TUBO cells and primary mammary cell cultures of BALB-NeuT mice. The remaining three 
cell lines do not regulate Her2 by cell density but respond to progesterone similarly to TUBO cell line and primary mammary cell cultures of 
BALB-NeuT mice. We did not perform functional assays with BT549 (TN), T47D (luminal, MCF7-like), MDA-MB-175, ZR75-1 (luminal, 
CAMA1-like), hTERT-HME (transformed normal, similar to MCF-10A) because of breast cancer subtype redundancy or poor growth 
(HCC1569). Y-axes show the percentage of migrating cells (left) and observed spheres (right) relative to seeded cells. All error bars 
correspond to standard deviation (Mean ±SD). 
 
In summary, although we note variation among the genetically different human cell lines, we 
obtained strong support for a model of metastatic dissemination in which cell density, Her2 
expression and progesterone signalling play major regulatory roles (Figure 56). 
 
 
Figure 56.  Graphical abstract of our mechanistic findings. In early lesions of Balb-NeuT mice which reflect low density of our in vitro 
condition (A part of graph), PgR activation upon progesterone treatment (A1) will increase PgR, Wnt4/Rankl and slightly Her2 expression 
(A2). Wnt4 and Rankl will target Her2 weak-moderate expressing cells which increased migration, stemness and gene expression signature 
of EL (A3). Cells in this state proliferate less but instead are migratory. In the PT which reflects high density of our in vitro condition (B part 
of graph), strong expression of Her2 (B1) activates miRNA transcription and secretion (B2). These miRNAs will shut down PgR expression 
(B3) and therefore all PgR signaling pathway which resulting in low migration, stemness and EL signature. Her2 strong expressing cells are 
more proliferative and further increase their proliferation if they receive progesterone-induced paracrine signals. As results a large tumor is 
forming. 
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3.9 Human samples and patient data analyses 
 
We examined role of cell density, Her2 and PgR cooperation in human breast cancer. In the Balb-
NeuT model PgR expression was lost in 100% of primary tumors (Figure 44) and co-expression 
of Her2 and PgR was only detectable in pre-malignant lesions (Figure 19 and 44). However, pre-
malignant lesions in humans comprise diverse, heterogeneous morphologies, which may or may 
not progress to malignancy and, in addition, are rarely available. Therefore, mechanism of early 
dissemination cannot be studied in patients because the event occurs before diagnosis. Instead, 
we asked if metastatic dissemination in early breast cancer (stage I-III) is correlated to Her2 and 
PgR expression. Patient data analyses were done in collaboration with Nina Patwary from our 
department; Andreas Hartkopf, Florin-Andrei Taran, and Sara Y. Brucker from department of 
gynecology and obstetrics, University of Tübingen; Tanja Fehm form department of Gynecology 
and Obstetrics, University of Düsseldorf; Brigitte Rack from department of Gynecology and 
Obstetrics, University Munich; Stefan Buchholz from department of Gynecology and Obstetrics, 
University Medical Center Regensburg. 
 
3.9.1 Her2 and PgR expression in primary tumors are correlated to cancer cell 
dissemination 
To answer the question if PgR and Her2 expression is correlated to dissemination in patients, we 
investigated bone marrow samples taken at surgery in UICC stage M0, i.e. without manifest 
metastasis, of 2239 breast cancer patients for disseminated cancer cells. DCCs were detected by 
cytokeratin staining (Fehm et al., 2006). We categorized the primary tumors for expression of 
PgR and Her2 status (Table 11 shows all patients based on pathological scores for PgR and 
Her2), each into three categories of absent, moderate and high expression (which in the case of 
Her2 was identified as genetic activation by amplification).  
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Table 11. Patient data classified based on DCC positivity and PgR/Her2 scores 
 
 
Without consideration of the Her2 status, we noted a significant lower dissemination rate 
for PgR
high
 tumors (p=0.013; chi-square test; Figure 57 A). On the other hand number of DCC 
positive patients increased with Her2 expression in primary tumors and was highest in Her2-
amplified tumors (p0.056; chi-square test; Figure 57 B). 
 
Figure 57. PgR and Her2 status of primary tumors correlated to dissemination.  Higher expression of PgR (A) correlated with lower DCC 
positive patients and higher expression of Her2 (B) is linked to higher number of DTC positive patients. Based on expression of PgR or 
Her2, patients were divided in three groups including low or negative (PgR IRS=0-1 and Her2=0), moderate (PgR IRS=2-8 and Her2=1-2 
without amplification) and high (PgR IRS=9-12 and Her2=2-3.with amplification). P values, chi-square test. 
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Strikingly, in breast cancers with high PgR score (9-12), we noted that genetic activation 
of Her2 increased the dissemination rate (p=0.02; Figure 58), similar to the EL lesions in the 
Balb-NeuT model.  
 
Figure 58.  PgR and Her2 expression identifies Her2high/PgRhigh subgroup of patients with highest seeding rates. Based on expression of PgR 
and Her2, patients were divided in three groups including low or negative (PgR IRS=0-1 and Her2=0), moderate (PgR IRS=2-8 and Her2=1-
2 without amplification) and high (PgR IRS=9-12 and Her2=2-3.with amplification). P values calculated by Chi-square test; N.S, not 
significant. 
 
3.9.2 New subtype of human breast cancer with caractarastics like EL of Balb-
NeuT   
We had never observed high PgR expression in established primary tumors of the Balb-NeuT 
model. In humans, we identified this subgroup comprising 3.7% of all patients (85/2239) or 
24.6% of Her2-amplified tumors (85/345). We performed IHC double-staining for Her2 and PgR 
in these samples (Table 12) and found Her2 and PgR single positive cells and also double-
negative and double-positive cells in low density invasive regions (Figure 59 A) similar to EL in 
Balb-NeuT mice. When also noted areas of high cell density without PgR expression and (Figure 
59 A and B), providing within the same samples evidence for density-associated PgR regulation.  
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Table 12. Her2amp/PRhigh samples used for double staining for PgR and Her2 
 
 
 
 
Figure 59.  Immunohistochemical double staining of a Her2high/PgRhigh breast cancer and Balb-NeuT samples. (A) Double staining of 
Her2high/PgRhigh human breast cancer sample (PgR: brown, nucleus; Her2: red/pink, membrane). Cells with varying expression levels of Her2 
and PgR, as well as negative, single- or double-positive cells can be seen (scale bar = 100 µm). Arrows indicate DP, double-positive; DN, 
double-negative; SP, single-positive. (B) Comparison of Her2high/PgRhigh human breast cancers and primary tumour Balb-NeuT mouse for 
Her2/PgR staining.  (a) Early lesion (EL) from Balb-NeuT (10x magnification). (b) primary tumour (PT) from Balb-NeuT model. (c-d) 
Human breast cancer. Note in human sample (d) and Balb-NeuT PT (b) high-density regions displaying strong expression of Her2 that lack 
PgR indicated by arrows. In human sample (c) and EL of Balb-NeuT (a) regions of invasive cells stain strongly positive for PgR and Her2. 
 
3.9.3 miR9-5p and 30a-5p are upregulated in Her2high/PgRneg 
Next, we checked the expression level of the miRNAs those found in mouse regulate PgR. We 
compared miRNA expression in fresh samples of Her2
amp
/PgR
high
 and Her2
amp
/PgR
neg
 patients. 
As reference, classical Her2
neg
/PgR
high
 luminal breast cancers with high PgR expression were 
used (Table 13 shows details of samples). Indeed, Her2
amp
/PgR
neg
 displayed a median 5-fold 
(miR30a-5p; p=0.04; Mann-Whitney test) to 20-fold (miR9-5p; p=0.006; Mann-Whitney test) up-
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regulation over Her2
amp
/PR
high
 tumors, indicating that lack of miRNA-mediated PgR down-
regulation enabled the Her2
amp
/PR
high
 phenotype in these patients (Figure 60).  
 
Table 13. Three groups of samples used for miRNA analyses 
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Figure 60.  miR9-5p and 30a-5p are upregulated in Her2high/PRneg samples of patients. PgR-downregulating miRNAs show lower expression 
levels in Her2high/PgRhigh human mammary carcinomas compared to Her2high/PgRneg carcinomas. Expression of miR9-5p and miR30a-5p is 
normalized to Her2-/PgRhigh breast cancers (see Table 13 for details on patients).  P-values, Mann-Whitney test; shown are median and 
individual values. 
 
Sample ID PgR IRS 
HER2 Score/ 
amplification 
PgRhigh/Her2neg 
T 3653 12 0 
T 3441 12 0 
T 3283 12 0 
T 2171 12 1 
T 2127 12 0 
T 2376 12 0 
T 2188 12 1 
T 2307 12 0 
T 2355 12 1 
PgRneg/Her2high 
T 3732 0 2/amp* 
T 3744 0 3 
T 3751 0 2/amp 
T 2886 0 3 
T 2946 0 3 
T 2312 0 3 
T 2103 0 3 
T 2080 0 3 
T 2504 0 3 
PgRhigh/Her2high 
T 4404 12 3 
T 2420 12 3 
T 2670 12 3 
T 1877 12 2/amp 
T 2299 12 3 
T 2362 12 2/amp 
T 2203 12 3 
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3.9.4 Human DCCs do not express hormone receptors 
Finally, we tested whether human DCCs isolated from bone marrow are characterized by the 
absence of PgR expression as predicted from the Balb-NeuT model, where migrating cells lacked 
PgR expression (Figure 22). For 27 EpCAM-positive cells, isolated from 19 M0 breast cancer 
patients, we isolated the genomic DNA and mRNA and performed single cell whole genome 
(WGA) and transcriptome amplification (WTA) as previously published (Guzvic et al., 2014). 
After confirmation of the malignant origin by CGH analysis and quality control of the WTA we 
tested for transcript expression of ER-α, PgR and Her2 by PCR (Figure 61). Indeed, none of the 
DCCs expressed the ER-α/PgR, but one DCC expressed Her2 consistent with our finding in the 
mouse model where we found migratory cells are PgR negative and low expressing Her2 (See 
figure 34).   
 
Figure 61.  ER and PgR genes are not expressed in human M0 DCCs. Estrogen receptor (ESR1) and progesterone receptor (PGR) transcripts 
expression in human breast cancer DCCs (26 DCCs from 19 M0 patients; only 10 samples are shown). One DCC out 26 was Her2 positive 
which originated from a DCIS patient. ACTB, EEF1A, and GAPDH serve as controls for single cell expression profiling. The first 3 lanes 
depict results from BT474 single cells which is positive for ESR1, PgR and Her2. This figure generated by Nina Patwary. 
3.10 Summary of numbers and type of replications 
All statistical tests, calculated p values, and numbers are mentioned in the legends and figures. 
Numbers for all in vivo experiments are shown in the figure or legends. All experiment on cell 
lines and primary cultures including sphere assays, migration assays and qPCR are done in at 
least triplicates (biological). I made a summary table (Table 14) for all numbers and type of 
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replicates which used in each given figure in the result section. The source data which used to 
generate all graphs can be found in the supplementary data 3. 
 
Table 14. Summary of numbers and type of replications 
Figure N replication # N mice is addressed  in 
12 Not applicable 
13     In the figure 
14     Table 7 
15     Table 7 
16     Table 7 
17 ≥3     
18 ≥3     
19     Fig 44 
20 ≥3     
21 Not applicable 
22 A, ≥3; B, ≥3     
23   2 per condition In the figure 
24 ≥3     
25     In the figure 
26   3 per condition In the figure 
27 ≥3     
28 ≥3     
29 ≥3     
30 ≥3     
31 ≥3     
32 ≥3     
33 ≥3     
34 ≥3     
35 Not applicable 
36     In the figure 
37     In the figure 
38     In the figure 
39     In the figure 
40   4   
41 ≥3     
42     In the figure 
43     In the figure 
44     In the figure 
45   6   
46 ≥3     
47 ≥3     
48 ≥3     
49 ≥3     
50 ≥3     
51 ≥3     
52 ≥3     
53 ≥3     
54 ≥3     
55 ≥3     
56 Not applicable 
57     Table 11 
58     Table 11 
59     Table 12 
60     Table 13 
61     In the figure 
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# I consider all experiments were done in ≥3 biological replicates. The “biological replicates” is 
based on assumption that all conditions of experiments were constant and the differences 
measured between ≥3 biological replicates were the result of tested conditions (Blainey et al., 
2014). 
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4 Discussion 
In this work we studied the early steps of metastasis.  For this we used the Balb-NeuT mouse 
model of breast cancer and investigated the dissemination of cancer cells in early stages of 
carcinoma development, which are considered as non-invasive stages by light microscopy. We 
further addressed why late-stage tumors are less successful in seeding metastases. Our results 
reveal a mechanism of early dissemination of murine mammary cancer cells that taps into 
mammary branching morphogenesis programs and thereby enables efficient migration and 
dissemination of cancer cells from pre-invasive lesions. This mechanism consists of three key 
players: cell density, PgR, and Her2 signaling, and is shut down as primary tumors grow and 
overt lesions develop. Our suggested model comprises a stage-dependent interpretation of 
microenvironmental signals as a function of cell density, and oncogenic signals, which leads to a 
switch from dissemination to proliferation mode. Moreover, we demonstrate that early 
disseminated cancer cells are able to complete all steps of metastatic cascade from dissemination 
to colonization at distant site. Finally, analyses of human samples confirmed the fundamental 
findings from our mouse model and, interestingly, we found a group of patients (comprising 4% 
of all breast cancer patients) with higher dissemination rate, whose tumors are morphologically 
similar to early stages of Balb-NeuT model.   
 
4.1 Mechanisms of early metastatic dissemination 
4.1.1 A transient cooperation of progesterone and Her2 signaling in early 
mammary lesions of Balb-NeuT mice 
To identify mechanisms regulating early dissemination of tumor cells, we first investigated the 
gene expression profile of mammary lesions in the Balb-NeuT mouse model at the time point of 
maximal relative seeding - around week 7-12, long before tumors are palpable or visible -when 
mammary lesions morphologically resemble atypical ductal hyperplasia (ADH). We established 
unique and stage dependent expression profiles of Balb-NeuT model including one characteristic 
for ELs. The gene expression analyses suggested the putative role of nuclear receptor signaling. 
A role for steroid hormones as regulators of early dissemination is consistent with their role in 
breast carcinogenesis and control of postnatal mammary gland development (Brisken and 
O'Malley, 2010).  
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The EL-signature was only induced in early lesions and only by progesterone treatment. 
Lack of PgR in PTs or lack of Her2 in aged matched BALB/c samples abrogated the EL-
program. This suggested that PgR signaling has been hijacked in the context of Her2-induced 
transformation for an EL dissemination program. In support of this, we found that PgR signaling 
initially increased Her2 expression, which was independent from MMTV-driven Her2 
expression. On the other hand, while increased PgR signaling and expression of Her2 were 
mandatory to generate the EL signature, strong expression of Her2 and high cell density 
abrogated PgR expression and consequently the EL signature. These results are supported by 
previous findings that showed progesterone receptor and Her2 participating in a bidirectional 
cross-talk during breast cancer development (Beguelin et al., 2010). It has been reported that 
Her2 could migrate into the nucleus where Her2 binds to DNA at specific sequences named Her2 
Associated Sequences (HASs) (Wang et al., 2004). In addition, progesterone could activate the 
HRG (heregulin)/Her2 pathway (Balana et al., 1999; Labriola et al., 2003). Moreover, Her2 
expression and its signaling pathway can be regulated by Rankl which is the downstream target 
of progesterone signaling (Ithimakin et al., 2013; Liu et al., 2010a) indicating links between 
progesterone and Her2 signaling. These observations are consistent with our findings of a 
transient window of PgR and Her2 cooperation in a dissemination program of cancer cells from 
ELs. 
 
4.1.2 A branching morphogenesis program is recruited for migration and 
dissemination of cancer cells from early lesions 
We investigated how progesterone can regulate dissemination of cells from very early lesions. 
Since progesterone induces side branches by its paracrine signals, Wnt4 and Rankl, from 
mammary epithelial cells invading into the mammary fat pad (Brisken, 2013; Brisken et al., 
2000; Muschler and Streuli, 2010), we evaluated the role of progesterone signaling in this 
process. Our results indicated that progesterone and its paracrine signals (Rankl and Wnt4) and 
the EL-signature are upregulated in young mammary glands, which is associated with the 
migration of EL-derived cells. In addition, we observed higher numbers of PgR
+
 cells in the 
anterior sprouting ducts in the normal mammary glands, where differentiation process occurs. 
Consistently, in vitro results revealed higher differentiation ability of EL-derived cells. The 
differentiated structures of EL-derived cells were able to express PgR in their formed acini, 
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which were induced by progesterone. Moreover, we found that the B form of PgR is the relevant 
isoform in early dissemination - in the line with other findings showing that progesterone 
receptor isoform B is the main player during pregnancy and mammary gland morphogenesis in 
puberty (Aupperlee et al., 2005; Fernandez-Valdivia et al., 2005; Mulac-Jericevic et al., 2003). 
Based on these results, we concluded that a normal local invasion program is exploited for early 
metastatic dissemination in our model. This is in line with notions that biological programs which 
are used during normal development are also used by carcinoma cells (Yang and Weinberg, 
2008). Therefore, all findings are supporting a dual role of progesterone in both metastasis and 
side branching during normal morphogenesis.  
 
4.1.3 Expression of Her2 regulates the switch from migration to proliferation  
We found that changes in the expression level of Her2 are associated with switching from a 
migratory to proliferative phenotype. In the early lesions of Balb-NeuT mice, lower expression of 
Her2 was correlated with higher migration and sphere formation ability. Conversely, strong 
expression of Her2 in MM3MG (by retroviral transduction) and PT-derived cells induced 
proliferation. Additionally, in the transduced MM3MG-Her2 cell line the Wnt4/Rankl-induced 
migration phenotype could be rescued by reducing Her2 signaling. Finally, we noted that the up-
regulation of Her2 by high cellular density of primary cultures of murine PT and, TUBO cells, 
and human breast cancer cell lines was correlated with loss of stemness and migratory 
phenotypes.  
 
Although it is known that overexpression of Her2 in breast cancer cells increases 
proliferation (Moody et al., 2002; Ursini-Siegel et al., 2007; Yang et al., 2004),  not much is 
known about the correlation between expression level of oncogenes and different phenotypes of 
cancer cells. However, there are several studies which are consistent with our findings. In one 
study the authors showed that overexpression of Myc in human metastatic breast cancer cells 
decreased their metastatic traits, while increasing tumorigenicity of these cells (Liu et al., 2012). 
Another study found that simultaneous activation of Akt-1 and Her2 strongly increased 
proliferation and growth of tumors whereas significantly fewer metastatic lesions were observed 
compared to the activated Her2 strain alone (Hutchinson et al., 2004). Another study in the 
intestinal adenocarcinoma mouse model (APC
-/-
/K-Ras
wt/mut(V12)
)
 
observed that activation of K-
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Ras at the initial stages did not change proliferation. Although K-Ras is a strong mitogenic factor, 
the authors found no evidence of elevated proliferation in early stages. In contrast, activation of 
metastasis was dependend on the presence of mutant K-Ras (Sansom et al., 2006). Therefore, 
proliferation and invasion are not concomitant phenotypes (Evdokimova et al., 2009; Svensson et 
al., 2003), which is in line with our observations that EL-derived cells migrate more and 
proliferate less, but PT-derived cells migrate less and proliferate more. This is further supported 
by other studies in melanoma (Hoek et al., 2008) and glioblastoma (Zhong et al., 2010) which 
reported that cancer cells switch between proliferative and invasive states, and suggested that a 
cancer cell has only one of these phenotypes at a given time.  
 
We further observed that cell density may be involved in the phenotypic changes. It has 
been reported two decades ago by Berner’s group that high cell density or non-permissive 
substrates inhibit cell motility, and favor a more proliferative phenotype(Giese et al., 1996). 
Conversely, active migration suppresses cell proliferation (Giese et al., 1996).  
 
4.1.4 Migration and stemness are concomitant phenotypes  
We found more mammosphere-forming and differentiation potential in EL cells which were able 
to differentiate and re-express PgR. Comparing sphere formation of BALB/c and Balb-NeuT 
mammary epithelial cells showed that Her2 expression induced stemness, in line with other 
reports (Ginestier et al., 2007; Korkaya et al., 2008). We also found that progesterone induced 
stemness, via paracrine factors. The paracrine mode of action was shown by experiments in 
which we were exposing MM3MG and MM3MG-Her2 cells to either Wnt4 / Rankl or to co-
culture with MM3MG-PgR cells. Both conditions generated similar results. The stemness and 
migration induction could be ablated by addition of inhibitors of Wnt4 and Rankl. Interestingly, 
we could not detect PgR expression in migratory cells of cell lines or primary cultures of EL in 
vitro. Consistently, we could not find any expression of PgR in the DCCs of patients with luminal 
primary tumors. These results supported the concept that paracrine signals of PgR
+
 cells target 
PgR
-
 cells for migration. 
 
Under physiological conditions, the paracrine factors Wnt4/Rankl released after 
progesterone stimulation activate adult MaSCs (mammary stem cells) in the mammary stem cell 
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niche during reproductive cycles. Here, MaSCs are important target cells of ovarian hormones 
and therefore are putative targets for cell transformation events leading to breast cancer (Asselin-
Labat et al., 2006; Asselin-Labat et al., 2010; Joshi et al., 2010; Mukherjee et al., 2010; Schramek 
et al., 2010). Indeed, we observed that cells from young mammary glands of mice formed more 
spheres indicating activation of stemness features. Young mammary glands in both wild type and 
transgenic models contained more PgR
+
 cells, expressed more paracrine signals, and faintly 
expressed Her2 compared to older mammary gland, which did not express Her2. Therefore, 
progesterone induced stemness of Her2
low
 cells which then differentiated in a positive feedback 
loop and generated PgR
+
 cells (See section 3.1.2).  
 
We showed that in vitro migrating cells have stemness potential and disseminating cancer 
cells in vivo can colonize and form metastasis. All DCCs from M0 patients were PgR and ER 
negative despite the fact that the PTs where they were derived from expressed these molecules. 
This is in line of our previous study and other studies, showing that disseminated cancer cells in 
breast cancer have stem-like features (Aktas et al., 2011; Balic et al., 2006; Fehm et al., 2009; 
Hüsemann et al., 2008; Weng et al., 2012). Therefore, stemness traits of cancer cells are tightly 
correlated to a migration phenotype.  
 
When we compared the number of formed spheres, number of DCC seeding mice, and 
number of DCCs in BM of mice, we observed a similar ratio of around 2 fold higher in EL 
compared to PT, which was also found for metastasis outgrowth for transplanted young 
mammary gland versus of PT. This suggests that colonization success may be similar for 
different DCCs from PT and EL and that the main reason for different number of metastatic mice 
transplanted with PT or mammary gland does not reside in a higher/intrinsic propensity of early 
DCCs to colonize, but rather reflects the higher numbers of DCCs that disseminated from early 
lesions. One may further speculate that the intratumoral heterogeneity of Her2 expression 
(Bartlett et al., 2011; Seol et al., 2012), generates cells within the primary tumor with metastatic 
potential.  
 
Finally, we observed that strong Her2 expression in PTs or high cellular density affected 
the stemness of cancer cells. As mentioned before, strong expression of Her2 increases 
proliferation. It has been suggested that increase in proliferation potential yields larger 
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populations of non-stem cancer cells that compete with CSC and, thus, inhibit CSC division. 
Conversely, decrease in proliferation potential loosens such inhibition and facilitates frequent 
CSC division (Morton et al., 2011; Poleszczuk et al., 2015; Sadler et al., 2013). 
 
4.1.5 Loss of PgR and strong expression of Her2 marks the switch from migration 
to proliferation 
Next, we tried to answer why the mechanism of early dissemination is not working in PTs which 
may explain a decreased seeding rate of PTs. We focused on the regulation of PgR, which is lost 
in all primary tumors of the Balb-NeuT model. Using PgR expression as a marker, we identified 
its regulation by cell density-regulated miRNAs. These miRNAs were also abundantly found in 
exosomes, which could spread the signal for PgR down-regulation among tumor forming cells. 
We identified a link between cell density and PgR expression via up-regulation of the PgR-
targeting miR9-5p, known to be density-regulated (Mori et al., 2014). However, we could not 
detect regulation of miR30-5p by density, which may due to our inability to specifically target 
only this member of the miR30 family which all have very similar sequences with only 1-2 
nucleotides difference (Chugh and Dittmer, 2012; van Rooij, 2011).  
 
We observed that PT-derived TUBO cells could re-express PgR under conditions of low 
cell density. The same was true for primary tumors of the Balb-NeuT model. Interestingly, under 
low cell density TUBO cells displayed all major features of EL cells, including Wnt4/Rankl 
stimulated migration and sphere formation, and induction of the EL surrogate signature. Increase 
of cell density was a key factor in this phenotypic change. Density upregulates Her2 expression 
and miR9-5p and upregulation of Her2 increases miR30a-5p expression. Consequently, these 
miRNAs decrease PgR expression. Interestingly, progesterone-induced factors induce 
proliferation of PgR negative PT cells. Therefore, PgR and density in advanced PT cells mark a 
phenotype of cancer cells that either responses to progesterone-induced cytokines with migration 
or proliferation. We conclude that higher cell density and upregulation of Her2 turns on 
proliferative machinery and therefore change the translation of environmental signals.  
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4.1.6 Early and late lesions of Balb-NeuT represent different subtypes of breast 
cancer 
The mechanism of early dissemination identified in our murine model is also activated in human 
breast cancer cells. We found that cell lines from all subtypes of breast cancer displayed cell 
density regulation of stemness and migration in response to progesterone or its induced paracrine 
factors. We saw that some triple negative and Her2-amplified cell lines displayed 
migration/stemness phenotypes at lower density under Wnt4/Rankl treatment. The decreasing 
migration and stemness of triple negative and Her2 cell lines at high density can be explained by 
following facts. First, progesterone paracrine-induced factors target mammary stem cells(Asselin-
Labat et al., 2006; Asselin-Labat et al., 2010; Joshi et al., 2010; Mukherjee et al., 2010; Schramek 
et al., 2010). Second, since the higher cell density decreases the stemness property of cell, 
(Morton et al., 2011; Poleszczuk et al., 2015; Sadler et al., 2013) the target cell population of 
progesterone paracrine-induced factors is diluted at higher cell density. Remarkably, we observed 
that some of Her2 negative luminal cell lines also displayed phenotype switching which was 
linked to the changes of Her2 expression level at different densities. This is of interest because an 
intermediate expression of Her2 confers stemness in luminal breast cancer cells (Ithimakin et al., 
2013). Furthermore, gene expression analyses revealed more similarity of Balb-NeuT tumors to 
human luminal breast tumors
46
 which is higher for early lesions compared to advanced 
tumors(Astolfi et al., 2005; Herschkowitz et al., 2007). Therefore, the Balb-NeuT model may 
represent a luminal like phenotype in earlier stage of tumor development and Her2-like 
phenotype in later stages. 
 
4.2 Potential relevance for human breast cancer 
4.2.1 Progesterone mechanisms in tumor growth and dissemination can explain 
pregnancy-associated breast cancers 
Pregnancy-associated breast cancer is associated with poor prognosis (Schedin, 2006). During 
pregnancy high levels of progesterone are secreted which activate proliferation of mammary 
epithelial cells and induce side branching, a physiological fat pad invasion program
49
. Although 
PgR signaling induces proliferation and migration of normal mammary epithelial cells, it 
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prevents their terminal differentiation. Terminal differentiation and lactation start shortly after a 
sharp decrease of progesterone at the end of pregnancy(Ismail et al., 2003; Ismail et al., 2002). In 
the Balb-NeuT model, we found that pregnancy during early lesions induced dissemination, while 
pregnancy during later stages induced proliferation and tumor growth. These results can be 
explained based by the differential response of EL and PT cells to progesterone. It may also 
address the question why pregnancy-associated breast cancers develop to a highly metastatic 
phenotype. During pregnancy mammary epithelial cells undergo many mitotic cycles, and in 
addition an EL-like dissemination program is activated because of the progesterone surge. If a 
cancer favoring mutation has already been acquired or happens during pregnancy-induced 
mammary cell expansion (Pike et al., 1983; Russo and Russo, 2011; Schedin, 2006), it may favor 
tumor growth and dissemination. 
 
4.2.2 Risk of breast cancer is related to PgR expression, age, and subtypes  
We found that PgR expression suppressed dissemination of advanced cancer cells in the mouse 
model. This was confirmed in patients where we saw less dissemination in PgR
+
 tumors. 
Previous data showed that the presence of PgR in primary breast cancers is an independent 
marker associated with less invasive phenotype, despite the fact that progesterone induces 
proliferation and is risk factor for breast cancer(Obr and Edwards, 2012). It was also reported that 
loss of PgR in ER
+
 tumors is associated with a more aggressive tumor phenotype, reduced 
responsiveness to endocrine therapies, and a shorter overall survival (Liu et al., 2010b; 
Mohammed et al., 2015). 
 
On the other hand, breast cancer in young women is associated with a higher frequency of 
metastasis and death (Fredholm et al., 2009; Tjokrowidjaja et al., 2014). Interestingly, Her2
+
 and 
basal like breast cancers, which are considered as more stem-like, are more frequent subtypes in 
young women (Jenkins et al., 2014; Kurian et al., 2010; McGuire et al., 2015; Yankaskas, 2005). 
Consistently, our observations corroborated that young mammary glands/EL are PgR-rich 
environment which supports dissemination of EL stem-like cells. We saw that EL lesions have a 
high dissemination potential and were generating more metastases. The number of dissemination 
events and metastases from EL were twice as high compared to those from advanced lesions, 
which are depleted of PgR expressing cells. We speculate that in young women with breast 
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cancer, cancer stem cells are more abundant, on one hand, and have more PgR
+
 cells as a proper 
mechanism of cancer stem cell dissemination, on the other hand. Therefore, the presence of PgR-
expressing cells may be part of the worse of outcome of young women. This conclusion is in line 
with recent data showing that death from DCIS is significantly higher in young women(Narod et 
al., 2015). 
 
4.2.3 Early dissemination can explain CUP syndrome 
Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It 
constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without 
an established primary site (van de Wouw et al., 2002).  The syndrome may be explained by 
dissemination of cancer cells with metastatic potential whereas cancer cells at the primary lesion 
fail to progress. We also noted in the transplantation experiments of small pieces of mammary 
glands or low numbers of spheres that cancer cells disseminate and form metastases while at the 
primary site no tumor is forming .  
 
4.2.4 Her2-PgR crosstalk in dissemination mechanism and DCC subtypes in 
patients 
Another debated issue in the field of breast cancer is the disparity between Her2 expression in 
DCCs, metastases, and primary tumors (Bock et al., 2012; Fehm et al., 2010; Guzvic et al., 2014; 
Stoecklein et al., 2008). We noted that migrating EL cells display a phenotype comprising 
low/intermediate expression of Her2, and absence of PgR-expression during migration. In 
addition, PgR mechanism of EL-dissemination targets low-moderate Her2 expressing stem-like 
cells. Interestingly, when we tested human DCCs from bone marrow, we could confirm the 
absence of ER-α and PgR, which suggests that stem-like cells are the main targets of the 
identified dissemination program. Therefore, these results interpret how Her2 negative DCCs 
disseminate in patients with Her2 positive breast tumors and, consequently, may explain why 
Her2-targeted therapies fail in many patients. This may also explain why up-regulation of Her2 
(not amplification) is observed frequently in in human in situ carcinoma (Ignatiadis et al., 2011) 
and linked to the detection of CTCs.  
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4.2.5 New subtype of breast cancer as the most aggressive group of breast cancer is 
similar to EL of Balb-NeuT 
We could not analyze EL in patients since these are only circumstantially diagnosed. Therefore 
we had to analyze advanced lesions regardless of their pathological stage of tumors. These 
analyses revealed that human breast cancers follow the suggested mechanism according to which 
dissemination of advanced cancer cells is decreased by PgR expression, but However, still there 
is small group of patients which have high expression of PgR and Her2 (Her2
high
/PgR
high
). This 
group of patients lacked the PgR-miRNA-regulating mechanism whereas Her2
high
/PgR
neg
 
expressed these miRNAs similar to mouse model. This is highlighting the importance of PgR-
regulation by miRNA and suggests that Her2
high
/PgR
high
 cells found a way to escape the miRNA-
mediated PgR-downregulation. The new group of patients comprises 24% of Her2-amplified 
breast cancers and 4% of total breast patients, and display highest DCC rates among all tested 
groups. This group shows high similarity in their invasive regions to the EL of Balb-NeuT. 
Tumors of these patients are composed of some regions lacking PgR expression and have higher 
cell density similar to PT of Balb-NeuT.  
 
4.3  Significance and conclusion  
This study mechanistically addresses metastatic early dissemination in one cancer model. In vitro, 
in vivo, and patient data cohere and suggest a model for metastasis from early lesions. During 
early stages, all pre-requisites for dissemination are naturally present, i.e. intermediate Her2 
expression, presence of PgR expressing cells, and low cell density. In advanced stages the EL 
dissemination program may become re-activated in areas of lower cell density. Indeed, primary 
tumor and PT spheres were able to seed and to form metastases, although at much lower rates 
than EL-derived cells.  
 
Moreover, these results suggest that although progesterone function is necessary for 
mammary gland morphogenesis and development, it may also provide an error prone mechanism 
and contribute to cancer cell growth or dissemination. The aberrant engagement of the normal 
physiological function of progesterone during mammary gland morphogenesis during early stages 
of breast cancer apparently results in fatal outcome. 
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The importance of these findings for the understanding of metastasis and development of 
adjuvant therapies is immediate: systemically spread cancer cells in the adjuvant therapy setting 
comprise cells that are derived from different stages of primary tumor evolution, including the 
earliest. DCCs from early and later stages have the potential to progress to metastasis. Therefore, 
therapies targeting the seed of metastasis need to address this heterogeneity. 
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5 Summary 
 
Current cancer therapies generally assume cancers to progress linearly from primary to metastatic 
sites. The model postulates a stepwise accumulation of genetic and epigenetic alterations within 
the primary tumor, and therefore, primary tumors may be used as surrogate markers for 
disseminated cancer cells. However, this model is challenged by (i) the insufficient therapy 
success and (ii) the genomic disparity between disseminated cancer cells (DCCs) and their 
matched primary tumors when isolated at surgery. The genomic disparity suggests that metastatic 
dissemination may occur early during tumor formation, however the mechanisms of early 
metastatic spread are unknown so far. 
 
To uncover mechanisms of early metastatic dissemination we microdissected mammary 
tissue from a Her2-driven mouse model (Balb-NeuT) of breast cancer before and after 
microscopic invasion and performed gene expression analysis. Identified pathways were tested in 
a series of in vitro and in vivo experiments. Finally, the findings were validated in a panel of 
human breast cancer cell lines and investigation of more than 2000 patient samples. 
 
Gene expression profiling identified a distinct signature at the time point of maximal 
seeding when only pre-invasive mammary lesions could be identified. The morphology of pre-
invasive lesions coincided with a transient time window of progesterone receptor (PgR) and Her2 
co-expression. Upon functional testing progesterone-induced signaling triggered migration of 
stem-like cells from early lesions shortly after Her2 activation, but promoted proliferation in 
advanced primary tumor cells. The switch from migration to proliferation was regulated by 
elevated Her2 expression and increased cell density involving miRNA-regulated PgR down-
regulation. The combined result was a differential response of cancer cells to progesterone and its 
paracrine-signal mediators Wnt4 and Rankl imposing stemness and migration at low and 
proliferation at high cellular density. Exploring human breast cancer cell lines we confirmed the 
observed phenotypes and mechanisms. Molecular-genetic and transcriptomic analysis of DCCs 
isolated from the bone marrow of breast cancer patients provided strong support for early 
metastatic dissemination. Finally, we identified a subtype of breast cancer mimicking the Balb-
NeuT model closest. 
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We identify microenvironmental signaling (PgR signaling), oncogenic signaling (Her2) 
and cellular density as central regulators of early dissemination and metastasis. In light of the 
patient-derived data we suggest that (i) dissemination is mostly early and (ii) clones that evolved 
over time at the primary site and became pre-dominant are less able to disseminate. We predict 
the findings not only to be relevant for Her2-driven cancers but for many other cancers as well.  
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7 Supplementary Data 
7.1  Supplementary data1  
List of 300 differentially expressed genes in EL which are conserved between human and mouse. 
Complete microarray gene expression data and analyses can be seen in the GEO data base with 
the accession number: GSE68683. 
 
  Gene Symbol Description 
1 Ahnak 
AHNAK nucleoprotein (desmoyokin) 
[Source:MarkerSymbol;Acc:MGI:1316648] 
2 BC035947 cDNA sequence BC035947 [Source:MarkerSymbol;Acc:MGI:2652858] 
3 4632404H22Rik 
RIKEN cDNA 4632404H22 gene 
[Source:MarkerSymbol;Acc:MGI:1926005] 
4 Fgfr1op Fgfr1 oncogene partner [Source:MarkerSymbol;Acc:MGI:1922546] 
5 LOC635841 - 
6 Q7TQ39_MOUSE Gag protein. [Source:Uniprot/SPTREMBL;Acc:Q7TQ39] 
7 Stac3 
SH3 and cysteine rich domain 3 
[Source:MarkerSymbol;Acc:MGI:3606571] 
8 Mreg melanoregulin [Source:MarkerSymbol;Acc:MGI:2151839] 
9 Ptn pleiotrophin [Source:MarkerSymbol;Acc:MGI:97804] 
10 Olfr142 olfactory receptor 142 [Source:MarkerSymbol;Acc:MGI:2177525] 
11 Nfatc3 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 
[Source:MarkerSymbol;Acc:MGI:103296] 
12 BC036313 cDNA sequence BC036313 [Source:MarkerSymbol;Acc:MGI:2448573] 
13 Acox3 
acyl-Coenzyme A oxidase 3, pristanoyl 
[Source:MarkerSymbol;Acc:MGI:1933156] 
14 Zcchc11 
zinc finger, CCHC domain containing 11 
[Source:MarkerSymbol;Acc:MGI:2445126] 
15 Msx1 homeo box, msh-like 1 [Source:MarkerSymbol;Acc:MGI:97168] 
16 2310047C04Rik 
RIKEN cDNA 2310047C04 gene 
[Source:MarkerSymbol;Acc:MGI:1917433] 
17 LOC635264 - 
18 Angptl4 angiopoietin-like 4 [Source:MarkerSymbol;Acc:MGI:1888999] 
19 Q78E13_MOUSE 
RNA for type IIB intracisternal A-particle (IAP) element encoding 
integrase, clone 111. (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q78E13] 
20 Hapln1 
hyaluronan and proteoglycan link protein 1 
[Source:MarkerSymbol;Acc:MGI:1337006] 
21 Baz2a 
bromodomain adjacent to zinc finger domain, 2A 
[Source:MarkerSymbol;Acc:MGI:2151152] 
22 Pstpip1 
proline-serine-threonine phosphatase-interacting protein 1 
[Source:MarkerSymbol;Acc:MGI:1321396] 
23 CN716893 
expressed sequence CN716893 
[Source:MarkerSymbol;Acc:MGI:3584456] 
24 Tnnt1 troponin T1, skeletal, slow [Source:MarkerSymbol;Acc:MGI:1333868] 
25 C330007P06Rik 
RIKEN cDNA C330007P06 gene 
[Source:MarkerSymbol;Acc:MGI:1924894] 
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26 Nox4 NADPH oxidase 4 [Source:MarkerSymbol;Acc:MGI:1354184] 
27 Dclre1c 
DNA cross-link repair 1C, PSO2 homolog (S. cerevisiae) 
[Source:MarkerSymbol;Acc:MGI:2441769] 
28 6530418L21Rik 
RIKEN cDNA 6530418L21 gene 
[Source:MarkerSymbol;Acc:MGI:1923497] 
29 Ankrd26 ankyrin repeat domain 26 [Source:MarkerSymbol;Acc:MGI:1917887] 
30 Dcn decorin [Source:MarkerSymbol;Acc:MGI:94872] 
31 Pard3b 
par-3 partitioning defective 3 homolog B (C. elegans) 
[Source:MarkerSymbol;Acc:MGI:1919301] 
32 Adam22 
a disintegrin and metallopeptidase domain 22 
[Source:MarkerSymbol;Acc:MGI:1340046] 
33 BC013712 cDNA sequence BC013712 [Source:MarkerSymbol;Acc:MGI:2446213] 
34 Ly6d 
lymphocyte antigen 6 complex, locus D 
[Source:MarkerSymbol;Acc:MGI:96881] 
35 LOC635297 - 
36 Tnpo2 
transportin 2 (importin 3, karyopherin beta 2b) 
[Source:MarkerSymbol;Acc:MGI:2384849] 
37 BC053393 cDNA sequence BC053393 [Source:MarkerSymbol;Acc:MGI:3039605] 
38 Hist2h3c2 histone cluster 2, H3c2 [Source:MarkerSymbol;Acc:MGI:2448357] 
39 Utp14a 
UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast) 
[Source:MarkerSymbol;Acc:MGI:1919804] 
40 Rhbdd1 
rhomboid domain containing 1 
[Source:MarkerSymbol;Acc:MGI:1924117] 
41 Nup54 nucleoporin 54 [Source:MarkerSymbol;Acc:MGI:1920460] 
42 Hs3st2 
heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
[Source:MarkerSymbol;Acc:MGI:1333802] 
43 Vsx1 
visual system homeobox 1 homolog (zebrafish) 
[Source:MarkerSymbol;Acc:MGI:1890816] 
44 Defb3 defensin beta 3 [Source:MarkerSymbol;Acc:MGI:1351612] 
45 Kcng1 - 
46 Asb8 
ankyrin repeat and SOCS box-containing protein 8 
[Source:MarkerSymbol;Acc:MGI:1925791] 
47 Mug4 murinoglobulin 4 [Source:MarkerSymbol;Acc:MGI:101843] 
48 Olfr323 olfactory receptor 323 [Source:MarkerSymbol;Acc:MGI:3030157] 
49 BC050196 cDNA sequence BC050196 [Source:MarkerSymbol;Acc:MGI:2687329] 
50 2810021B07Rik 
RIKEN cDNA 2810021B07 gene 
[Source:MarkerSymbol;Acc:MGI:1913558] 
51 4930535B03Rik 
RIKEN cDNA 4930535B03 gene 
[Source:MarkerSymbol;Acc:MGI:1922387] 
52 5730593F17Rik 
RIKEN cDNA 5730593F17 gene 
[Source:MarkerSymbol;Acc:MGI:2144564] 
53 Mast3 
microtubule associated serine/threonine kinase 3 
[Source:MarkerSymbol;Acc:MGI:2683541] 
54 Col6a2 procollagen, type VI, alpha 2 [Source:MarkerSymbol;Acc:MGI:88460] 
55 Galr3 galanin receptor 3 [Source:MarkerSymbol;Acc:MGI:1329003] 
56 EG234159 - 
57 Rab38 
Rab38, member of RAS oncogene family 
[Source:MarkerSymbol;Acc:MGI:1919683] 
58 Pdk1 
pyruvate dehydrogenase kinase, isoenzyme 1 
[Source:MarkerSymbol;Acc:MGI:1926119] 
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59 Smc2 
structural maintenance of chromosomes 2 
[Source:MarkerSymbol;Acc:MGI:106067] 
60 1810022C23Rik 
RIKEN cDNA 1810022C23 gene 
[Source:MarkerSymbol;Acc:MGI:1916373] 
61 Ptges prostaglandin E synthase [Source:MarkerSymbol;Acc:MGI:1927593] 
62 Prickle2 prickle-like 2 (Drosophila) [Source:MarkerSymbol;Acc:MGI:1925144] 
63 Gcap14 
granule cell antiserum positive 14 
[Source:MarkerSymbol;Acc:MGI:101859] 
64 Atp10d ATPase, Class V, type 10D [Source:MarkerSymbol;Acc:MGI:2450125] 
65 Tmem43 transmembrane protein 43 [Source:MarkerSymbol;Acc:MGI:1921372] 
66 4930534B04Rik 
RIKEN cDNA 4930534B04 gene 
[Source:MarkerSymbol;Acc:MGI:1922466] 
67 Nr3c2 
nuclear receptor subfamily 3, group C, member 2 
[Source:MarkerSymbol;Acc:MGI:99459] 
68 Arrdc3 arrestin domain containing 3 [Source:MarkerSymbol;Acc:MGI:2145242] 
69 Mal 
myelin and lymphocyte protein, T-cell differentiation protein 
[Source:MarkerSymbol;Acc:MGI:892970] 
70 BC107364 cDNA sequence BC107364 [Source:MarkerSymbol;Acc:MGI:3618860] 
71 Topbp1 
topoisomerase (DNA) II beta binding protein 
[Source:MarkerSymbol;Acc:MGI:1920018] 
72 4930511J11Rik 
RIKEN cDNA 4930511J11 gene 
[Source:MarkerSymbol;Acc:MGI:1921970] 
73 Olfr179 olfactory receptor 179 [Source:MarkerSymbol;Acc:MGI:3030013] 
74 Q8C1Z1_MOUSE 
Colon RCB-0549 Cle-H3 cDNA, RIKEN full-length enriched library, 
clone:G430046L24 product:hypothetical protein, full insert sequence. 
[Source:Uniprot/SPTREMBL;Acc:Q8C1Z1] 
75 Qrsl1 
glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 
[Source:MarkerSymbol;Acc:MGI:1923813] 
76 Csk c-src tyrosine kinase [Source:MarkerSymbol;Acc:MGI:88537] 
77 Podxl podocalyxin-like [Source:MarkerSymbol;Acc:MGI:1351317] 
78 Arpp21 
cyclic AMP-regulated phosphoprotein, 21 
[Source:MarkerSymbol;Acc:MGI:107562] 
79 Gm397 gene model 397, (NCBI) [Source:MarkerSymbol;Acc:MGI:2685243] 
80 Prkag3 
protein kinase, AMP-activated, gamma 3 non-catatlytic subunit 
[Source:MarkerSymbol;Acc:MGI:1891343] 
81 Mbtps2 
membrane-bound transcription factor peptidase, site 2 
[Source:MarkerSymbol;Acc:MGI:2444506] 
82 Mlh3 mutL homolog 3 (E coli) [Source:MarkerSymbol;Acc:MGI:1353455] 
83 Cyhr1 cysteine and histidine rich 1 [Source:MarkerSymbol;Acc:MGI:1859320] 
84 2310065K24Rik 
RIKEN cDNA 2310065K24 gene 
[Source:MarkerSymbol;Acc:MGI:1919637] 
85 Fbxo43 F-box protein 43 [Source:MarkerSymbol;Acc:MGI:1926053] 
86 Phgdhl1 
phosphoglycerate dehydrogenase like 1 
[Source:MarkerSymbol;Acc:MGI:1916139] 
87 ENSMUSG00000060559 
predicted gene, ENSMUSG00000060559 
[Source:MarkerSymbol;Acc:MGI:3642418] 
88 P2rxl1 
purinergic receptor P2X-like 1, orphan receptor 
[Source:MarkerSymbol;Acc:MGI:1337113] 
89 Olfr1361 olfactory receptor 1361 [Source:MarkerSymbol;Acc:MGI:3031195] 
90 Wdr4 WD repeat domain 4 [Source:MarkerSymbol;Acc:MGI:1889002] 
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91 Shprh 
SNF2 histone linker PHD RING helicase 
[Source:MarkerSymbol;Acc:MGI:1917581] 
92 Sgk3 
serum/glucocorticoid regulated kinase 3 
[Source:MarkerSymbol;Acc:MGI:2182368] 
93 6330416L07Rik 
RIKEN cDNA 6330416L07 gene 
[Source:MarkerSymbol;Acc:MGI:2442394] 
94 Defcr24 defensin related cryptdin 24 [Source:MarkerSymbol;Acc:MGI:3630383] 
95 Srrm2 
serine/arginine repetitive matrix 2 
[Source:MarkerSymbol;Acc:MGI:1923206] 
96 Pex11c 
peroxisomal biogenesis factor 11c 
[Source:MarkerSymbol;Acc:MGI:1920905] 
97 Cep290 centrosomal protein 290 [Source:MarkerSymbol;Acc:MGI:2384917] 
98 Sec31b 
Sec31 homolog B (S. cerevisiae) 
[Source:MarkerSymbol;Acc:MGI:2685187] 
99 Fgd3 
FYVE, RhoGEF and PH domain containing 3 
[Source:MarkerSymbol;Acc:MGI:1353657] 
100 1700025H01Rik 
RIKEN cDNA 1700025H01 gene 
[Source:MarkerSymbol;Acc:MGI:1922781] 
101 Dixdc1 DIX domain containing 1 [Source:MarkerSymbol;Acc:MGI:2679721] 
102 Atp13a3 ATPase type 13A3 [Source:MarkerSymbol;Acc:MGI:2685387] 
103 1110051M20Rik 
RIKEN cDNA 1110051M20 gene 
[Source:MarkerSymbol;Acc:MGI:1915079] 
104 Nrxn3 neurexin III [Source:MarkerSymbol;Acc:MGI:1096389] 
105 Kctd9 
potassium channel tetramerisation domain containing 9 
[Source:MarkerSymbol;Acc:MGI:2145579] 
106 D930028F11Rik 
RIKEN cDNA D930028F11 gene 
[Source:MarkerSymbol;Acc:MGI:1924792] 
107 Prkacb 
protein kinase, cAMP dependent, catalytic, beta 
[Source:MarkerSymbol;Acc:MGI:97594] 
108 Neu4 sialidase 4 [Source:MarkerSymbol;Acc:MGI:2661364] 
109 Gm817 gene model 817, (NCBI) [Source:MarkerSymbol;Acc:MGI:2685663] 
110 Smg6 
Smg-6 homolog, nonsense mediated mRNA decay factor (C. elegans) 
[Source:MarkerSymbol;Acc:MGI:2144117] 
111 Kif16b kinesin family member 16B [Source:MarkerSymbol;Acc:MGI:1098240] 
112 Sh3glb2 
SH3-domain GRB2-like endophilin B2 
[Source:MarkerSymbol;Acc:MGI:2385131] 
113 Shmt1 
serine hydroxymethyl transferase 1 (soluble) 
[Source:MarkerSymbol;Acc:MGI:98299] 
114 Tram2 
translocating chain-associating membrane protein 2 
[Source:MarkerSymbol;Acc:MGI:1924817] 
115 Nat2 
N-acetyltransferase 2 (arylamine N-acetyltransferase) 
[Source:MarkerSymbol;Acc:MGI:109201] 
116 Fmn2 formin 2 [Source:MarkerSymbol;Acc:MGI:1859252] 
117 4930486L24Rik 
RIKEN cDNA 4930486L24 gene 
[Source:MarkerSymbol;Acc:MGI:1922258] 
118 Ttc13 
tetratricopeptide repeat domain 13 
[Source:MarkerSymbol;Acc:MGI:2384573] 
119 Asb11 
ankyrin repeat and SOCS box-containing protein 11 
[Source:MarkerSymbol;Acc:MGI:1916104] 
120 Tnfrsf22 
tumor necrosis factor receptor superfamily, member 22 
[Source:MarkerSymbol;Acc:MGI:1930270] 
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121 Cdh16 cadherin 16 [Source:MarkerSymbol;Acc:MGI:106671] 
122 V1rc15 vomeronasal 1 receptor, C15 [Source:MarkerSymbol;Acc:MGI:2159451] 
123 IGKV6-17 
Immunoglobulin Kappa light chain V gene segment 
[Source:IMGT/GENE-DB;Acc:IGKV6-17] 
124 BC013672 cDNA sequence BC013672 [Source:MarkerSymbol;Acc:MGI:2384570] 
125 Ccdc56 
coiled-coil domain containing 56 
[Source:MarkerSymbol;Acc:MGI:1098757] 
126 LOC631256 - 
127 Eef2 
eukaryotic translation elongation factor 2 
[Source:MarkerSymbol;Acc:MGI:95288] 
128 Ccdc94 
coiled-coil domain containing 94 
[Source:MarkerSymbol;Acc:MGI:1920136] 
129 Sox15 SRY-box containing gene 15 [Source:MarkerSymbol;Acc:MGI:98363] 
130 Apobec3 
apolipoprotein B editing complex 3 
[Source:MarkerSymbol;Acc:MGI:1933111] 
131 Tsr2 
TSR2, 20S rRNA accumulation, homolog (S. cerevisiae) 
[Source:MarkerSymbol;Acc:MGI:1916749] 
132 Slc12a5 
solute carrier family 12, member 5 
[Source:MarkerSymbol;Acc:MGI:1862037] 
133 Megf11 multiple EGF-like-domains 11 [Source:MarkerSymbol;Acc:MGI:1920951] 
134 Fbxw8 
F-box and WD-40 domain protein 8 
[Source:MarkerSymbol;Acc:MGI:1923041] 
135 Dpysl3 dihydropyrimidinase-like 3 [Source:MarkerSymbol;Acc:MGI:1349762] 
136 Mapkbp1 
mitogen activated protein kinase binding protein 1 
[Source:MarkerSymbol;Acc:MGI:1347004] 
137 Cst12 cystatin 12 [Source:MarkerSymbol;Acc:MGI:1916612] 
138 Hmgcs2 
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 
[Source:MarkerSymbol;Acc:MGI:101939] 
139 Tmem41a transmembrane protein 41a [Source:MarkerSymbol;Acc:MGI:1913914] 
140 Rdh9 retinol dehydrogenase 9 [Source:MarkerSymbol;Acc:MGI:2143528] 
141 Ddx58 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 
[Source:MarkerSymbol;Acc:MGI:2442858] 
142 Crk 
v-crk sarcoma virus CT10 oncogene homolog (avian) 
[Source:MarkerSymbol;Acc:MGI:88508] 
143 Kcnip1 
Kv channel-interacting protein 1 
[Source:MarkerSymbol;Acc:MGI:1917607] 
144 Mier1 
mesoderm induction early response 1 homolog (Xenopus laevis 
[Source:MarkerSymbol;Acc:MGI:1918398] 
145 Sbno2 
strawberry notch homolog 2 (Drosophila) 
[Source:MarkerSymbol;Acc:MGI:2448490] 
146 Mrpl39 
mitochondrial ribosomal protein L39 
[Source:MarkerSymbol;Acc:MGI:1351620] 
147 Zswim6 
zinc finger, SWIM domain containing 6 
[Source:MarkerSymbol;Acc:MGI:1914513] 
148 5033413D22Rik 
RIKEN cDNA 5033413D22 gene 
[Source:MarkerSymbol;Acc:MGI:1923223] 
149 Fpr-rs2 
formyl peptide receptor, related sequence 2 
[Source:MarkerSymbol;Acc:MGI:1278319] 
150 Tnrc6a 
trinucleotide repeat containing 6a 
[Source:MarkerSymbol;Acc:MGI:2385292] 
151 Wnt4 wingless-related MMTV integration site 4 
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[Source:MarkerSymbol;Acc:MGI:98957] 
152 Galnt14 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 
[Source:MarkerSymbol;Acc:MGI:1918935] 
153 A830007P12Rik 
RIKEN cDNA A830007P12 gene 
[Source:MarkerSymbol;Acc:MGI:2442720] 
154 Slc19a2 
solute carrier family 19 (thiamine transporter), member 2 
[Source:MarkerSymbol;Acc:MGI:1928761] 
155 Il1rapl2 
interleukin 1 receptor accessory protein-like 2 
[Source:MarkerSymbol;Acc:MGI:1913106] 
156 Olfr1247 olfactory receptor 1247 [Source:MarkerSymbol;Acc:MGI:3031081] 
157 Zfp408 zinc finger protein 408 [Source:MarkerSymbol;Acc:MGI:2685857] 
158 Cyb5d2 
cytochrome b5 domain containing 2 
[Source:MarkerSymbol;Acc:MGI:2684848] 
159 ORF28 open reading frame 28 [Source:MarkerSymbol;Acc:MGI:2181053] 
160 Man1a mannosidase 1, alpha [Source:MarkerSymbol;Acc:MGI:104677] 
161 Frrs1 ferric-chelate reductase 1 [Source:MarkerSymbol;Acc:MGI:108076] 
162 Mtvr2 
Sjogren's syndrome/scleroderma autoantigen 1 homolog (human) 
[Source:MarkerSymbol;Acc:MGI:1913482] 
163 Pgbd1 
piggyBac transposable element derived 1 
[Source:MarkerSymbol;Acc:MGI:2441675] 
164 Dna2l 
DNA2 DNA replication helicase 2-like (yeast) 
[Source:MarkerSymbol;Acc:MGI:2443732] 
165 Apba2bp 
amyloid beta (A4) precursor protein-binding, family A, member 1 
binding protein [Source:MarkerSymbol;Acc:MGI:1861721] 
166 Rif1 
Rap1 interacting factor 1 homolog (yeast) 
[Source:MarkerSymbol;Acc:MGI:1098622] 
167 Cacna1a 
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
[Source:MarkerSymbol;Acc:MGI:109482] 
168 Wbscr25 
Williams Beuren syndrome chromosome region 25 (human) 
[Source:MarkerSymbol;Acc:MGI:1918554] 
169 Zfp62 zinc finger protein 62 [Source:MarkerSymbol;Acc:MGI:99662] 
170 Zfp69 zinc finger protein 69 [Source:MarkerSymbol;Acc:MGI:107794] 
171 Prnd prion protein dublet [Source:MarkerSymbol;Acc:MGI:1346999] 
172 Golt1a 
golgi transport 1 homolog A (S. cerevisiae) 
[Source:MarkerSymbol;Acc:MGI:1915588] 
173 5730406M06Rik 
RIKEN cDNA 5730406M06 gene 
[Source:MarkerSymbol;Acc:MGI:1913875] 
174 Zfp454 zinc finger protein 454 [Source:MarkerSymbol;Acc:MGI:2679253] 
175 Nut nuclear protein in testis [Source:MarkerSymbol;Acc:MGI:2661384] 
176 Pcbd2 
pterin 4 alpha carbinolamine dehydratase/dimerization cofactor of 
hepatocyte nuclear factor 1 alpha (TCF1) 2 
[Source:MarkerSymbol;Acc:MGI:1919812] 
177 L3mbtl l(3)mbt-like (Drosophila) [Source:MarkerSymbol;Acc:MGI:2676663] 
178 Elac1 elaC homolog 1 (E. coli) [Source:MarkerSymbol;Acc:MGI:1890495] 
179 Lmbrd2 LMBR1 domain containing 2 [Source:MarkerSymbol;Acc:MGI:2444173] 
180 Oas1h 
2'-5' oligoadenylate synthetase 1H 
[Source:MarkerSymbol;Acc:MGI:2180853] 
181 A930038C07Rik 
RIKEN cDNA A930038C07 gene 
[Source:MarkerSymbol;Acc:MGI:1915419] 
129 
 
182 Leng8 
leukocyte receptor cluster (LRC) member 8 
[Source:MarkerSymbol;Acc:MGI:2142195] 
183 Myo9a myosin IXa [Source:MarkerSymbol;Acc:MGI:107735] 
184 Dnahc1 
dynein, axonemal, heavy chain 1 
[Source:MarkerSymbol;Acc:MGI:107721] 
185 Xmr Xlr-related, meiosis regulated [Source:MarkerSymbol;Acc:MGI:99543] 
186 1700054O19Rik 
RIKEN cDNA 1700054O19 gene 
[Source:MarkerSymbol;Acc:MGI:1921522] 
187 LOC673755 - 
188 C87436 expressed sequence C87436 [Source:MarkerSymbol;Acc:MGI:2141787] 
189 Clca3 
chloride channel calcium activated 3 
[Source:MarkerSymbol;Acc:MGI:1346342] 
190 Nlrp3 
NLR family, pyrin domain containing 3 
[Source:MarkerSymbol;Acc:MGI:2653833] 
191 Fbf1 
Fas (TNFRSF6) binding factor 1 
[Source:MarkerSymbol;Acc:MGI:1922033] 
192 S3-12 
plasma membrane associated protein, S3-12 
[Source:MarkerSymbol;Acc:MGI:1929709] 
193 Snx16 sorting nexin 16 [Source:MarkerSymbol;Acc:MGI:1921968] 
194 BC005537 cDNA sequence BC005537 [Source:MarkerSymbol;Acc:MGI:2441726] 
195 ENSMUSG00000056606 
predicted gene, ENSMUSG00000056606 
[Source:MarkerSymbol;Acc:MGI:3641968] 
196 2210009G21Rik 
RIKEN cDNA 2210009G21 gene 
[Source:MarkerSymbol;Acc:MGI:1921493] 
197 1700020N01Rik 
RIKEN cDNA 1700020N01 gene 
[Source:MarkerSymbol;Acc:MGI:1914942] 
198 4933431E20Rik 
RIKEN cDNA 4933431E20 gene 
[Source:MarkerSymbol;Acc:MGI:3584041] 
199 Gipr 
gastric inhibitory polypeptide receptor 
[Source:MarkerSymbol;Acc:MGI:1352753] 
200 Tm4sf4 
transmembrane 4 superfamily member 4 
[Source:MarkerSymbol;Acc:MGI:2385173] 
201 Ankrd28 ankyrin repeat domain 28 [Source:MarkerSymbol;Acc:MGI:2145661] 
202 Abcg3 
ATP-binding cassette, sub-family G (WHITE), member 3 
[Source:MarkerSymbol;Acc:MGI:1351624] 
203 Olfr874 olfactory receptor 874 [Source:MarkerSymbol;Acc:MGI:3030708] 
204 Slc9a8 
solute carrier family 9 (sodium/hydrogen exchanger), member 8 
[Source:MarkerSymbol;Acc:MGI:1924281] 
205 Cttn cortactin [Source:MarkerSymbol;Acc:MGI:99695] 
206 Tmem97 transmembrane protein 97 [Source:MarkerSymbol;Acc:MGI:1916321] 
207 AI894139 
expressed sequence AI894139 
[Source:MarkerSymbol;Acc:MGI:2141515] 
208 Vbp1 
von Hippel-Lindau binding protein 1 
[Source:MarkerSymbol;Acc:MGI:1333804] 
209 5133401N09Rik 
RIKEN cDNA 5133401N09 gene 
[Source:MarkerSymbol;Acc:MGI:1922981] 
210 AI836003 
expressed sequence AI836003 
[Source:MarkerSymbol;Acc:MGI:2146066] 
211 Vegfa 
vascular endothelial growth factor A 
[Source:MarkerSymbol;Acc:MGI:103178] 
212 9230110C19Rik 
RIKEN cDNA 9230110C19 gene 
[Source:MarkerSymbol;Acc:MGI:3045346] 
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213 Mcpt6 mast cell protease 6 [Source:MarkerSymbol;Acc:MGI:96942] 
214 Ntn2l netrin 2-like (chicken) [Source:MarkerSymbol;Acc:MGI:1341188] 
215 Spag16 sperm associated antigen 16 [Source:MarkerSymbol;Acc:MGI:1913972] 
216 Gpr92 
G protein-coupled receptor 92 
[Source:MarkerSymbol;Acc:MGI:2685918] 
217 Pdcd11 
programmed cell death protein 11 
[Source:MarkerSymbol;Acc:MGI:1341788] 
218 1700069B07Rik 
RIKEN cDNA 1700069B07 gene 
[Source:MarkerSymbol;Acc:MGI:1923863] 
219 Olfr1231 olfactory receptor 1231 [Source:MarkerSymbol;Acc:MGI:3031065] 
220 Hlx1 
H2.0-like homeo box 1 (Drosophila) 
[Source:MarkerSymbol;Acc:MGI:96109] 
221 Itgb2l integrin beta 2-like [Source:MarkerSymbol;Acc:MGI:1277979] 
222 Mcf2l 
mcf.2 transforming sequence-like 
[Source:MarkerSymbol;Acc:MGI:103263] 
223 Cav1 caveolin, caveolae protein 1 [Source:MarkerSymbol;Acc:MGI:102709] 
224 Q8CDT6_MOUSE 
Adult male testis cDNA, RIKEN full-length enriched library, 
clone:4930415C24 product:hypothetical protein, full insert sequence. 
[Source:Uniprot/SPTREMBL;Acc:Q8CDT6] 
225 4933436C20Rik 
RIKEN cDNA 4933436C20 gene 
[Source:MarkerSymbol;Acc:MGI:1918546] 
226 Tpcn1 two pore channel 1 [Source:MarkerSymbol;Acc:MGI:2182472] 
227 Uck1 uridine-cytidine kinase 1 [Source:MarkerSymbol;Acc:MGI:98904] 
228 Olfr788 olfactory receptor 788 [Source:MarkerSymbol;Acc:MGI:3030622] 
229 Adam33 
a disintegrin and metallopeptidase domain 33 
[Source:MarkerSymbol;Acc:MGI:1341813] 
230 4930528F23Rik 
RIKEN cDNA 4930528F23 gene 
[Source:MarkerSymbol;Acc:MGI:1922428] 
231 Abi2 abl-interactor 2 [Source:MarkerSymbol;Acc:MGI:106913] 
232 Pax4 paired box gene 4 [Source:MarkerSymbol;Acc:MGI:97488] 
233 Nod1 
nucleotide-binding oligomerization domain containing 1 
[Source:MarkerSymbol;Acc:MGI:1341839] 
234 V2r4 vomeronasal 2, receptor, 4 [Source:MarkerSymbol;Acc:MGI:1316666] 
235 Prkar2a 
protein kinase, cAMP dependent regulatory, type II alpha 
[Source:MarkerSymbol;Acc:MGI:108025] 
236 Spon1 
spondin 1, (f-spondin) extracellular matrix protein 
[Source:MarkerSymbol;Acc:MGI:2385287] 
237 EG628893 - 
238 Aspn asporin [Source:MarkerSymbol;Acc:MGI:1913945] 
239 Trpm6 
transient receptor potential cation channel, subfamily M, member 6 
[Source:MarkerSymbol;Acc:MGI:2675603] 
240 Zfp780b zinc finger protein 780B [Source:MarkerSymbol;Acc:MGI:2444764] 
241 4932438A13Rik 
RIKEN cDNA 4932438A13 gene 
[Source:MarkerSymbol;Acc:MGI:2444631] 
242 Olfr513 olfactory receptor 513 [Source:MarkerSymbol;Acc:MGI:3030347] 
243 Wwc2 
WW, C2 and coiled-coil domain containing 2 
[Source:MarkerSymbol;Acc:MGI:1261872] 
244 Ppfibp1 
PTPRF interacting protein, binding protein 1 (liprin beta 1) 
[Source:MarkerSymbol;Acc:MGI:1914783] 
245 Ela3 elastase 3, pancreatic [Source:MarkerSymbol;Acc:MGI:1915118] 
246 Cdh10 cadherin 10 [Source:MarkerSymbol;Acc:MGI:107436] 
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247 6330569M22Rik 
RIKEN cDNA 6330569M22 gene 
[Source:MarkerSymbol;Acc:MGI:2443884] 
248 Si silver [Source:MarkerSymbol;Acc:MGI:98301] 
249 Defb40 defensin beta 40 [Source:MarkerSymbol;Acc:MGI:2672976] 
250 Abhd10 
abhydrolase domain containing 10 
[Source:MarkerSymbol;Acc:MGI:2442422] 
251 NP_808532.1 
RIKEN cDNA A030013N09 gene (A030013N09Rik), mRNA 
[Source:RefSeq_dna;Acc:NM_177864] 
252 Gsg2 germ cell-specific gene 2 [Source:MarkerSymbol;Acc:MGI:1194498] 
253 Msr2 
macrophage scavenger receptor 2 
[Source:MarkerSymbol;Acc:MGI:1933397] 
254 Olfr688 olfactory receptor 688 [Source:MarkerSymbol;Acc:MGI:3030522] 
255 1700041C02Rik 
RIKEN cDNA 1700041C02 gene 
[Source:MarkerSymbol;Acc:MGI:1920582] 
256 Olfr374 olfactory receptor 374 [Source:MarkerSymbol;Acc:MGI:3030208] 
257 A130090K04Rik 
RIKEN cDNA A130090K04 gene 
[Source:MarkerSymbol;Acc:MGI:2444159] 
258 Slc33a1 
solute carrier family 33 (acetyl-CoA transporter), member 1 
[Source:MarkerSymbol;Acc:MGI:1332247] 
259 4930458L03Rik 
RIKEN cDNA 4930458L03 gene 
[Source:MarkerSymbol;Acc:MGI:1925374] 
260 Med12l 
mediator of RNA polymerase II transcription, subunit 12 homolog 
(yeast)-like [Source:MarkerSymbol;Acc:MGI:2139916] 
261 1700063H04Rik 
RIKEN cDNA 1700063H04 gene 
[Source:MarkerSymbol;Acc:MGI:1921519] 
262 Cabp2 calcium binding protein 2 [Source:MarkerSymbol;Acc:MGI:1352749] 
263 Gsbs G substrate [Source:MarkerSymbol;Acc:MGI:1333876] 
264 8030423J24Rik 
RIKEN cDNA 8030423J24 gene 
[Source:MarkerSymbol;Acc:MGI:1924416] 
265 Olfr1446 olfactory receptor 1446 [Source:MarkerSymbol;Acc:MGI:3031280] 
266 Ccdc93 
coiled-coil domain containing 93 
[Source:MarkerSymbol;Acc:MGI:1918079] 
267 NP_997045.1 - 
268 Nlrp4d 
NLR family, pyrin domain containing 4D 
[Source:MarkerSymbol;Acc:MGI:3056574] 
269 Sp5 
trans-acting transcription factor 5 
[Source:MarkerSymbol;Acc:MGI:1927715] 
270 Otor otoraplin [Source:MarkerSymbol;Acc:MGI:1888678] 
271 Cnih3 
cornichon homolog 3 (Drosophila) 
[Source:MarkerSymbol;Acc:MGI:1920228] 
272 Scn1b 
sodium channel, voltage-gated, type I, beta 
[Source:MarkerSymbol;Acc:MGI:98247] 
273 Evl 
Ena-vasodilator stimulated phosphoprotein 
[Source:MarkerSymbol;Acc:MGI:1194884] 
274 Fancd2 
Fanconi anemia, complementation group D2 
[Source:MarkerSymbol;Acc:MGI:2448480] 
275 Rsc1a1 
regulatory solute carrier protein, family 1, member 1 
[Source:MarkerSymbol;Acc:MGI:3526447] 
276 Map2k6 
mitogen activated protein kinase kinase 6 
[Source:MarkerSymbol;Acc:MGI:1346870] 
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277 NP_780727.2 
RIKEN cDNA D730040F13 gene (D730040F13Rik), mRNA 
[Source:RefSeq_dna;Acc:NM_175518] 
278 Grlf1 
glucocorticoid receptor DNA binding factor 1 
[Source:MarkerSymbol;Acc:MGI:1929494] 
279 Mepe 
matrix extracellular phosphoglycoprotein with ASARM motif (bone) 
[Source:MarkerSymbol;Acc:MGI:2137384] 
280 Ankhd1 
ankyrin repeat and KH domain containing 1 
[Source:MarkerSymbol;Acc:MGI:1921733] 
281 E2f8 E2F transcription factor 8 [Source:MarkerSymbol;Acc:MGI:1922038] 
282 Tmem106b 
transmembrane protein 106B 
[Source:MarkerSymbol;Acc:MGI:1919150] 
283 3222402P14Rik 
RIKEN cDNA 3222402P14 gene 
[Source:MarkerSymbol;Acc:MGI:2442104] 
284 Trpm8 
transient receptor potential cation channel, subfamily M, member 8 
[Source:MarkerSymbol;Acc:MGI:2181435] 
285 Mga MAX gene associated [Source:MarkerSymbol;Acc:MGI:1352483] 
286 Dcst1 
DC-STAMP domain containing 1 
[Source:MarkerSymbol;Acc:MGI:1925022] 
287 Arhgap21 
Rho GTPase activating protein 21 
[Source:MarkerSymbol;Acc:MGI:1918685] 
288 Dgat2 
diacylglycerol O-acyltransferase 2 
[Source:MarkerSymbol;Acc:MGI:1915050] 
289 Tmem169 transmembrane protein 169 [Source:MarkerSymbol;Acc:MGI:2442781] 
290 Olfr437 olfactory receptor 437 [Source:MarkerSymbol;Acc:MGI:3030271] 
291 Trpc3 
transient receptor potential cation channel, subfamily C, member 3 
[Source:MarkerSymbol;Acc:MGI:109526] 
292 Ccdc102a 
coiled-coil domain containing 102A 
[Source:MarkerSymbol;Acc:MGI:2686927] 
293 Dtx3l deltex 3-like (Drosophila) [Source:MarkerSymbol;Acc:MGI:2656973] 
294 Rxrb retinoid X receptor beta [Source:MarkerSymbol;Acc:MGI:98215] 
295 Gna12 
guanine nucleotide binding protein, alpha 12 
[Source:MarkerSymbol;Acc:MGI:95767] 
296 5031414D18Rik 
RIKEN cDNA 5031414D18 gene 
[Source:MarkerSymbol;Acc:MGI:2685590] 
297 V1rh12 vomeronasal 1 receptor, H12 [Source:MarkerSymbol;Acc:MGI:2159675] 
298 Proz 
protein Z, vitamin K-dependent plasma glycoprotein 
[Source:MarkerSymbol;Acc:MGI:1860488] 
299 4933417A18Rik 
RIKEN cDNA 4933417A18 gene 
[Source:MarkerSymbol;Acc:MGI:1914011] 
300 Esr2 estrogen receptor 2 (beta) [Source:MarkerSymbol;Acc:MGI:109392] 
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7.2 Supplementary data 2  
List of upregulated miRNAs secreted in exosomes and supernatant of TUBO cells compare to 
non-secretory miRNAs extracted from TUBO cells, exosomes from TUBO, exosome free 
supernatant from TUBO cells and miRNA extracted from MM3MG-Her2 cell line compare to 
MM3MG cells are shown respectively in 7.2.1, 7.2.2, 7.2.3 and 7.2.4 sections. Complete miRNA 
sequencing data and analyses can be seen in the GEO data base with the accession number: 
GSE68683. 
7.2.1 miRNAs upregulated in TUBO 
Annotation (miRBase V20; mus 
musculus; no mismatchess allowed) 
Mean 
RPMannot. 
relative STDV 
mmu-miR-30a-5p 147,314.4 3.4% 
mmu-miR-21a-5p 81,163.2 1.6% 
mmu-miR-92a-3p 67,084.8 4.3% 
mmu-miR-182-5p 57,019.1 11.7% 
mmu-miR-9-5p 52,488.0 2.3% 
mmu-miR-143-3p 48,617.0 0.3% 
mmu-miR-181a-5p 40,799.0 3.2% 
mmu-let-7c-5p 32,818.3 4.2% 
mmu-let-7f-5p 32,625.4 5.3% 
mmu-miR-204-5p 30,492.6 1.8% 
mmu-miR-148a-3p 26,058.3 7.0% 
mmu-let-7i-5p 25,733.5 3.3% 
mmu-miR-25-3p 23,367.2 8.4% 
mmu-miR-146b-5p 20,385.7 6.3% 
mmu-miR-30d-5p 19,605.8 2.3% 
mmu-miR-27b-3p 19,159.4 3.3% 
mmu-let-7b-5p 17,033.0 5.7% 
mmu-miR-181b-5p 14,912.7 4.0% 
mmu-let-7a-5p 11,467.4 6.0% 
mmu-let-7g-5p 11,094.2 3.7% 
mmu-miR-200a-3p 10,852.1 4.8% 
mmu-miR-30e-5p 9,190.7 1.8% 
mmu-miR-103-3p 8,410.6 4.3% 
mmu-miR-22-3p 8,084.7 4.5% 
mmu-miR-378a-3p 7,688.9 2.1% 
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mmu-miR-26a-5p 7,417.8 8.8% 
mmu-miR-181c-5p 7,092.6 1.6% 
mmu-miR-183-5p 7,081.8 4.7% 
mmu-miR-200b-3p 6,593.4 6.0% 
mmu-miR-93-5p 6,296.8 4.5% 
mmu-miR-24-3p 5,943.9 3.7% 
mmu-miR-99b-5p 5,822.0 5.5% 
mmu-miR-101b-3p 5,626.4 6.1% 
mmu-miR-30c-5p 5,244.0 3.8% 
mmu-miR-31-5p 4,901.2 1.1% 
mmu-miR-340-5p 4,606.9 12.0% 
mmu-miR-16-5p 4,603.8 5.3% 
mmu-miR-19b-3p 4,349.2 15.4% 
mmu-miR-200c-3p 4,157.5 8.3% 
mmu-let-7e-5p 3,933.2 6.8% 
mmu-miR-26b-5p 3,530.7 12.0% 
mmu-miR-181d-5p 3,461.7 3.5% 
mmu-miR-191-5p 3,376.8 3.3% 
mmu-miR-151-3p 3,093.4 7.3% 
mmu-miR-222-3p 3,003.6 2.8% 
mmu-miR-125b-5p 2,865.3 6.2% 
mmu-miR-125a-5p 2,793.6 5.5% 
mmu-miR-29a-3p 2,776.6 4.5% 
mmu-miR-103-3p, mmu-miR-107-3p 2,388.1 1.4% 
mmu-miR-210-3p 2,386.2 5.5% 
mmu-miR-532-5p 2,359.7 3.2% 
mmu-miR-30a-3p 2,275.4 9.0% 
mmu-let-7d-5p 2,228.3 3.0% 
mmu-miR-429-3p 2,216.9 12.0% 
mmu-miR-141-3p 2,157.8 3.4% 
mmu-miR-101a-3p, mmu-miR-101c 2,156.9 2.5% 
mmu-miR-20a-5p 2,108.4 6.5% 
mmu-miR-151-5p 2,066.2 8.9% 
mmu-miR-23b-3p 1,806.6 5.9% 
mmu-miR-221-3p 1,513.5 10.8% 
mmu-miR-148b-3p 1,467.2 4.7% 
mmu-miR-19a-3p 1,437.6 15.1% 
mmu-miR-423-3p 1,375.1 1.4% 
mmu-miR-140-3p 1,353.8 2.7% 
mmu-miR-7a-5p 1,309.6 4.3% 
mmu-miR-30c-2-3p 1,191.9 4.1% 
mmu-miR-30b-5p 1,146.5 3.1% 
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mmu-miR-320-3p 1,068.1 10.1% 
mmu-miR-27a-3p 1,022.0 3.7% 
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7.2.2 miRNAs upregulated in exosomes of TUBO 
 
Annotation (miRBase V20; mus 
musculus; no mismatchess allowed) 
Mean RPMannot. 
relative 
STDV 
mmu-miR-30a-5p 101,037.9 24.9% 
mmu-miR-21a-5p 79,956.9 24.5% 
mmu-miR-182-5p 65,360.4 34.1% 
mmu-let-7c-5p 60,376.5 21.0% 
mmu-miR-181a-5p 53,138.5 20.1% 
mmu-miR-9-5p 52,779.7 14.4% 
mmu-miR-143-3p 44,145.0 3.0% 
mmu-miR-25-3p 42,264.8 18.1% 
mmu-let-7f-5p 40,074.9 8.8% 
mmu-miR-92a-3p 36,845.4 19.2% 
mmu-let-7b-5p 29,005.5 21.5% 
mmu-miR-148a-3p 27,910.0 7.1% 
mmu-miR-146b-5p 19,234.9 8.7% 
mmu-let-7a-5p 18,578.6 22.2% 
mmu-miR-204-5p 18,356.1 11.8% 
mmu-miR-30d-5p 17,317.9 22.6% 
mmu-miR-27b-3p 16,752.7 17.7% 
mmu-let-7i-5p 15,212.6 22.6% 
mmu-miR-93-5p 14,958.7 4.3% 
mmu-miR-486-5p, mmu-miR-3107-5p 14,516.7 57.4% 
mmu-let-7g-5p 13,193.3 11.8% 
mmu-miR-181b-5p 12,524.5 7.8% 
mmu-miR-183-5p 10,878.8 15.5% 
mmu-miR-103-3p 9,259.9 16.1% 
mmu-miR-210-3p 8,820.2 47.5% 
mmu-miR-26a-5p 8,479.2 4.0% 
mmu-miR-200a-3p 7,215.5 45.0% 
mmu-miR-99b-5p 6,454.6 13.0% 
mmu-miR-19b-3p 6,306.7 73.0% 
mmu-miR-378a-3p 6,273.3 6.5% 
mmu-miR-30e-5p 5,982.8 18.4% 
mmu-miR-200c-3p 5,867.1 20.2% 
mmu-miR-101c 5,853.4 7.0% 
mmu-miR-200b-3p 5,355.2 29.4% 
mmu-miR-101b-3p 5,308.3 45.2% 
mmu-miR-101a-3p, mmu-miR-101c 5,088.0 39.7% 
mmu-miR-26b-5p 4,777.3 4.4% 
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mmu-let-7e-5p 4,762.3 29.7% 
mmu-miR-22-3p 4,716.3 0.8% 
mmu-miR-30a-3p 4,575.7 0.8% 
mmu-miR-181c-5p 4,404.1 42.2% 
mmu-miR-30c-5p 4,004.1 21.0% 
mmu-miR-151-3p 3,470.0 22.4% 
mmu-miR-340-5p 3,014.4 22.6% 
mmu-miR-140-3p 2,893.3 5.0% 
mmu-miR-181d-5p 2,754.9 12.7% 
mmu-miR-16-5p 2,745.3 16.1% 
mmu-miR-103-3p, mmu-miR-107-3p 2,636.9 2.4% 
mmu-miR-24-3p 2,415.1 11.2% 
mmu-miR-19a-3p 2,233.5 66.0% 
mmu-miR-221-3p 2,103.4 13.7% 
mmu-miR-31-5p 2,075.3 1.3% 
mmu-miR-532-5p 1,915.2 7.2% 
mmu-miR-429-3p 1,879.2 13.1% 
mmu-miR-191-5p 1,868.4 25.5% 
mmu-miR-20a-5p 1,721.3 2.6% 
mmu-miR-125a-5p 1,693.1 16.1% 
mmu-miR-23b-3p 1,605.8 10.0% 
mmu-miR-106b-3p 1,536.3 19.4% 
mmu-miR-125b-5p 1,522.1 3.3% 
mmu-miR-320-3p 1,519.7 32.6% 
mmu-let-7d-5p 1,408.2 19.6% 
mmu-miR-29a-3p 1,349.3 19.1% 
mmu-miR-152-3p 1,168.5 5.3% 
mmu-miR-151-5p 1,127.6 14.5% 
mmu-miR-148b-3p 1,113.0 5.8% 
mmu-miR-98-5p 1,041.1 7.6% 
mmu-miR-451a 1,029.4 15.8% 
mmu-miR-28a-3p 1,020.5 27.4% 
mmu-miR-423-3p 1,018.0 10.7% 
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7.2.3 miRNAs upregulated in exosomes free supernatant 
Annotation (miRBase V20; mus musculus; no 
mismatchess allowed) 
Mean RPMannot. 
relative 
STDV 
mmu-miR-92a-3p 258,291.5 2.3% 
mmu-let-7c-5p 103,634.7 10.0% 
mmu-miR-25-3p 96,367.3 32.8% 
mmu-miR-204-5p 64,322.1 18.6% 
mmu-let-7b-5p 62,914.1 20.6% 
mmu-miR-30a-5p 37,861.5 34.7% 
mmu-miR-143-3p 25,682.0 17.1% 
mmu-miR-182-5p 25,516.2 44.4% 
mmu-miR-148a-3p 23,133.4 38.6% 
mmu-miR-30d-5p 23,078.6 6.6% 
mmu-miR-99b-5p 19,835.4 16.2% 
mmu-miR-151-3p 16,998.1 49.5% 
mmu-miR-27b-3p 14,599.3 13.7% 
mmu-miR-146b-5p 13,376.1 15.6% 
mmu-miR-320-3p 11,345.1 27.1% 
mmu-miR-181a-5p 11,037.6 28.0% 
mmu-miR-423-5p 10,519.9 9.7% 
mmu-miR-92b-3p 10,320.7 26.0% 
mmu-miR-21a-5p 9,944.6 38.8% 
mmu-let-7d-3p 8,498.2 15.6% 
mmu-miR-328-3p 5,933.5 27.1% 
mmu-miR-24-3p 5,760.0 6.5% 
mmu-miR-378a-3p 4,979.8 21.4% 
mmu-miR-200c-3p 4,844.9 25.2% 
mmu-miR-9-5p 4,822.3 53.1% 
mmu-miR-125b-5p 4,574.9 10.2% 
mmu-miR-22-3p 4,541.7 12.5% 
mmu-miR-486-5p, mmu-miR-3107-5p 4,369.6 56.2% 
mmu-miR-181b-5p 4,313.2 25.1% 
mmu-miR-204-3p 4,057.6 31.4% 
mmu-miR-125a-5p 3,739.5 17.6% 
mmu-miR-210-3p 3,387.3 59.3% 
mmu-let-7i-5p 3,381.8 20.7% 
mmu-miR-191-5p 3,375.5 6.1% 
mmu-miR-532-5p 3,355.9 33.0% 
mmu-miR-183-5p 3,161.7 15.8% 
mmu-miR-423-3p 3,134.5 21.8% 
mmu-miR-16-5p 3,079.6 12.0% 
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mmu-miR-200a-3p 2,861.5 39.7% 
mmu-miR-103-3p, mmu-miR-107-3p 2,715.0 35.6% 
mmu-miR-106b-3p 2,621.6 25.0% 
mmu-miR-93-5p 2,525.1 31.0% 
mmu-miR-200b-3p 2,382.0 19.4% 
mmu-miR-30a-3p 2,377.9 5.6% 
mmu-miR-28a-3p 2,327.5 22.7% 
mmu-miR-140-3p 2,315.5 18.2% 
mmu-miR-221-3p 1,927.7 49.2% 
mmu-let-7g-5p 1,878.7 27.9% 
mmu-let-7a-5p 1,702.2 15.6% 
mmu-miR-181c-5p 1,695.4 64.1% 
mmu-miR-484 1,682.1 13.0% 
mmu-miR-26a-5p 1,647.5 32.0% 
mmu-let-7f-5p 1,523.3 28.1% 
mmu-miR-744-5p 1,492.8 27.7% 
mmu-miR-30e-5p 1,403.0 32.8% 
mmu-miR-429-3p 1,373.5 38.2% 
mmu-miR-27b-3p, mmu-miR-27a-3p 1,234.4 22.5% 
mmu-miR-23a-3p 1,211.3 56.0% 
mmu-miR-339-5p 1,091.5 34.4% 
mmu-miR-100-5p 1,039.2 42.3% 
mmu-miR-425-5p 1,013.8 33.3% 
mmu-miR-222-3p 994.9 22.4% 
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7.2.4 miRNAs upregulated in MM3MG v.s MM3MG-Her2 
Annotation (miRBase V20; mus musculus; no 
mismatchess allowed) 
Mg-Her2 vs. Mg 
log2fold p-value 
Mean 
RPMannot. 
mmu-miR-6539 4.62608112 4.24E-05 204.8487 
mmu-miR-212-3p 4.274491594 0.005134 50.9419 
mmu-miR-7a-1-3p 4.138220121 9.04E-05 6.596053 
mmu-miR-3061-3p 3.790244502 0.019721 5.258391 
mmu-miR-7224-3p 3.718086363 0.062192 5.019148 
mmu-miR-452-5p 3.521375935 0.014839 4.424576 
mmu-miR-297a-5p 3.464715541 0.037902 4.267825 
mmu-miR-210-5p 3.40185678 0.004171 37.8121 
mmu-let-7c-1-3p 3.297099799 0.031674 21.93988 
mmu-miR-196b-3p 3.2969582 0.080797 3.838237 
mmu-miR-690 3.273103337 0.136218 3.781107 
mmu-miR-1983 3.083593576 0.002583 15.63564 
mmu-miR-7a-5p 2.943694597 0.000201 1306.558 
mmu-miR-378c 2.715538135 0.095227 2.682688 
mmu-miR-200c-3p 2.657471536 0.119915 6.235515 
mmu-miR-155-5p 2.655630038 0.002794 136.1589 
mmu-miR-3473b, mmu-miR-3473e 2.647932711 0.02839 102.4302 
mmu-let-7a-2-3p 2.614982157 0.124958 5.051873 
mmu-miR-344d-3-5p 2.545498483 0.008699 19.30172 
mmu-miR-503-5p 2.54147329 2.17E-06 767.175 
mmu-miR-92a-1-5p 2.46578573 0.000207 205.8652 
mmu-miR-365-2-5p 2.313435576 0.030522 7.209907 
mmu-miR-20a-5p 2.299275147 1.52E-05 2307.254 
mmu-miR-16-1-3p 2.28650958 7.23E-05 83.85507 
mmu-miR-125a-3p 2.273308841 0.014181 49.5699 
mmu-miR-17-5p 2.266316675 0.000114 880.4865 
mmu-miR-132-3p 2.256061722 1.79E-05 816.1163 
mmu-miR-32-5p 2.237717635 0.067868 21.71276 
mmu-miR-466b-3p, mmu-miR-466c-3p, mmu-miR-466p-
3p 2.187907156 0.011651 7.510836 
mmu-miR-18a-5p 2.125343722 0.000549 171.0609 
mmu-miR-130b-3p 2.122259019 0.09352 17.1257 
mmu-miR-466a-3p, mmu-miR-466e-3p 2.08381048 0.249185 1.857105 
mmu-miR-98-3p 2.07857562 0.139045 8.912993 
mmu-miR-342-5p 2.006791425 0.203736 5.886448 
mmu-miR-450b-5p 2.004122807 0.000482 69.00143 
mmu-miR-3066-5p 1.984634566 0.061548 15.59532 
mmu-miR-3473b 1.974768892 0.048508 26.96948 
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mmu-miR-466d-3p 1.959831932 0.170054 3.466735 
mmu-miR-1949 1.941609367 0.030431 4.828149 
mmu-miR-297c-5p 1.916019507 0.258314 1.692122 
mmu-miR-219a-1-3p 1.892354829 0.010959 12.78566 
mmu-miR-669b-5p 1.878099512 0.176875 4.663165 
mmu-miR-92a-3p 1.844125287 3.42E-05 70965.04 
mmu-miR-378d 1.804588392 0.145893 2.240526 
mmu-miR-25-5p 1.796506325 0.020939 13.52529 
mmu-miR-1198-5p 1.784300287 4.02E-05 169.7109 
mmu-miR-101a-5p 1.765769707 0.045183 3.119639 
mmu-miR-99b-3p 1.760776708 0.000242 481.3809 
mmu-miR-30c-2-3p 1.760757945 0.001387 149.685 
mmu-miR-190a-5p 1.743930358 0.015927 17.52934 
mmu-miR-3470b 1.726852158 0.143094 4.676699 
mmu-miR-5099 1.584678446 0.000759 5143.971 
mmu-miR-423-3p 1.572599265 9.2E-05 939.0329 
mmu-miR-19b-1-5p 1.570618666 0.170527 2.32832 
mmu-miR-93-5p 1.552112998 7.71E-05 3430.599 
mmu-miR-8103 1.551286744 0.219176 3.920075 
mmu-miR-15b-3p 1.550998968 0.03241 57.10887 
mmu-miR-421-3p 1.544448889 0.020502 49.80006 
mmu-let-7f-1-3p 1.528560532 0.148337 4.691335 
mmu-let-7b-3p 1.523207222 0.052386 32.78266 
mmu-miR-1940 1.509983154 0.174761 1.918791 
mmu-miR-3470a 1.509983154 0.174761 1.918791 
mmu-miR-6909-5p 1.509983154 0.174761 1.918791 
mmu-miR-6952-3p 1.509983154 0.174761 1.918791 
mmu-miR-21a-3p 1.503160876 0.000178 346.4298 
mmu-miR-7666-3p 1.500625299 0.183028 2.245828 
mmu-miR-344d-3p 1.485913518 0.013329 82.45667 
mmu-miR-122-5p 1.482630667 0.289026 1.345026 
mmu-miR-3058-3p 1.482630667 0.289026 1.345026 
mmu-miR-466i-5p 1.482630667 0.289026 1.345026 
mmu-miR-669f-3p 1.482630667 0.289026 1.345026 
mmu-miR-7226-3p 1.482630667 0.289026 1.345026 
mmu-miR-16-2-3p 1.471583421 0.002997 55.50337 
mmu-miR-342-3p 1.459345346 0.096285 21.38055 
mmu-miR-8106 1.365839664 0.172506 4.835512 
mmu-miR-374b-5p, mmu-miR-374c-5p 1.356063824 0.000213 95.94959 
mmu-miR-378a-5p 1.322062016 0.009582 17.476 
mmu-miR-125b-1-3p 1.317253386 0.003779 454.232 
mmu-miR-466a-3p, mmu-miR-466b-3p, mmu-miR-466c-
3p, mmu-miR-466e-3p, mmu-miR-466p-3p 1.309680974 0.157139 6.54647 
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mmu-miR-374c-5p 1.276013427 0.20889 2.006585 
mmu-miR-19a-3p 1.27166894 0.005896 2638.734 
mmu-miR-30a-5p 1.227517313 0.000108 23128.29 
mmu-miR-30a-3p 1.226770005 5.71E-05 285.4946 
mmu-miR-615-5p 1.222249784 0.008006 25.09964 
mmu-miR-210-3p 1.212624766 0.000217 1144.554 
mmu-miR-219a-5p 1.20698337 0.195125 6.412509 
mmu-miR-1291 1.189679972 0.317062 1.924093 
mmu-miR-27a-5p 1.175758452 0.026276 97.59772 
mmu-miR-15b-5p 1.163148336 0.001009 284.5802 
mmu-miR-3082-3p 1.147621839 0.31082 3.882881 
mmu-miR-148a-5p 1.118546948 0.000112 203.933 
mmu-miR-30e-3p 1.116502698 0.004374 260.8848 
mmu-miR-872-5p 1.115864816 0.000751 267.1922 
mmu-miR-93-3p 1.11519183 0.133401 17.21911 
mmu-miR-221-5p 1.091415003 0.000596 168.8836 
mmu-miR-744-5p 1.090102342 0.02334 404.5584 
mmu-miR-100-3p 1.08381048 0.328891 1.105783 
mmu-miR-103-2-5p 1.08381048 0.328891 1.105783 
mmu-miR-141-3p 1.08381048 0.328891 1.105783 
mmu-miR-3102-5p 1.08381048 0.328891 2.211565 
mmu-miR-429-3p 1.08381048 0.328891 1.105783 
mmu-miR-466n-3p 1.08381048 0.328891 1.105783 
mmu-miR-505-3p 1.08381048 0.328891 1.105783 
mmu-miR-5132-5p 1.08381048 0.328891 1.105783 
mmu-miR-130b-5p 1.071234426 0.212126 4.192043 
mmu-miR-99a-3p 1.068339823 3.88E-05 361.3195 
mmu-miR-128-1-5p 1.049854942 0.020805 10.37061 
mmu-miR-378a-3p 1.046407625 2.88E-05 8418.672 
mmu-miR-671-3p 1.040971392 0.024018 85.24312 
mmu-miR-30e-5p 1.039290003 0.000313 7437.372 
mmu-miR-10a-3p 1.035551677 0.052008 30.43866 
mmu-miR-301a-5p 1.025573786 0.078221 5.712655 
mmu-miR-3057-5p 1.024415599 0.026686 28.09093 
mmu-miR-92b-5p 1.006014799 0.268423 5.132842 
mmu-miR-17-3p 1.003328581 0.002057 110.3944 
mmu-miR-7068-3p 0.999216525 0.111076 5.74735 
mmu-miR-467e-5p 0.997372038 0.078978 3.618277 
mmu-miR-181b-1-3p 0.997126242 0.054216 22.46717 
mmu-miR-3962 0.99026086 0.340141 1.489204 
mmu-miR-130a-5p 0.97340369 0.096571 17.22134 
mmu-miR-30c-1-3p 0.960660809 0.151955 12.72342 
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7.3 Supplementary data3  
All source data which used to generate graphs and statistical material are listed here for each 
figure independently.  
 
7.3.1 Source data for Figure 13 
Age in 
week 
Mean number of DCC / 
Tumor area S.D 
Number of mice per data 
point 
4 42.5 28.61381 3 
7 48 37.62978 5 
9 45 22.91288 4 
11 30 2.5 2 
18 2.336083 2.86053 4 
22 0.390671 0.476405 5 
28 0.144011 0.009985 4 
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7.3.2 Source data for Figure 15 
  Transcript EL PT Met 
Ava. Fold changes over normal  AR 76.86451 1.643832 0.175492 
STDV   57.6713 1.5247 0 
          
    EL Tumor Meta 
Ava. Fold changes over normal Nr3c1 12.92824 2.97704 1.536018 
STDV   9.592439 3.072271 1.625111 
          
    EL Tumor Met 
Ava. Fold changes over normal ER-α 43.10078 49.42275 13.31518 
STDV   79.96272 125.1211 0 
          
    EL Tumor Meta 
Ava. Fold changes over normal Nr3C2 3.43781 1.08 1.03 
STDV   2.30952 1.00214 0 
          
    EL Tumor Met 
Ava. Fold changes over normal ER-β 166.5792 16.44682 8.033571 
STDV   87.79785 14.87284 4.275056 
          
    EL Tumor Meta 
Ava. Fold changes over normal PgR A&B 3.375428 0 0 
STDV   2.775341 0 0 
          
    EL Tumor Meta 
Ava. Fold changes over normal PgR B 208.6187 0 0 
STDV   29.721 0 0 
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7.3.3 Source data for Figure 16 
    Ahnak Nfatc3 Baz2a Nr3c1 Nr3c2 
Fold change 
EL 3.70928 62.36703 76.14834 14.46 44.49096 
Avarage of other stages 0.930677 14.07462 18.25849 2.755 20.10031 
           Ahnak Nfatc3 Baz2a Nr3c1 Nr3c2 
Fold change 
EL/Other Stages 3.985572 4.431169 4.170571 5.248639 2.213447 
  
      
 
7.3.4 Source data for Figure 17 
  Ahnak Baz2a Nfatc3 Nr3c1 Nr3c2 
  F.C Ava S.D F.C Ava S.D F.C Ava S.D F.C Ava S.D F.C Ava S.D 
P 1n 
3.1
0     2.84     3.87     4.35     2.48     
P 1n 
4.0
2 3.86 0.70 3.05 3.27 0.56 4.06 4.22 0.45 2.01 3.66 1.43 3.37 3.53 1.14 
P 1n 
4.4
6     3.91     4.73     4.60     4.74     
P 10n 
7.1
5     4.09     7.24     5.88     2.94     
P 10n 
5.2
2 6.35 1.01 3.47 3.71 0.33 5.06 5.70 1.34 4.77 4.57 1.43 4.56 3.58 0.87 
P 10n 
6.6
9     3.58     4.80     3.05     3.23     
P 100n 
2.8
1     2.83     2.30     4.99     2.92     
P 100n 
2.6
9 2.68 0.13 2.06 2.37 0.41 2.21 2.21 0.09 3.39 4.46 0.92 2.39 2.52 0.35 
P 100n 
2.5
6     2.22     2.13     4.99     2.26     
E 1n 
2.0
7     2.64     1.96     0.60     1.79     
E 1n 
0.5
6 1.00 0.93 0.91 1.35 1.13 0.73 1.04 0.81 0.13 0.68 0.59 0.99 1.11 0.63 
E 1n 
0.3
8     0.50     0.42     1.29     0.56     
E 10n 
0.3
5     0.84     0.92     0.45     0.88     
E 10n 
0.2
6 0.32 0.05 0.49 0.80 0.29 0.70 0.83 0.12 0.67 0.74 0.33 0.47 0.80 0.30 
E 10n 
0.3
4     1.07     0.88     1.10     1.06     
E 100n 
0.4
3     0.87     0.88     4.72     0.77     
E 100n 
0.4
9 0.53 0.12 0.95 1.00 0.16 0.82 0.89 0.07 0.67 4.73 4.06 1.06 1.00 0.21 
E 100n 
0.6
7     1.18     0.96     8.80     1.16     
C 1n 
0.9
7     1.92     1.05     2.10     1.54     
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C 1n 
0.6
7 0.61 0.39 1.19 1.16 0.78 1.30 0.91 0.48 1.59 1.39 0.84 1.54 1.18 0.63 
C 1n 
0.2
0     0.36     0.37     0.46     0.45     
C 10n 
2.1
3     1.88     1.63     1.03     2.78     
C10 n 
0.9
9 1.30 0.73 1.63 1.67 0.19 1.38 1.30 0.37 0.35 1.64 1.68 2.74 2.26 0.86 
C 10n 
0.7
7     1.50     0.90     3.54     1.27     
C 100n 
0.7
3     1.00     1.57     1.71     1.98     
C 100n 
0.6
8 0.67 0.05 0.87 1.19 0.45 1.32 1.64 0.35 4.73 2.19 2.33 1.65 1.50 0.57 
C 100n 
0.6
2     1.71     2.01     0.14     0.87     
A 1n 
0.3
7     0.47     0.68     1.91     1.02     
A 1n 
0.4
3 0.38 0.05 0.57 0.77 0.44 0.55 0.68 0.12 0.90 1.04 0.81 1.12 1.08 0.05 
A 1n 
0.3
4     1.28     0.80     0.30     1.10     
A 10 n 
0.5
9     0.71     1.27     1.44     0.92     
A 10 n 
0.4
9 0.48 0.12 0.82 0.83 0.12 0.91     0.12 0.78 0.66 1.03 1.03 0.12 
A 10n 
0.3
6     0.95     0.54 0.91 0.37 0.78     1.15     
A 100n 
0.2
4     0.35     0.32     2.15     0.43     
A 100n 
0.7
8 0.50 0.27 1.06 0.74 0.36 1.46 0.84 0.57 2.08 1.61 0.87 1.09 0.80 0.34 
A 100 n 
0.4
9     0.81     0.74     0.60     0.89     
T 1n 
0.1
5     0.33     0.29     1.41     0.56     
T 1n 
1.0
7 0.54 0.47 1.16 0.65 0.45 1.11 0.66 0.42 2.88 2.72 1.23 1.20 0.78 0.37 
T 1n 
0.4
0     0.46     0.57     3.85     0.57     
T 10n 
0.4
6     0.85     0.61     1.15     0.76     
T 10n 
0.7
2 0.74 0.30 1.03 1.10 0.29 3.09 1.71 1.27 10.63 4.40 5.40 0.90 1.10 0.46 
T 10n 
1.0
5     1.42     1.42     1.42     1.63     
T 100n 
0.6
3     1.20     1.08     0.90     1.56     
T 100n 
0.4
0 0.68 0.32 1.12 1.53 0.65 0.69 1.31 0.76 7.73 7.55 6.56 0.71 1.50 0.76 
T 100n 
1.0
3     2.28     2.16     14.01     2.23     
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7.3.5 Source data for Figure 18 
  
F.C F.C F.C Ava S.D 
  Ahnak 6.75 7.95 5.87 6.86 1.04 
EL + P 10 nM Baz2a 3.99 4.82 5.41 4.74 0.72 
  Nfatc3 7.81 8.35 5.64 7.27 1.43 
  Nr3c1 4.69 4.13 5.50 4.78 0.69 
  Nr3c2 3.32 4.18 5.16 4.22 0.92 
    
       Ahnak 0.75 1.12 1.34 1.07 0.30 
  Baz2a 2.31 1.47 1.49 1.76 0.48 
PT + P 10 nM Nfatc3 1.91 1.44 1.60 1.65 0.24 
  Nr3c1 1.70 1.38 2.17 1.75 0.40 
  Nr3c2 1.54 0.73 1.31 1.19 0.42 
    
       Ahnak 0.63 1.53 0.35 0.84 0.62 
  Baz2a 1.08 1.17 0.62 0.96 0.30 
BALB/c 9 week + P 10 nM Nfatc3 0.87 0.85 1.23 0.98 0.21 
  Nr3c1 1.32 0.94 0.99 1.08 0.20 
  Nr3c2 1.22 0.80 2.25 1.42 0.75 
 
7.3.6 Source data for Figure 20 
  
Ahnak Baz2a Nfatc3 Nr3c1 Nr3c2 
4T1 + P 10 nM 
F.C 4.16 2.26 3.22 2.85 6.34 
F.C 3.46 3.96 3.98 3.65 3.91 
F.C 6.07 3.32 4.91 2.57 6.31 
  Avarage 4.56 3.18 4.03 3.03 5.52 
  STDV 1.35 0.86 0.85 0.56 1.40 
67 NR + P 10 nM 
F.C 0.52 1.36 0.88 0.85 2.27 
F.C 1.68 0.36 1.63 0.21 1.96 
F.C 1.23 1.17 0.20 1.85 0.70 
  Avarage 1.15 0.96 0.90 0.97 1.64 
  STDV 0.58 0.53 0.72 0.83 0.83 
MM3MG + P 10 
nM 
F.C 0.85 1.35 0.79 1.88 1.19 
F.C 0.42 0.98 0.28 1.29 0.20 
F.C 1.12 0.28 1.19 1.15 1.99 
  Avarage 0.80 0.87 0.75 1.44 1.13 
  STDV 0.36 0.55 0.45 0.39 0.90 
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7.3.7 Source data for Figure 22A 
  
RANKL PR-B RANK PR-AB Wnt4 
PT 
F.C over BALB/c 8 
weeks 0.073379 0.047211 5.801532 0.073954 0.282293 
F.C over BALB/c 8 
weeks 0.060608 0.018318 3.059312 0.045026 0.423197 
F.C over BALB/c 8 
weeks 0.065862 0.021409 3.513204 0.076778 0.346117 
F.C over BALB/c 8 
weeks 0.057023 0.004176 4.36578 0.012949 0.040008 
F.C over BALB/c 8 
weeks 0.06581 0.002233 3.36532 0.005121 0.025176 
F.C over BALB/c 8 
weeks 0.048834 0.003552 4.53501 0.009891 0.031748 
  Average 0.061919 0.01615 4.106693 0.037286 0.191423 
  STDV 0.008473 0.017279 1.01212 0.032685 0.179982 
    
     
BC25 
F.C over BALB/c 8 
weeks 1.047678 0.066336 2.559649 0.253217 1.537883 
F.C over BALB/c 8 
weeks 1.629696 0.07048 3.793036 0.25452 1.781822 
F.C over BALB/c 8 
weeks 1.144393 0.368142 1.30888 0.618066 0.935191 
F.C over BALB/c 8 
weeks 0.726294 0.428503 1.081007 0.397734 0.73835 
  Average 1.137016 0.233365 2.185643 0.380884 1.248311 
  STDV 0.373926 0.192071 1.253332 0.172052 0.492135 
    
     
EL 
F.C over BALB/c 8 
weeks 1.257038 1.197372 1.213167 1.985999 1.970796 
F.C over BALB/c 8 
weeks 0.407788 1.917504 0.685221 1.097554 1.681374 
F.C over BALB/c 8 
weeks 0.410486 1.141827 1.520089 1.660511 2.77821 
F.C over BALB/c 8 
weeks 0.704514 1.326455 3.601131 1.004109 2.400692 
  Average 0.694957 1.39579 1.754902 1.437043 2.207768 
  STDV 0.399757 0.356305 1.278201 0.466896 0.481619 
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7.3.8 Source data for Figure 22B 
  
AHNAK Baz2a Nfatc3 Nr3c1 Nr3c2 
P (10 nM) F.C over untreated samples 3.242072 3.506522 3.984192 3.203381 3.335428 
Wnt4  (5 ng) F.C over untreated samples 2.697961 3.285782 2.914412 2.6797 3.381309 
RANKL (50 ng) F.C over untreated samples 3.302766 3.268202 3.216782 2.677282 3.736106 
Wnt4 + 
RANKL F.C over untreated samples 5.713623 4.85313 4.241014 3.870453 5.859924 
P (10 nM) STDV 0.35047 0.573533 0.186473 0.63028 0.169092 
Wnt4  (5 ng) STDV 0.246244 0.081637 0.616441 0.590552 0.171418 
RANKL (50 ng) STDV 0.49816 0.177999 0.091672 0.180908 0.414212 
Wnt4 + 
RANKL STDV 2.470851 0.085592 0.061453 0.224216 0.565216 
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7.3.9 Source data for Figure 23B 
 
%PgR+ cells in ductal structures of 
12 weeks old FVB mouse 
  %PgR+ cells in ductal structures of 5 
weeks old FVB mouse 
 
  
 
PgR in 
Proximal PgR in Distal   
PgR in 
Proximal PgR in Distal 
 
13.2 37.5 
 
16.5 36.6 
 
9.4 18.5 
 
23 41.1 
 
10.6 22.6 
 
24 40.6 
 
5.6 33.3 
 
22.7 29.2 
 
5.1 23.5 
 
25.3 40.7 
 
21.7 43.5 
 
18.7 36.6 
 
16.7 45.5 
 
18.1 27.8 
 
9.8 69.2 
 
12.5 32.3 
 
20.5 34.8 
 
4.3 21 
 
19.2 30.2 
 
5.6 30.1 
 
9.6 22.3 
 
22.8 22 
 
2.6 33.3 
 
2.3 36.8 
 
9.9 41.4 
 
39.3 37.2 
 
5.8 21.1 
 
29.2 39.3 
 
12.8 29.1 
 
29.5 37.3 
 
13 22.7 
 
21.1 40.4 
 
9.9 32.8 
 
29.2 36.5 
 
17.9 28.7 
 
41.3 48.5 
 
44.4 63.2 
 
42.9 43.8 
  
42.7 
 
29 36.6 
    
32.3 24.5 
     
44.7 
Average 13.56315789 34.795 
 
23.31428571 35.61818182 
SEM 2.112 3.002 
 
2.451 1.55 
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7.3.10 Source data for Figure 24B 
 
Migration assay for cells isolated from 
spheres (sphere digestion) 
 
EL 
Repli 
1 
Repli 
2 
Repli 
3 Ava S.D 
Control 128 119 100 115.7 14.29 
PR 10 nm 390 340 380 370 26.46 
Wnt4  5ng 270 200 240 236.7 35.12 
RANKL 50ng 250 200 280 243.3 40.41 
Wnt4+RANKL 340 430 460 410 62.45 
  
       
     
PT 
Repli 
1 
Repli 
2 
Repli 
3 Average  STDV 
Control 18 25 13 18.67 6.028 
PR 10 nm 15 14 11 13.33 2.082 
Wnt4  5ng 13 10 4 9 4.583 
RANKL 50ng 6 8 10 8 2 
Wnt4+RANKL 0 0 0 0 0 
 
 
7.3.11 Source data for Figure 24D 
 Migration assay for cells isolated from primary cells 
 EL Repli 1 Repli 2 Repli 3 Ava S.D 
Control 67 33 45 48.33333 17.24336 
PR 10 nm 109 110 89 102.6667 11.84624 
Wnt4  5ng 84 110 100 98 13.11488 
RANKL 50ng 186 113 153 150.6667 36.55589 
Wnt4+RANKL 198 289 240 242.3333 45.54485 
PT Repli 1 Repli 2 Repli 3 Average  STDV 
Control 66 72 80 72.66667 7.023769 
PR 10 nm 36 24 30 30 6 
Wnt4  5ng 30 22 25 25.66667 4.041452 
RANKL 50ng 33 53 40 42 10.14889 
Wnt4+RANKL 9 8 7 8 1 
 
 
 
 
152 
 
7.3.12 Source data for Figure 25A 
  
Sphere 
number 
Ava S.D 
Balb-C 9W 
1000 
  
965 
  
937 870.4 135.7509 
750 
  
700 
  
Balb-C 25W 
600 
  
460 515.8333 65.60615 
500 
  
575 
  
530 
  
430 
  
Balb-NeuT 9weeks 
1280 
  
1410 
  
1440 
  
1230 
  
1460 
  
1250 1357.273 116.6114 
1250 
  
1530 
  
1250 
  
1530 
  
1300 
  
Balb-NeuT PT 
750 
  
670 
  
600 
  
490 
  
620 692.2222 136.178 
600 
  
950 
  
800 
  
750 
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7.3.13 Source data for Figure 26B 
 
EL PT Week 4 Week 8 
Week 
25 
Week 
40 
 
40.3 0 28.2051 42.3 15.7 2.8 
 
39.7 0 27.2727 59.2 27.4 5.5 
 
56.7 0 29.8507 50.5 31.1 4.3 
 
64.3 0 32.7273 54.2 16.9 18.5 
 
55.1 0 27.2727 35.7 19.2 13.7 
 
42.2 0 15.5556 45 29.4 4.6 
 
58.7 0 21.0526 38.8 37.3 2.5 
 
48.2 0 40 49.1 12.7 9.3 
 
46.1 0 21.0526 34.4 22.5 5.4 
 
42.8 0 24.3902 42.6 20.6 3.6 
 
51.7 0 20.4 56.9 25.8 5.8 
 
49 0 27.8 39.3 28.1 4.1 
 
45.5 0 32.6 35.4 19.5 8.4 
 
47.4 0 26.3 54.5 22.4 4.6 
 
53.7 0 
 
43.6 22.6 2.1 
 
47.6 0 
 
49.2 26.7 12.4 
 
39.1 0 
 
38.4 17.3 3.8 
  
0 
 
49.4 25.2 9.9 
  
0 
 
45.1 24.1 
 
  
0 
 
42.3 
  
  
0 
    
  
0 
    
  
0 
    
  
0 
    
  
0 
    
  
0 
    
  
0 
    
  
0 
    Ava 48.7 0 26.7485 45.295 23.39 6.73889 
S.D 7.17 0 6.17204 7.35659 5.978 4.45832 
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7.3.14 Source data for Figure 27 
  EL Average STDV PT Average STDV 
Control 
1320 
  
630 
  1236 1367.667 160.8861 695 706.6667 83.11638 
1547 
  
795 
  
PR 
1920     650     
2430 2133.333 265.0157 620 673.3333 68.06859 
2050     750     
Wnt4 
1725 
  
370 
  1640 1748.333 121.6895 385 443.3333 114.2731 
1880 
  
575 
  
RANKL 
1930     300     
2750 2385 417.3428 290 343.3333 83.86497 
2475     440     
W+R 
2720 
  
180 
  2450 2906.667 573.2655 230 240 65.57439 
      
3550 
  
310 
   
7.3.15 Source data for Figure 28c 
 
  PT 
PT + P 10 
nM EL EL  + P 10 nM 
Sphere 
0 2 32 60 
3 1 45 65 
1 0 40 69 
Avarage 1.333333 1 39 64.66666667 
STDV 1.527525 1 6.557439 4.509249753 
     
single cell migration 
25 35 125 225 
30 37 101 210 
35 34 110 260 
Avarage 30 35.33333333 112 231.6666667 
STDV 5 1.527525232 12.12436 25.6580072 
 
 
 
 
155 
 
7.3.16 Source data for Figure 29B 
 
Replication Average STDV 
MM3MG 
220 
  240 250 29.4392 
250 
  290 
  
MM3MG-PgR B 
160 135 21.79449 
120 
  125 
  
MM3MG-PgR B +P 10 
nM 
125 
  170 145 22.91288 
140 
  
MM3MG-Her2 
580 
  410 536.6667 111.5049 
620 
   
 
7.3.17 Source data for Figure 29C 
 
Replication Average STDV 
MM3MG 
47 
  49 
  43 47 5.477226 
55 
  41 
  
MM3MG-PgR 
29 
  25 
  19 22.2 4.604346 
19 
  19 
  
MM3MG-PgR + P (10 
nM) 
7 
  6 
  17 12 5.147815 
14 
  16 
  
MM3MG-Her2 
126 
  98 
  93 109.75 16.66083 
122 
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7.3.18 Source data for Figure 30B 
  
Control P (10 nM) Wnt4 + Rankl 
MM3MG-
PgR B 
220 450 900 755 
240 430 840 970 
250 385 730 650 
290 
 
1100 1000 
    Average 250 421.6666667 892.5 843.75 
STDV 29.43920289 33.29164059 155.2149048 169.0845449 
 
7.3.19 Source data for Figure 30C 
  Replication Average STDV 
Control 
47 
  49 
  43 47 5.477226 
55 
  41 
  
P 10 nM 
63 
  55 
  58 61.4 6.580274 
72 
  59 
  
W+R 
85 
  96 
  64 85.6 15.46932 
104 
  79 
   
7.3.20 Source data for Figure 30E 
  
Control P (10 nM) 
Wnt4 + 
Rankl 
MM3MG-PgR 
B 
580 280 30 100 
410 330 50 90 
620 450 70 70 
Average 536.6666667 353.3333333 50 86.66666667 
STDV 111.5048579 87.36894948 20 15.27525232 
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7.3.21 Source data for Figure 30F 
  Replication  Average STDV 
MM3MG-Her2 
126 
  98 
  93 109.75 16.66083 
122 
    
  
MM3MG-Her2 + P 
93 
  102 
  84 94 7.245688 
100 
  91 
  
MM3MG-Her2 + 
Wnt4+RANKL 
45 
  39 
  58 44.2 8.467585 
43 
  36 
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7.3.22 Source data for Figure 31 
 Migration assay and inhibitors  
   Cont P P+Wi P+Ri P+Wi+Ri 
Progesterone (10 
nM)   √ √ √ √ 
 nAB-Rankl (1 µg/ml)       √ √ 
IWP-2 (3 nM)     √   √ 
Replicate 1 340 456 156 245 125 
Replicate 2 270 390 213 275 79 
Replicate 3 230 532 187 192 85 
Average 280 459.3333 185.3333 237.3333 96.33333 
STDV 55.67764 71.05866 28.53653 42.02777 25.00667 
      
 Sphere culture and inhibitors  
   Cont P 10 nM P+Wi P+Ri P+Wi+Ri 
Progesterone 10 nM   √ √ √ √ 
 nAB-Rankl 1 µg/ml       √ √ 
IWP-2 3 nM     √   √ 
Replicate 1 39 66 13 29 9 
Replicate 2 43 69 19 20 7 
Replicate 3 35 95 26 21 11 
Average 39 76.66667 19.33333 23.33333 9 
STDV 4 15.94783 6.506407 4.932883 2 
 
7.3.23 Source data for Figure 32A 
Day MM3MG MM3MG + WR MM3MG-Her2 MM3MG-Her2 + WR 
1 0.03 0.02 0.04 0.02 0.02 0 0.02 0.01 0.04 0.04 0.025 0.05 0.01 0 0.01 0.01 
2 0.22 0.18 0.23 0.2 0.08 0 0.01 0.01 0.16 0.11 0.21 0.19 0.23 0.17 0.21 0.19 
3 0.23 0.34 0.25 0.33 0.18 0.1 0.21 0.18 0.37 0.3 0.455 0.35 0.54 0.76 0.95 0.79 
4 0.39 0.37 0.42 0.36 0.34 0.3 0.39 0.36 0.66 0.64 0.795 0.57 1.72 1.27 1.57 1.65 
5 0.7 0.64 0.87 0.79 0.61 0.6 0.56 0.63 1.2 0.98 1.38 0.94 2.15 1.85 2.06 1.78 
6 1.35 1.15 1.25 1.23 0.96 0.8 0.85 0.73 2.15 1.95 1.85 1.65         
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7.3.24 Source data for Figure 32B 
  EL 
Days Control Wnt4 & RANKL 
1 23 20 28 13 19 17 22 14 
2 10 26 18 33 24 14 22 16 
3 50 66 60 55 40 74 70 100 
4 150 142 136 140 90 104 96 85 
5 235 208 258 208 86 115 116 167 
6 232 248 327 259 195 253 271 175 
7 320 368 327 347 320 266 226 253 
8 392 383 468 402 268 323 256 290 
         
           PT 
Days Control + Wnt4 & RANKL 
1 0.009 0.011 0.003 0.006 0.005 0.015 0.012 0.01 
2 0.013 0.009 0.01 0.014 0.018 0.011 0.016 0.012 
3 0.028 0.036 0.024 0.026 0.045 0.055 0.06 0.04 
4 0.055 0.04 0.053 0.045 0.062 0.075 0.065 0.065 
5 0.075 0.08 0.092 0.1 0.097 0.108 0.096 0.099 
6 0.122 0.161 0.118 0.14 0.21 0.156 0.16 0.16 
7 0.294 0.276 0.295 0.286 0.4 0.36 0.37 0.43 
8 0.356 0.396 0.355 0.409 0.507 0.487 0.5 0.48 
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7.3.25 Source data for Figure 33B 
  Replication Average STDV 
Control 
685 
  498 535.3333 134.9308 
423 
  
WR 
107 
  46 68.66667 33.38163 
53 
  
WR+LAP 10 
nM 
108 
  83 94 10.55146 
95 
  90 
  
WR+LAP 100 
nM 
470 
  430 456.25 57.93315 
530 
  395 
  
WR+LAP 100 
nM 
783 
  634 694.6667 78.25812 
667 
  
WR+LAP 1 µM 
164 
  265 248.5 57.84174 
295 
  270 
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7.3.26 Source data for Figure 36A 
Time to form Tumor 
(week) 
Gland 
Model 
Tumor 
Model 
15.29 6 
16.57 6 
16.57 6 
16.71 7 
16.71 8 
16.71 8 
16.71 8 
16.71 8 
17 8 
17 8 
17 8 
17 9.5 
17 9.5 
17.86 9.5 
17.86 9.5 
17.86 10 
17.86 11 
17.86 12.9 
17.86 14.5 
18 17 
18 17 
18 17 
18 17 
18.14 17 
18.29 22 
18.29 23 
18.29 23 
18.71 23 
18.71 23 
18.71 23 
18.71 26 
18.86 26 
18.9 26 
18.86 26 
19 26 
19.29 
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19.57 
 19.71 
 19.71 
 19.71 
 19.71 
 20 
 20 
 20 
 20.4 
 20.4 
 20.4 
 20.4 
 20.4 
 20.4 
 20.4 
 20.57 
 20.57 
 20.57 
 20.57 
 20.57 
 20.57 
 20.7 
 20.7 
 20.86 
 21 
 21 
 21 
 21.43 
 21.43 
 21.43 
 21.57 
 21.57 
 21.57 
 21.71 
 21.86 
 22 
 22 
 22.71 
 23 
 23 
 23 
 23 
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23.43 
 23.43 
 23.43 
 23.43 
 23.43 
 23.5 
 23.5 
 23.5 
 23.7 
 23.86 
 23.86 
 24 
 24.43 
 24.43 
 24.7 
 24.9 
 24.9 
 24.86 
 25 
 25 
 25.14 
 25.14 
 25.43 
 25.43 
 26 
 26 
 26 
 26 
 26.29 
 26.29 
 26.29 
 26.29 
 26.43 
 26.5 
 26.5 
 26.86 
 27 
 27.14 
 27.14 
 27.14 
 28.43 
 29 
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29 
 29 
 29.71 
 29.86 
 30.71 
 31.43 
 31.57 
 32 
 32 
 33.5 
 33.5 
 33.5 
 33.5 
 33.5 
 35.43 
 35.7 
 35.7 
 35.7 
 35.7 
 36.43 
 36.57 
 36.57 
 37.43 
 38.57 
 39.29 
 39.29 
 39.29 
 39.29 
 42.29 
 42.86 
 51.29 
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7.3.27 Source data for Figure 36B 
Time after curative 
surgery (week) 
Gland 
Model 
Tumor 
Model 
3.14 3.14 
4.14 3.14 
6.71 3.14 
6.86 18.3 
8.71 35.57 
9.43 6 
9.43 6 
11.57 6 
11.57 6 
11.86 6 
11.86 6 
11.86 31.14 
11.86 14.57 
11.86 31.14 
12 21.29 
12.43 10.86 
12.71 18 
12.71 9.9 
12.71 14 
12.71 17.9 
12.86 17.9 
13.29 17.9 
13.29 17.9 
13.43 23.71 
13.43 24.29 
13.43 21.86 
13.71 23.71 
13.71 23.71 
13.71 23.71 
13.71 23.71 
13.71 17 
13.71 24.29 
13.71 17 
13.86 18.86 
13.86 24.29 
14.14 
 14.57 
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14.57 
 14.57 
 14.57 
 14.57 
 14.57 
 14.57 
 14.57 
 14.86 
 15.14 
 15.14 
 15.57 
 15.57 
 15.57 
 15.57 
 15.57 
 15.57 
 15.57 
 15.57 
 15.57 
 15.57 
 15.57 
 16 
 16 
 16.3 
 16.29 
 16.29 
 16.29 
 16.29 
 16.57 
 16.57 
 16.57 
 16.86 
 16.86 
 16.86 
 16.86 
 16.86 
 16.86 
 17.9 
 17.9 
 17.9 
 17.9 
 18 
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18.14 
 18.14 
 18.71 
 18.71 
 18.7 
 18.71 
 18.71 
 18.71 
 18.71 
 18.71 
 18.71 
 18.7 
 19.43 
 19.43 
 19.43 
 19.43 
 19.57 
 19.57 
 19.57 
 19.57 
 19.57 
 19.57 
 19.57 
 19.57 
 19.57 
 19.57 
 19.57 
 19.57 
 19.57 
 19.57 
 19.71 
 19.71 
 19.71 
 19.71 
 19.71 
 19.71 
 19.71 
 19.71 
 19.71 
 19.71 
 19.71 
 19.71 
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19.71 
 19.71 
 20.1 
 20.14 
 20.14 
 20.3 
 21 
 21 
 21 
 21 
 21 
 21.14 
 21.14 
 21.14 
 21.3 
 21.43 
 23.43 
 23.43 
 24.43 
 24.43 
 24.43 
 24.57 
 24.57 
 24.57 
 24.57 
 24.57 
 26.43 
 26.57 
 28.57 
 28.57 
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7.3.28 Source data for Figure 36D 
  
Gland 
model 
Tumor 
Model 
Number of Met+ 
mice 101 10 
Number of Met- 
mice 50 25 
   
  
Gland 
model 
Tumor 
Model 
% of Met+ mice 67 29 
% of Met- mice 33 71 
 
7.3.29 Source data for Figure 37A 
Time to tumor formation (Week) 
Gland Model Tumor Model 
15.29 14.5 
16.57 17 
16.57 17 
16.71 17 
16.71 17 
16.71 17 
16.71 22 
16.71 23 
17 23 
17 23 
17 23 
17 23 
17 26 
17.86 26 
17.86 26 
17.86 26 
17.86 26 
17.86 
 17.86 
 18 
 18 
 18 
 18 
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18.14 
 18.29 
 18.29 
 18.29 
 18.71 
 18.71 
 18.71 
 18.71 
 18.86 
 18.9 
 18.86 
 19 
 19.29 
 19.57 
 19.71 
 19.71 
 19.71 
 19.71 
 20 
 20 
 20 
 20.4 
 20.4 
 20.4 
 20.4 
 20.4 
 20.4 
 20.4 
 20.57 
 20.57 
 20.57 
 20.57 
 20.57 
 20.57 
 20.7 
 20.7 
 20.86 
 21 
 21 
 21 
 21.43 
 21.43 
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21.43 
 21.57 
 21.57 
 21.57 
 21.71 
 21.86 
 22 
 22 
 22.71 
 23 
 23 
 23 
 23 
 23.43 
 23.43 
 23.43 
 23.43 
 23.43 
 23.5 
 23.5 
 23.5 
 23.7 
 23.86 
 23.86 
 24 
 24.43 
 24.43 
 24.7 
 24.9 
 24.9 
 24.86 
 25 
 25 
 25.14 
 25.14 
 25.43 
 25.43 
 26 
 26 
 26 
 26 
 26.29 
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26.29 
 26.29 
 26.29 
 26.43 
 26.5 
 26.5 
 26.86 
  
7.3.30 Source data for Figure 37B 
  
Gland 
model 
Tumor 
Model 
Number of Met+ 
mice 77 7 
Number of Met- 
mice 37 10 
   
   
  
Gland 
model 
Tumor 
Model 
% of Met+ mice 67.5 41.2 
% of Met- mice 32.5 58.8 
 
 
7.3.31 Source data for Figure 37c 
Time after curative surgery 
(week) 
Gland Model Tumor Model 
15.57 14 
11.57 17.9 
19.57 17.9 
19.57 17.9 
19.71 17.9 
19.71 23.71 
19.71 24.29 
26.57 21.86 
9.43 23.71 
14.57 23.71 
14.57 23.71 
14.57 23.71 
14.57 17 
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11.57 24.29 
16.57 17 
19.57 18.86 
19.57 24.29 
19.57 
 19.57 
 14.57 
 18.71 
 18.71 
 21.3 
 21.14 
 13.86 
 15.57 
 15.57 
 13.71 
 15.14 
 15.14 
 19.71 
 14.57 
 18.7 
 24.43 
 20.3 
 16.86 
 15.57 
 12.43 
 13.29 
 19.57 
 19.57 
 18.71 
 18.71 
 18.71 
 3.14 
 13.71 
 13.71 
 13.71 
 13.71 
 13.71 
 13.71 
 14.57 
 19.57 
 19.57 
 19.57 
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19.71 
 19.71 
 21 
 21 
 18 
 19.43 
 19.43 
 19.43 
 4.14 
 14.86 
 21.14 
 12.86 
 21 
 21 
 28.57 
 21.43 
 18.14 
 18.14 
 14.57 
 13.29 
 16.3 
 16.57 
 19.43 
 19.57 
 24.57 
 24.57 
 24.57 
 24.57 
 18.71 
 18.71 
 18.71 
 17.9 
 24.43 
 24.43 
 21.14 
 15.57 
 15.57 
 17.9 
 17.9 
 17.9 
 19.71 
 18.7 
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20.1 
 16 
 16 
 15.57 
 15.57 
 9.43 
 14.14 
 16.29 
 16.29 
 19.57 
 20.14 
 20.14 
 28.57 
 19.71 
 16.29 
 16.29 
 16.57 
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7.3.32 Source data for Figure 38A 
Size of Tumors 8 weeks after 
transplantation of 50 spheres 
 
EL PT 
 
 
0 462 
 
 
0 225 
 
 
0 350 
 
 
0 230 
 
 
0 380 
 
 
0 220 
 
 
0 210 
 
 
0 0 
 
 
0 160 
 
 
0 175 
 
 
0 362 
 
 
0 60 
 
 
0 144 
 
 
0 128 
 
 
0 0 
 
 
0 504 
 
 
0 0 
 
  
120 
 
  
125 
 
  
160 
 
  
235 
 
  
512 
 
  
120 
  
7.3.33 Source data for Figure 38 
  
EL 
(number) 
PT 
(number) 
DCC+ 15 13 
DCC- 2 10 
     EL  PT 
%Seeding 88 56 
%non-
seeding 12 44 
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7.3.34 Source data for Figure 38C 
Number of DCCs/1 milion bone marrow cells 
 
EL PT 
  
 
8 1 
  
 
4 1 
  
 
4 1 
  
 
7 2 
  
 
2 2 
  
 
3 1 
  
 
2 1 
  
 
1 3 
  
 
2 5 
  
 
3 4 
  
 
5 3 
  
 
5 2 
  
 
8 1 
  
 
6 0 
  
 
2 0 
  
 
0 0 
  
 
0 0 
  
  
0 
  
  
0 
  
  
0 
  
  
0 
  
  
0 
  
  
0 
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7.3.35 Source data for Figure 39A 
Number of DCCs/1 milion bone marrow cells 
EL in 4 
Week 
EL in 40 
Week 
PT in 4 
Week 
PT in 40 
Week 
8 2 2 1 
4 1 1 3 
4 2 1 5 
7 3 1 2 
3 5 1 4 
2 5 0 3 
8 
 
0 2 
6 
 
0 1 
2 
 
0 0 
0 
 
0 0 
0 
 
0 0 
  
0 
  
7.3.36 Source data for Figure 39B 
Day PT in 4 Weeks  
33 1 0 0 1 0 1 
40 12 2 1 12 1 18 
45 27 24 4 45 8 48 
50 72 60 18 60 24 60 
60 462 225 350 230 380 220 
         PT in 40 Weeks  
33 0 0 0 0 0 0 
40 1 0 1 0 2 0 
45 2 0 2 6 15 0 
50 12 0 12 18 60 30 
60 210 0 160 175 362 60 
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7.3.37 Source data for Figure 41A 
  
Day until start of differentiation 
EL EL + P PT PT + P 
25 13 0 0 
21 14 0 0 
22 14 0 0 
17 16 0 0 
20 15 0 0 
Average  21 14.4 0 0 
STDV 2.91548 1.1402 0 0 
 
7.3.38 Source data for Figure 42A 
Number of DCC in 106 BM 4 weeks after 
transplantation 
PT PT + MM3MG PT + MM3MG-Pgr-B 
2 5 0 
0 1 0 
1 2 0 
0 5 1 
3 0 1 
5 
  0 
  4 
  3 
  2 
  2 
  1 
  0 
   
7.3.39 Source data for Figure 42B 
  
Number of mice with tumor 4 week  after 
transplantation (mice from ED Fig 6h) 
PT PT + MM3MG-PgR B PT + MM3MG 
No-
Tumor 23 0 4 
Tumor 0 5 1 
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7.3.40 Source data for Figure 43A 
Number of  DCC in 106 BM cells at the 
end of prgnancy or age matched controls 
 
Pregnant Control 
 
 
3 1 
 
 
3 2 
 
 
6 3 
 
 
5 0 
 
 
4 1 
 
  
3 
  
 
7.3.41 Source data for Figure 43C 
Week Pregnant Control 
15 0 0 0 0 0 0 0 0 0 0 
16 0 1 2 0 1 0 0 1 0 0 
17 2 3 5 2 3 0 0 2 0 1 
18 6 8 10 7 9 1 0 3 0 2 
19           2 1 5 1 4 
20           5 3 7 3 7 
21           8 6 10 6 10 
 
 
7.3.42 Source data for Figure 47A 
  
Ava. of F.C over 
PT   
PgR expression STDV 
EL 2.075048328 0.289 
EL/PT  
Transwell 0.851787162 0.18 
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7.3.43 Source data for Figure 47B 
  
PgR expression in T47D 
cell line 
  
STDV 
T47D 1 0 
T47D+ 
TUBO C.M 0.512747447 0.18918074 
 
7.3.44 Source data for Figure 47C 
  
Ava. of F.C over untreated 
samples   
PR expression in T47D  STDV 
Exosome 
Free  1.006617111 0.068550279 
Exosome  0.473436482 0.009902528 
 
 
7.3.45 Source data for Figure 49A 
  
Fold change 
over control   
PR expression STDV 
mmu-miR-30a-5p 0.698423688 0.036945 
mmu-miR-30a-3p 0.901668247 0.033377 
mmu-miR-21a-5p 0.916871994 0.08526 
mmu-miR-25-3p 1.022307605 0.021711 
mmu-miR-92a-3p 1.141797736 0.15066 
mmu-miR-340-5p 0.98533219 0.108733 
mmu-miR-9-5p  0.70764369 0.114005 
mmu-miR-92a-1-5p 1.050305835 0.049744 
mmu-miR-21a-3p 0.840751989 0.16917 
mmu-miR-9-5p+30a-
5p  0.593328938 0.024271 
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7.3.46 Source data for Figure 50A 
  
Fold change over 
LD   
TUBO Cells H.D STDV 
miR9-5p 5.438969491 0.528617966 
miR30a-
5p 1.561933827 1.030378309 
 
7.3.47 Source data for Figure 50B 
  
Fold change over 
BALB/c 8 weeks   
miR9-5p STDV 
EL 2.525896176 0.041212 
PT 31.07053776 5.753632 
   
  
Fold change over 
BALB/c 8 weeks   
miR30a-5p STDV 
EL 4.227355831 1.616353 
PT 5.303869328 1.784827 
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7.3.48 Source data for Figure 51 
  TUBO low and high density (replication of F.C) 
  Ahnak Baz2a Nfatc3 Nr3c1 Nr3c2 
Tubo low 
density + P 10 
nM 
5.49 6.47 5.61 3.26 2.36 
4.83 7.21 9.51 3.55 1.60 
6.67 4.12 8.06 4.25 1.87 
avarage  5.66 5.93 7.73 3.69 1.94 
STDV 0.93 1.62 1.97 0.51 0.38 
  Ahnak Baz2a Nfatc3 Nr3c1 Nr3c2 
Tubo high 
density + P 10 
nM 
2.09 1.08 1.64 1.26 0.51 
1.51 1.30 1.30 1.25 1.31 
1.62 1.29 1.52 1.62 0.71 
avarage  1.74 1.23 1.49 1.38 0.84 
STDV 0.31 0.12 0.17 0.21 0.41 
        PT low and high density (replication of F.C) 
  Ahnak Baz2a Nfatc3 Nr3C1 Nr3C2 
PT LD + P 10 
nM 
3.03 4.71 2.64 2.86 1.74 
4.60 3.33 2.71 3.66 2.74 
2.14 3.07 3.63 3.41 2.52 
avarage  3.26 3.70 2.99 3.31 2.34 
STDV 1.25 0.88 0.55 0.41 0.53 
  Ahnak Baz2a Nfatc3 Nr3c1 Nr3c2 
PT HD + P 10 
nM 
0.71 1.38 1.90 2.07 1.45 
1.32 1.54 1.54 1.32 1.42 
1.12 2.28 1.44 1.95 0.71 
avarage  1.05 1.73 1.63 1.78 1.19 
STDV 0.31 0.48 0.24 0.40 0.42 
 
 
 
 
 
 
 
 
184 
 
7.3.49 Source data for Figure 52A 
High Density migration assay Low Density migration assay 
50000/well Replicates Average STDV 10,000/well Replicates Average STDV 
Control 
460     
Control 
40 
  370     21 
  590 473.3333 110.6044 27 29.33333 9.712535 
P 10 nM 
20     
P 10 nM 
264 
  15 11.66667 10.40833 480 
  0     335 359.6667 110.0924 
W+R 
25     
W+R 
480 
  10 13.33333 10.40833 560 570.6667 96.44342 
5     672 
   
 
7.3.50 Source data for Figure 52B 
High Density migration assay Low Density migration assay 
10,000/ml Replication Average STDV 1000/ml Replication Average STDV 
Control 
347     
Control 
38 
  400     53 
  368 368.2 27.26 43 43.6 11.371 
336     56 
  390     28 
  
P 10 nM 
119     
P 10 nM 
50 
  116     58 
  105 124.25 22.65 77 58.75 12.7377 
157     50 
  
W+R 
47     
W+R 
120 
  70     165 
  41 51.5 12.71 115 145 32.4037 
48     180 
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7.3.51 Source data for Figure 53A 
  Ava of F.C of 
Her2 over 
HME cells 
  
  STDV 
BT549 0.439825198 0.001078 
HME 1 0 
HS 578T 1.013147581 0.174786 
HCC1937 1.274073581 0.093585 
ZR751 2.42645187 0.833344 
MDA-MB-231 3.55316947 0.48593 
MDA MB 468 4.692809347 0.367636 
MCF10A 6.229922992 1.068481 
MCF7 7.127599989 4.372407 
Cama1 8.064003248 1.482832 
HCC1806 34.41797381 0.787163 
T47D 50.54810834 4.459325 
MDA MB175 57.177583 2.708012 
HCC 1569 205.485518 29.43602 
SKBR3 354.8043092 99.24162 
BT474 662.4819615 60.59161 
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7.3.52 Source data for Figure 53B 
  
Ava. of F.C of  
miR9-5p over 
HME STDV 
BT549 3.332729133 2.037336 
HME 1 0 
HS 578T 0.226085392 0.036505 
HCC1937 21.83154001 0.107002 
ZR751 106.872075 18.93185 
MDA-MB-
231 0.391158887 0.041634 
MDA MB 
468 66.76928103 3.706991 
MCF10A 0.093280954 0.003002 
MCF7 12.39652289 4.906299 
Cama1 1.607976502 0.480337 
HCC1806 110.4093464 9.278767 
T47D 0.216578678 0.060437 
MDA MB175 99.25929019 13.25799 
HCC 1569 979.4099291 114.3389 
SKBR3 68.72797286 3.371164 
BT474 2.782005856 0.015207 
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7.3.53 Source data for Figure 54A 
  
Ava. F.C of 
Her2 in HD 
over LD STDV 
BT549 1.04303084 0.048548 
HME 3.733749588 0.860825 
HS 578T 1.15832182 0.3872 
HCC1937 1.974467715 0.125722 
ZR751 3.553361794 0.524979 
MDA-MB-
231 2.427640738 0.625865 
MDA MB 
468 1.291626798 0.096228 
MCF10A 4.47689248 0.854279 
MCF7 2.529896913 0.967495 
Cama1 0.793578071 0.366488 
HCC1806 2.26539331 0.345621 
T47D 2.891377052 0.505508 
MDA 
MB175 1.110787107 0.249401 
HCC 1569 0.953091487 0.788232 
SKBR3 2.722359114 0.722432 
BT474 2.030684445 0.393527 
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7.3.54 Source data for Figure 54B 
  
miR9-5p fold 
change over 
LD STDV 
BT549 1.660599383 1.015143 
HME 0.985094022 0 
HS 578T 0.285673612 0.046127 
HCC1937 1.687641728 0.008272 
ZR751 0.419887416 0.074381 
MDA-MB-
231 0.545881602 0.058102 
MDA MB 
468 0.625368851 0.03472 
MCF10A 0.620309314 0.01996 
MCF7 2.04520326 0.592239 
Cama1 0.375941388 0.112302 
HCC1806 1.601272114 0.13457 
T47D 0.531741309 0.148385 
MDA 
MB175 0.948660357 0.126712 
HCC 1569 0.091272532 0.010655 
SKBR3 6.490731411 0.318376 
BT474 0.293437561 0.001604 
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7.3.55 Source data for Figure 55 
  
Migration assay  Sphere assay 
  Ava S.D   Ava S.D 
BT474 
LD 
Control 4 5 0 9 4.5 3.7 
HD 
Control 68 64 72 56 65 6.83 
WR 65 76 75 94 77.5 12.1 WR 320 325 287 364 324 31.5 
P 5 0 10 7 5.5 4.2 P 59 36 45   46.7 11.6 
HD 
Control 54 37 49 30 42.5 11 
HD 
Control 359 330 307 410 352 44.4 
WR 10 8 0 6 6 4.32 WR 48 65 58 36 51.8 12.6 
P 33 45 60   46 13.5 P 360 395 450   402 45.4 
HCC1937 
LD 
Control 11 16 13 19 14.8 3.5 
HD 
Control 11 16 13 19 14.8 3.5 
WR 21 28 19 23 22.8 3.86 WR 21 28 19 23 22.8 3.86 
P 10 18 15   14.3 4.04 P 10 18 15   14.3 4.04 
LD 
Control 202 180 169   184 16.8 
HD 
Control 202 180 169   184 16.8 
WR 85 123 153   120 34.1 WR 85 123 153   120 34.1 
P 193 159 207   186 24.7 P 193 159 207   186 24.7 
HCC1806 
LD 
Control 3 3 15 11 8 6 
HD 
Control 32 22 26 38 29.5 7 
WR 28 38 30 23 29.8 6.24 WR 40 49 54 58 50.3 7.76 
P 5 12 7 6 7.5 3.11 P 29 27 30   28.7 1.53 
LD 
Control 153 95 79 168 124 43.4 
HD 
Control 188 163 195 203 187 17.3 
WR 0 6 15 14 8.75 7.09 WR 127 115 109 138 122 12.9 
P 96 137 109 69 103 28.3 P 168 209 232   203 32.4 
MCF10A 
LD 
Control 6 3 7 2 4.5 2.38 
HD 
Control 6 3 7 2 4.5 2.38 
WR 10 13 12 9 11 1.83 WR 10 13 12 9 11 1.83 
P 5 8 6   6.33 1.53 P 5 8 6   6.33 1.53 
LD 
Control 121 139 142 132 134 9.33 
HD 
Control 121 139 142 132 134 9.33 
WR 70 63 85 76 73.5 9.33 WR 70 63 85 76 73.5 9.33 
P 132   125 155 137 15.7 P 132   125 155 137 15.7 
HS587T 
LD 
Control 19 38 38   31.7 11 
HD 
Control 33 31 27   30.3 3.06 
WR 12 13 29   18 9.54 WR 33 35 39   35.7 3.06 
P 75 83 94   84 9.54 P 53 44 39   45.3 7.09 
LD 
Control 343 393 267   334 63.4 
HD 
Control 198 191 180   190 9.07 
WR 204 152 166   174 26.9 WR 233 228 240   234 6.03 
P 28 52 17   32.3 17.9 P 167 199 211   192 22.7 
Cama1 
LD 
Control 29 25 16   23.3 6.66 
HD 
Control 107 83 94   94.7 12 
WR 22 28 36   28.7 7.02 WR 75 67 63   68.3 6.11 
P 55 63 49   55.7 7.02 P 81 104 85   90 12.3 
LD 
Control 243 176 269   229 48 
HD 
Control 304 278 240   274 32.2 
WR 236 323 287   282 43.7 WR 236 323 287   282 43.7 
P 54 15 39   36 19.7 P 265 232 287   261 27.7 
MDA- LD Control 700 550 450   567 126 HD Control 17 14 13   14.7 2.08 
190 
 
MB231 
WR 3000 2500 2800   2767 252 WR 26 23 28   25.7 2.52 
P 500 450 200   383 161 P 14 16 18   16 2 
LD 
Control 5400 6000 5000   5467 503 
HD 
Control 240 257 262   253 11.5 
WR 2000 3000 1500   2167 764 WR 176 157 205   179 24.2 
P 6000 5500 4000   5167 1041 P 238 271 233   247 20.6 
MDA-
MB468 
LD 
Control 4 0 0   1.33 2.31 
HD 
Control 25 21 27   24.3 3.06 
WR 10 7 0   5.67 5.13 WR 29 25 19   24.3 5.03 
P 39 28 26   31 7 P 29 19 26   24.7 5.13 
LD 
Control 78 50 43   57 18.5 
HD 
Control 112 173 142   142 30.5 
WR 293 153 123   190 90.7 WR 106 152 166   141 31.4 
P 0 0 0   0 0 P 132 169 159   153 19.1 
MCF7 
LD 
Control 5 9 24   12.7 10 
HD 
Control 72 86 65   74.3 10.7 
WR 83 54 68   68.3 14.5 WR 95 103 115   104 10.1 
P 42 6 16   21.3 18.6 P 112 103 123   113 10 
LD 
Control 40 38 63   47 13.9 
HD 
Control 203 243 251   232 25.7 
WR 0 0 0   0 0 WR 139 166 129   145 19.1 
P 0 0 0   0 0 P 189 198 167   185 15.9 
SKBR3 
LD 
Control 0 0 0   0 0 
HD 
Control 90 84 63   79 14.2 
WR 67 13 29   36.3 27.7 WR 92 71 79   80.7 10.6 
P 15 4 3   7.33 6.66 P 81 76 73   76.7 4.04 
LD 
Control 11 8 14   11 3 
HD 
Control 673 437 566   559 118 
WR 0 0 0   0 0 WR 634 511 599   581 63.4 
P 0 0 0   0 0 P 518 598 627   581 56.5 
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7.3.56 Source data for Figure 57A 
  DTC- DTC+ total  ratio 
PR (IRS0-1) 362 138 500 0.276 
PR (IRS2-8) 582 183 765 0.239216 
PR (IRS9-12) 771 203 974 0.208419 
 
7.3.57 Source data for Figure 57B 
  DTC- DTC+ total  ratio 
Her2 (0-1) 885 254 1139 0.223003 
Her2 (2) 583 172 755 0.227815 
Her2 (+2/3) 247 98 345 0.284058 
 
7.3.58 Source data for Figure 58 
PGR IRS 
HER2 IHC 
Negative 
HER2  IHC 
positive 
Her2  
amplification 
0-1 61 35 42 
 2-8 73 82 28 
9-12 120 55 28 
  Total Total Total 
PGR IRS 
HER2 IHC 
Negative 
HER2  IHC 
positive 
Her2  
amplification 
0-1 218 140 142 
 2-8 313 334 118 
9-12 608 281 85 
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7.3.59 Source data for Figure 60 
Fold changes over HER2neg/PGRhigh 
miR9-5p miR30a-5p 
HER2
amp
/PGR
neg
 HER2
amp
/PGR
high
 HER2
amp
/PGR
neg
 HER2
amp
/PGR
high
 
9.800163 0.893665 19.72178 1.812007 
40.58306 2.325927 1.861951 2.148928 
26.96107 2.959927 9.366719 4.774659 
35.32961 0.618912 37.95895 0.732072 
18.41495 5.474798 14.70425 1.585505 
12.72738 1.162963 1.58832 1.668068 
1.869164 0.708483 4.803932 0.80778 
15.6664 
 
2.322775 
 11.71772 
 
4.593411 
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7.4 Supplementary data4  
All source figures of protein blotting which used to generate figures for result section are listed 
here for each figure separately.  
 
7.4.1 Source blotting figure 21A 
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7.4.2 Source blotting figure 21B 
 
 
 
7.4.3 Source blotting figure 21C 
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7.4.4 Source blotting figure 21D 
 
 
 
7.4.5 Source blotting figure 21E 
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7.4.6 Source blotting figure 33A 
 
 
7.4.7 Source blotting figure 46B 
 
 
 
7.4.8 Source blotting figure 47B 
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7.4.9 Source blotting figure 47D 
 
 
 
7.4.10 Source blotting figure 49B 
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7.4.11 Source blotting figure 54A 
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